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A superfusion chamber was constructed to allow the monitoring
of rapid changes in neurotransmitter overflow and metabolism from
isolated tissue preparations in vitro, before, during and after applica¬
tion of depolarizing stimuli. An electrochemical detector (modified
after Keller et al. , 1976; Kissinger et al., 1973) was used in con¬
junction with high performance (ion-pair) chromatography to allow the
monitoring of endogenous catecholaminergic transmitters and their
metabolites in the superfusate from striatal slices.
High K+ ion concentration and electrical stimulation, Ca++
dependently, evoked the overflow of DA and DOPAC. While the small
electrically evoked overflow of DA was greatly enhanced by uptake
inhibitors, the already larger DA overflow with high K+ stimulation
remained unaffected, suggesting that uptake processes are inoperative
during high K+ stimulation. The high basal and evoked overflow of
DOPAC remained unaltered under conditions of uptake inhibition,
implying a presynaptic site of origin of DOPAC. Changes in DOPAC
overflow appeared to follow changes in DA synthesis better than
changes in DA release.
Muscarinic agonists enhanced the overflow of both DA and DOPAC
evoked by high K or electrical stimulation even in the presence of
uptake inhibitors implying that the release and turnover of DA were
enhanced. The simultaneous determination of 3H (3H-DA preincubation)
and endogenous DA/DOPAC overflow suggested that although the
uptake of DA was partially inhibited, 3H overflow followed changes in
DA overflow only under control conditions. When the rate of synthesis
and release was altered by drugs (uptake inhibitors, muscarinic
agonists, dopaminergic agents), 3H overflow failed to follow accurately
changes in DA overflow, adding weight to the suggestion of preferential
release of newly-synthesized DA. This hypothesis was further sup¬
ported by examining the effects of DA synthesis inhibition on DA over¬
flow.
Dopaminergic agonists (3PPP) prevented the increase of DA/
DOPAC basal overflow found in the absence of depolarizing stimuli
in vitro as has been reported in vivo after impulse inhibition. 3PPP
also appeared to decrease synthesis and release mainly of newly
synthesized DA, hence simultaneous 3H overflow was slightly but not
significantly altered under these conditions. Haloperidol appeared to
increase the synthesis and release of DA, again the effect of haloperidol
was most marked on endogenous rather than preincubated 3H-DA overflow.
The release of endogenous DA from the median eminence and





The presence of presynaptic receptors on nerve terminals was
suggested in the early part of this century, by the observation that
Acetyl Choline (ACh) and cholinesterase inhibitors (eserine and
prostijmin) initiated depolarizations of motor nerve terminals, which
would propagate antidromically (Masland and Wilton, 1940), as well
as causing muscular twitching (Langley and Kato, 1915). More
detailed studies by Feng and Li (1941) and Eccles et al. (1942) showed
that while repetitive firing of the nerve endings can arise from various
changes in the chemical environment, the effects produced by cholin-
esterase inhibitors are almost certainly due to the local accumulation
of ACh around the axon terminal after each impulse. However, these
cholinergic (nicotinic) presynaptic receptors are unusual in that they
can generate antidromic action potentials, as well as inducing release of
transmitter, not only from motor nerve endings but also from post¬
ganglionic noradrenergic nerve fibres (Hoffman et al., 1945; Ferry,
1963).
In retrospect, initial evidence for the existence of stimulation
induced release regulating presynaptic receptors came from the work
of Brown and Gillespie (1957). Working on the perfused cat spleen,
the authors noted that the overflow of NA per impulse, into the venous
blood was related to the frequency of stimulation of the splenic nerve,
being maximal by about 30Hz. The overflow was unaltered by inhibitors
of monoamineoxidase or catechol-O-methyl transferase but greatly
increased by ct-adrenergic antagonists (phenoxybenzamine, PBZ, and
dibenamine), i.e. by as much as 10-fold at 10Hz with smaller increases
seen at 30Hz stimulation. At the time the authors concluded that NA
once released first bound to the postsynaptic receptors and was sub-
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sequently taken up and metabolized, but when these receptors were
blocked, the released transmitter escaped into the overflow immediately.
The action of a-adrenergic antagonists on NA overflow generated
much interest and controversy as to their mechanism of action. Paton
(1960), working on the overflow of NA and Adr from the Adrenal medulla,
suggested that the uptake referred to by Brown and Gillespie ( 1957)
and Brown (1960) may be intra- rather than extra-neuronal. Although
at the time Brown (1960) considered this "a most attractive heresy",
the whole concept of neuronal uptake was quickly established during
the early 1960's, especially after the availability of radiolabeled
catecholamines with a high specific activity (for a complete discussion
of the evidence see Iversen, 1965, 1967, 1975). With increasing
evidence for neuronal and extraneuronal uptake the important distinction
between release (total amount of transmitter released by nerve terminals),
and overflow (diffusion of part of the released transmitter into the
perfusing/incubation fluid) was made (see Figure 1.1). The common
suggestion in both hypothesis presented above, therefore, was that
ct-antagonists induced an increase of NA overflow but not of NA release.
Thoenen et at. (1964) provided some evidence in favour of
Paton's (1960) hypothesis by showing that the "uptake inhibition" of
NA and the inhibition of splenic contractions during stimulation of the
nerve had a different time-course and sensitivity to PBZ, suggesting
dual sites of action. Although other workers (Hertting et al., 1961;
Iversen, 1965; Iversen and Langer, 1969) were able to show inhibition
of neuronal uptake by PBZ several pieces of data did not fit into this
explanation. Most importantly, some potent inhibitors of NA uptake
(e.g. cocaine and desmethylimipramine) did not markedly increase NA
overflow, and PBZ and other a-adrenergic antagonists, were effective
3.
FIGURE 1.1: Main sites of loss of noradrenaline (NA) released
during sympathetic nerve stimulation.
R - Release; total amount of NA release by the nerve
terminal during nerve stimulation.
Uptake 1 - neuronal uptake, the NA being subsequently recycled
or deaminated.
Uptake 2 - extra neuronal uptake and subsequent catabolism,
mainly by 'o'-methylation.
Overflow - Fraction of released NA diffusing into the perfusing/
superfusing medium.
MAO - monoamine oxidase.
COMT - catechol-O-methyl transferase.
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in increasing NA overflow even in the presence of these uptake
inhibitors (Blake ley eta!., 1963; Geffen, 1965; Kirpekar and Misu,
1967). Subsequently, Langer (1970) and Langer and Vogt (1971)
showed that although PBZ was able to inhibit intra- and extra-neuronal
uptake and so inhibit the degradation of NA, this effect was not
important in the action of cc-blockers on NA overflow, as indicated by
the lack of effect of phentolamine on NA metabolism but its effectiveness
on increasing NA overflow.
Around that time, Davis et al. (1968) reported the release of
prostaglandins (PGE2) along with NA, into splenic venous blood during
splenic nerve stimulation. With the finding that PG's of the E series
could reduce NA overflow during nerve stimulations (Hedqvist, 1969a)
and that PGE could antagonize the effects of PBZ on this system
(Hedqvist, 1969b) came the "transsynaptic regulation of transmitter
release" hypothesis (Hedqvist, 1969a,b ; Kaggendal, 1969). It was
suggested by these authors that the release of NA (i.e. changes in
overflow reflected changes in the release not uptake of NA) by some
transsynaptic signal (e.g. PG's, changes in intrasynaptie ion concentra¬
tions leading to changes in membrane potential or the reduced availabil¬
ity of Ca++ ions for stimulation-secretion coupling) which was inversely
related to the intensity of effector cell activity (although "presynaptic"
actions were not ruled out). However, this hypothesis had to be
abandoned with the finding that a-agonists and antagonists could modify
the overflow of NA in tissues where the postsynaptic response was
mediated by 0-receptors (e.g. heart) where overflow could be shown
to directly relate to effector cell response (Kaumann, 1970; Starke, 1971).
The finding that PBZ is effective in doses lower than those
required for uptake inhibition ana in tissues where the postsynaptic
5.
effects are mediated by 8-receptors (Starke et al., 1971) effectively
ended the ideas that uptake (neuronal and extraneuronal) or trans-
synaptic regulation were major mechanisms affected by a-adrenergic
antagonists.
Subsequently it was shown that ct-adrenergic agonists could
depress the stimulation evoked overflow of NA from the cat's spleen
(Starke, 1971). So, in 1971 several authors working independently in
different laboratories, more or less simultaneously put forward the
"presynaptic-a-receptor mediated feedback hypothesis" in the regula¬
tion of stimulation induced NA release (Farnebo and Bamberger, 1971a;
Kirpekar and Puig, 1971; Langer eta/., 1971; Starke, 1971). Starke
(1971) proposed that:
"the adrenergic nerve terminals are endowed with structures
related to the a-adrenoceptive sites of effector cells. On reaction
with ct-stimulants, e.g. with liberated NA, these neuronal a-
receptors mediate ... inhibition of NA liberation; in the presence
of a-blockers, this restriction is attenuated".
Earlier studies had demonstrated the existence of other types of
presynaptic receptor systems, e.g. inhibitory ct-presynaptic receptors
on parasympathetic nerves (Paton and Vizi, 1969) and on motor nerves
(Kr njevic and Miledi, 1958; Bowman and Nott, 1969); and inhibitory
muscarinic presynaptic receptors on noradrenergic nerves (Linamar
et al., 1968), regulating the release of the respective transmitters.
Studies on the overflow of false transmitters (see Muscholl, 1972)
lent further support to the hypothesis that the release of neurotrans¬
mitters was regulated by presynaptic receptors. Muscholl (1973)
demonstrated that the evoked overflow of ct-methyladrenaline from the
rabbit heart, could be reduced by the muscarinic agonist, methacoline,
as was the overflow of endogenous NA.
6.
The discovery by Frank and Fourtes (1957) that depolarizations
induced in gastrocnemius motor neurons on stimulation of gastro¬
cnemius nerves, could be reduced by a preceding (7 msec) volley
in the hamstring afferents of the cat, without itself inducing hyper-
polarization (or changes in excitability), led to the discovery of a
different form of "presynaptic inhibition". Part of the difference
stems from the fact that the evidence for this type of presynaptic
inhibition is almost exclusively electrophysiological and morphological,
rather than neurochemical, and hence it has developed independently
of the rest of the evidence for presynaptic inhibition stated here (see
Schmidt, 1971; Ryall, 1978, for reviews).
1.2 Nature of the presynaptic receptor mediated feedback control
of neurotransmitter release in the peripheral nervous system
The suggestion that the release of NA is regulated by presynaptic
a-adrenoceptors generated a lot of interest. In the eleven years that
have followed, an enormous amount of evidence has been gathered to
support the ideas that various types of presynaptic receptors can
modulate the release of NA from the peripheral nervous system (see
page 7 and 9). Majority of the papers concerning the release of NA use
the overflow of 3H (after preincubation of the tissue with 3H-NA) as
an index of endogenous NA release. The basal overflow of 3H from
tissues precincubated with 3H-NA, however, consists mainly of the 3H-
metabolites of the 3H-NA (Jayasundar and Vohra, 1978), and even
during stimulation only 25-45% of the overflow of 3H can be attributed
to authentic 3H-NA (Langer and Enero, 1974; Brandao et al., 1980;
Graefe et al., 1973). Most authors refer to the overflow of 3H as an
overflow of 3H-NA, complications may arise from this, as this measure
7.
is probably a better index of NA release and metabolism than of NA
release alone.
In addition to these difficulties, with improved methods of
separation and detection of NA and its metabolites, it is becoming
clear that the metabolism of endogenous and exogenous NA is different
(Graefe, 1981; Starke etal., 1981; Majewski et at., 1982).
After all the possibilities of drug induced effects on the sites of
loss of neurotransmitters (see Figure 1.1) have been ruled out, there
is evidence to support the claim that the following presynaptic receptors
modulate the induced release of NA from the peripheral nervous system:
1. Facilitatory: a) g-Adrenergic (Weinstock etal., 1978; Dahlof
etal., 1980; Dahlof, 1981).
b) Angiotensin II (Zimmerman and Kraft, 1979;
Gothert, 1977).
c) Nicotinic (Nedergaard and Schrold, 1977;
Kirpekar et al., 1980).
2. Inhibitory a) crAdrenergic (Gothert, 1977; Alberts et al. ,
1981).
b) Prostaglandin (Hedqvist, 1977; Stjarne, 1979).
c) Dopamine (Hope et a!., 1979; Fuder and Muscholl,
1978; Dubocovich and Langer, 1980).
d) Muscarinic (Gothert, 1977; Muscholl et al., 1979).
e) Opiates (Henderson et al., 1979).
f) Adenosine (Khan and Malik, 1980; Clanachan,
1979).
Evidence for GABA (Weitzell and Starke, 1980), Serotonin (Martinez
and Lokhandwala, 1980), and Histamine (Powell, 1979), presynaptic
receptors is as yet incomplete.
Similarly, a whole range of ACh release modulating presynaptic
receptors have been reported, both on motor and pre-post-ganglionic
cholinergic neurones (see Vizi, 1979; Miyamoto, 1978; Starke, 1977,
1981b; Gustafsson, 1980; Fredholm and Hedqvist, 1980).
8.
Since the subject has been extensively reviewed by numerous
authors (Stjarne, 1975b; Baidessarini, 1975; Starke, 1977, 1981b;
We st fall, 1977; Vizi, 1979; Langer, 1974, 1977, 1979, 1980, 1981;
Rand et al., 1980; Gillespie, 1980), only some of the more important
and controversial areas will be considered here.
7. Tissue and species differences
Numerous presynaptic receptor mediated controls of NA overflow
have been described (see Figure 1.2 and above), from a variety of
tissue preparations. However, not all the presynaptic receptors can
be demonstrated in every tissue preparation. Angiotensin, for example,
increases the evoked overflow of NA from the rat vas deferens (Johnson
et al. , 1974) and the rabbit vas deferens (Henderson and Hughes, 1974)
but not the mouse vas deferens (Henderson and Hughes, 1974). Such
differences occur intraspecifically as well, e.g. PG's are effective in
decreasing NA overflow in the cat spleen (Hedqvist et al -, 1971) but
they have no such effect in the cat nictitating membrane (Langer et al.,
1975a). In a careful survey of the presynaptic receptors on the rabbit
pulmonary artery, Endo et al., (1977) found release modulating
cradrenergic, angiotensin, muscarinic, nicotinic and PG type receptors,
however, there appeared to be no g-adrenergic or DA presynaptic
receptors. Although the complete absence of presynaptic receptors is
difficult to establish, the significance of tissue and species difference
in the effectiveness of presynaptic receptor systems is obscure.
Interestingly, noradrenergic neurons can take up and release
adrenaline (as a false transmitter), after which presynaptic g-receptors
which are not normally functional, become active (Guimaraes et al. ,
1978; Rand et al., 1979). Similarly, when noradrenergic nerves are
made to release DA (by preincubation with 3H-DA and a dopamine -
9.
Noradrenergic
FIGURE 1.2: Schematic representation of the pre- and post-synaptic
receptors in a noradrenergic neuroeffector junction in
the peripheral nervous system.
Presynaptic ct2-NA, dopamine (DA), muscarinic (Muse) cholinergic,
prostaglandin E (PGE), adenosine (ADN), enkephalin (ENK) opiate,
and serotonergic (5-HT) receptors mediate inhibition of the evoked
release of NA.
Presynaptic angiotensin II (Ang.II), nicotinic (Nic) cholinergic and
g-noradrenergic (g-NA) receptors mediate facilitation of evoked NA
release.
The effect of presynaptic receptors on NA synthesis (tyrosine hydroxy¬
lase activity) is incomplete.
The post-synaptic response may be mediated by als a2 or g-noradren-
ergic and other receptors.
10.
g-hydroxylase (D-g-H) inhibitor [Hope et al., 1979]; or by
administering L-DOPA [Lokhandwala and Buckley, 1978]), presynaptic
DA receptors which are normally 'silent' become active in their ability
to depress the induced release of the transmitter. These findings
suggest that some presynaptic receptors may be silent under normal
physiological conditions.
2. The effect of presynaptic receptor mechanisms on the release
of newiy synthesised NA
The release of both endogenous NA (Bell and Vogt, 1971;
Geffen, 1965) and previously taken up 3H-NA (Stjarne, 1974; Starke,
1972; Langer, 1970) is enhanced by a-antagonists, despite differences
in their presynaptic storage and metabolism (Brandao et al., 198Q;
Starke et al., 1981; Majewski et al., 1982) indicating that the effects
of presynaptic receptors are at least partially independent of de novo
synthesis.
There is some evidence to suggest that newly synthesised NA is
preferentially released (Stjarne and Wennmalm, 1970; Kopin et al.,
1968; Wennmalm, 1971). Despite findings that ce-antagonists can
increase synthesis of NA (Dairman et al., 1968; Ikeno et al., 1981;
Dairman and Udenfriend, 1970) crucial evidence for the influence (or the
lack of it) of presynaptic receptor mechanisms on the release of newly
synthesised NA appears to be missing from the literature. Such evidence
may help resolve some of the differences of opinion that exist in the
current literature.
3. One pulse release of NA
Alpha-antagonists do not appear to modify the overflow of 3H-NA
in response to one electrical pulse, but are effective after two or more
successive pulses (Rand eta!., 1973; Markiewicz et al., 1980; Wakade
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and Wakade, 1981), as would be expected from the feedback hypothesis,
since no prior released NA is available to stimulate presynaptic a-
receptors during a one pulse stimulation.
The negative results reported by Kalsner (1979) and Angus and
Korner (1980), both using PBZ, may be explained by the uptake inhibi¬
tion effects of PBZ when used in high doses (c.f. Story et al
1981).
Exogenous NA reduces the overflow of 3H~NA (in the presence of
uptake inhibitors to reduce the effects of uptake of "cold" NA diluting
the 3H-NA stores), during one pulse or trains of pulses, an effect
that is stereospecific (Rand et al., 1980; Starke, 1972b; Stjarne, 1974).
Endogenously released NA reduces the effectiveness of ct-blockers at
the presynaptic site, especially in the presence of uptake inhibitors
(Reichenbacher et al., 1982; Hope et al., 1976; Dubocovich et al.,
1979; for more detailed analysis see Baumann and Koella, 1980; Pelayo
et a!., 1980). Depletion of NA stores with reserpine or a-methyl-para-
tyrosine (AMPT) pretreatment reduces the effectiveness of ct-adrenergic
antagonists on increasing the stimulation induced overflow of 3H-NA
(Cubeddu and Weiner, 1975; Enero and Langer, 1973); because the
biophase concentration of NA available to stimulate presynaptic
cradrenoceptors is lowered.
4. Frequency dependence
The inhibition of nerve stimulated release of NA by a-agonists
is inversely correlated with the frequency of nerve stimulation (Starke
et al. , 1975; Westfall and Leighton, 1976; Langer eta!., 1975a). This
has been interpreted as follows: at high frequencies of stimulation
(or with uptake blockers) NA levels in the synaptic cleft will be
elevated to the point where presynaptic ct-receptors are maximally
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activated (by endogenous NA) hence addition of cragonists will show
no effect.
Alberts et al. (1981) have suggested that at high frequencies
of stimulation,the decreased "Ca++ availability" induced by presynaptic
ct-receptors is ineffective as there is sufficient intracellular Ca++ to
overcome this inhibition. So, presynaptic ct-adrenergic inhibition of
release and "facilitation" of release (seen at high frequency stimulation)
are seen as being mutually antagonistic.
5. Regulation of Ca++ dependent (exocytotic) release
During nerve stimulation the release of NA is accompanied by the
release of other contents of "no^drenergic vesicles", i.e. D-g-H,
chromogranins, ATP (Geffen and Livett, 1971; De Potter et al., 1972);
findings that are taken as evidence for "exocytotic release". The
finding that increases in the stimulation evoked overflow of NA produced
by ^adrenoceptor blocking drugs is accompanied by an increase in
release of D-g-H (De Potter et al., 1972; Johnson et al., 1971;
Cubeddu etal., 1974a,b; Cubeddu and Weiner, 1975; see, however,
Smith et al., 1970) suggested that the increased overflow of NA was
due to an increased "exocytotic" release of NA. Uptake inhibitors
slightly decrease the release of D-g-H, while increasing the stimulation
evoked overflow of 3H-NA (De Potter et al., 1971), consistent with the
idea that the increased biophase concentration of NA due to the uptake
inhibitors, had led to a feedback inhibition of actual NA release,
reflected by the decreased D-g-H release.
The finding that the tyramine induced overflow of NA (non-
exocytotic, Ca++ independent release; Chubb et al., 1972) was unaltered
by a-antagonists (Starke and Montel, 1974), suggesting that only Ca++
dependent release processes are regulated by presynaptic receptors.
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The basal overflow (overflow of transmitters/metabolites in the absence
of depolarizing stimuli), of catecholamines is also Ca++ independent
(Henseling et al., 1976) and remains unaffected by cradrenergic
antagonists. The potassium induced release of NA is Ca+"t' dependent
and is influenced by cradrenergic agents (Starke and Montel, 1974;
Stjarne, 1973b; Alberts et al., 1981) as is the release induced by
nicotinic agents (Furchgott et al., 1975).
6. Topographic location of presynaptic receptors
Direct evidence for a presynaptic location of release modulating
receptors is lacking, there are however several pieces of evidence
suggesting that "presynaptic" receptors are located somewhere on nerve
terminals.
Noradrenaline release modulating cr and ^-adrenoceptors have been
demonstrated on the axonal sprouts of sympathetic ganglion cells grown
in organ culture (Vogel et al., 1972; Weinstock et al., 1978) where no
effector cells are present.
Increases in the stimulation induced overflow of NA by a-antagonists
are unaffected by the atrophy of postsynaptic effector cells, as demon¬
strated by Filinger et al. (1978), after duct ligation of the rat sub¬
maxillary gland, which results in the atrophy of gland cells but not
nerve terminals.
After degeneration of noradrenergic nerve endings in the rat
heart by chemical sympathectomy with 6-hydroxydopamine (6-OHDA),
there is a significant reduction in the specific binding of an cradreno-
ceptor ligand (3H-dihydroergocryptine ; Story et al., 1979). Earlier,
Sharma and Banerjee ( 1977) reported the reduction of muscarinic binding
sites (3H-quinucRdinyl benzilate) in the rat heart after 6-OHDA treat¬
ment; Story et aI. ( 1979a,b), however, were unable to repeat this and
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suggested that muscarinic receptors were located largely on effector
cells. Recently, Dahlof (1981) demonstrated a decreased binding of
a 3-adrenergic ligand ([1251]-iodo-hydroxybenzylpindolol) in the cat
spleen, but not the heart, after 6-OHDA treatment and suggested that
in the cat spleen, g-adrenoceptors were located mainly on sympathetic
nerve terminals. Small decreases in muscarinic antagonist binding in
the striatum, ipsilateral to a unilateral 6-OHDA lesion may be due to
loss of presynaptic receptors or a decrease in soma-dendritic receptors
(due, for example, to an ovaractivity of effector cells after the removal
of an inhibitory influence; Kato et al., 1978; Giorgi and Rubio, 1981).
Similar studies involving lesions of primary afferents to specific brain
areas, in an attempt to find decreases in the binding of specific ligands
after degeneration of nerve terminals, have led to conflicting reports
(see Starke, 1981b), reaffirming the view that binding studies should
be viewed with caution.
Drug induced modulation of the overflow of neurotransmitters from
brain synaptosomal preparations (Werner et al. , 1981; De Langen et al.,
1979; De Belleroche and Bradford, 1978), and presynaptic modulation
of the release induced local depolarization of terminals (e.g. with high
K+ion concentrations; Giorguieff-Chesselet et al., 1979; Starke and
Montel, 1974; Werner et al., 1981), from isolated preparations (especially
where no cell bodies are present), all add further weight to the
suggestion of a presynaptic topographic location of presynaptic receptors.
An "extra-synaptic" location of presynaptic receptors has been
suggested based on differences in the potency of antagonists to endog-
enously released and exogenously applied NA at the presynaptic receptor
sites (Langer et al., 1981a,b; Wilffert, 1981). The effect of drugs on
the release of NA from ligated nerves (Esquerro et al. , 1980a,b) may
provide some interesting results.
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7. Pharmacological difference between pre- and post-synaptic
receptors
In retrospect, the earliest clue to a difference between pre-
and post-synaptic receptors came from the work of Thoenen et al.
(1964) (see 1.1). Langer (1973), comparing the pre- and post-synaptic
effects of NA and DA in the cat spleen, suggested that the pre- and
post-synaptic a-adrenoceptors, were probably different. This was
supported by Cubeddu et a I., (1974c) and Dubocovich and Langer
(1974), when they showed that PBZ, in the same preparation, was
30-100 times more potent in blocking post- than pre-synaptic receptor
mediated effects. Starke et al., (1975a,b) compared the relative
potencies of several a-adrenergie agonists on pre- and post-synaptic
a-receptors in the rabbit pulmonary artery. They reported that
methoxamine and phenylephrine had a preferential post-synaptic
action, i.e. contraction of the preparation. The actions of oxymeta-
zoline, a-methylnoradrenaline, tramazoline and clonidine on the other
hand were preferentially pre-synaptic, i.e. inhibition of transmitter
release. Noradrenaline, adrenaline and naphazoline were equally
effective at both sites. Drew (1977, 1978) extended these studies in
the rat vas deferens and guinea-pig ileum.
Langer (1974) originally suggested the terms aj for the post¬
synaptic a-adrenoceptor, and a2 for the pre-synaptic a-adrenoceptor.
Although many authors have since demonstrated a pharmacological
difference between pre- and post-synaptic receptors (Wikberg, 1979;
Starke, 1981a), binding studies with 3H-dihydroergocryptine (DHE),
and its displacement by preferential pre- or post-synaptic antagonists
(Hoffman et al., 1979), demonstrated that a2-adrenoceptors may also
be located post-synaptically on effector cells, functionally this has
also found to be so (Docherty and Starke, 1982). The subclassification
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of ct-adrenoceptors as axand ct2 should therefore be based only on
pharmacological characteristics.
Comparisons of the pharmacological properties of pre- and post¬
synaptic muscarinic receptors suggest that the two are identical in the
heart (Fuder et al., 1981a,b) and neocortex (Bowen and Marek, 1982).
8. Mechanism of action
Relatively little is known about the mechanism of action of pre¬
synaptic receptor mediated actions.
The observations that presynaptic receptors: 1) modify only
Ca++ dependent release processes; 2) action is inversely related to
the frequency of stimulation; 3) are most active in low Ca++ media
and ineffective when the extracellular Ca++ ion concentration is high
(Stjarne, 1975b; Langer ef o/., 1975a; Westfall and Leighton, 1976;
Drew, 1978a); have led to the suggestion that presynaptic receptors
modify "Ca++ availability" in the presynaptic terminal (Starke, 1977;
Westfall, 1977; Langer, 1977, 1979; Gillespie, 1980; Rand et al.,
1980; see however Kalsner, 1981).
Stjarne (1978) and his colleagues (Alberts et al., 1981) have
suggested that control of invasion (recruitment) of varicosities by
action potentials is perhaps more important than the regulation of the
excitation-secretion coupling (both involving utilization of external
Ca++ ions) in the mode of action of presynaptic receptors, however
direct evidence is lacking. Similarly, the proposal by Vizi (1978, 1979;
see however Vizi and Vyskocil, 19793 of the involvement of ATPases
lacks direct evidence (for evidence against, see Alberts et al., 1981;
Wakade, 1981).
Although cyclic AMP (Phosphodiesterase inhibitors and stable
analogues of cAMP) does increase the overflow of 3H-NA (Cubeddu
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et at., 1974b,1975; Stjarne, 1976; North and Vitek, 1980) no correla¬
tion was found between this and the presynaptic effects of a-antagonists
(see, however, Stjarne et al., 1979), opiates and PGE2. Although
Stjarne et al. (1979) report no effect of cGMP in the guinea-pig vas
deferens, there is fairly convincing evidence that the presynaptic
os-adrenoceptor effects on NA overflow from the pineal gland, may be
mediated by cGMP (O'Dea and Zatz, 1976; Pelayo et al., 1978).
Yonehara et al. (1980) have provided some evidence that cGMP may be
involved in the presynaptic muscarinic inhibition of 3H-ACh overflow
from rat cortex. Clearly, much more information is required to sort
out the role of cyclic nucleotides in the control of neurotransmitter
release.
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1.3 Dopaminergic presynaptic receptors in the central nervous system
7. 3. 7:
Strong evidence for a presynaptic receptor mediated regulation
of the release of neurotransmitters in the CNS began to emerge in the
early 1970's (Farnebo and Hamberger, 1971b). Although in the
periphery a direct action of presynaptic modulators on nerve endings
has come to be generally accepted, such an action in the CNS is less
certain.
Within the CNS, as cells may have several receptor types/subtypes
regulating both the generation of action potentials (soma-dendritic or
postsynaptic receptors) and presynaptic effects, the term 'presynaptic
receptor' therefore, is used cautiously for sites that are: 1) distinct
from soma-dendritic receptors and do not control the generation of
action potentials in the perikarya; 2) modify Ca++ dependent release
processes and/or neurotransmitter 'turnover'; 3) are not necessarily
located exclusively within synapses. The term 'autoreceptor' (as
suggested by Carlsson, 1975, to emphasise a neuron's sensitivity to its
own transmitter, rather than its functional/locational distinction) will
be avoided in this text, as it has not been generally accepted (except
perhaps for dopaminergic 'autoreceptors') and is more ambigious
(Starke and Langer, 1979).
In order to avoid some of the variables, brain slice preparations
have been used with some advantage in the field of transmitter release
studies. They allow careful control of the chemical environment, and
avoid the loss of metabolites into the blood stream. Furthermore, drug
induced alterations in the firing rate of cells can be avoided by using
slices which do not have cell bodies.
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Rat striatal slices made from the head of the caudate, for example,
contain the terminals of the dopaminergic nigro-striatal pathway, the
cell bodies being in the A9 region (Ungerstedt, 1971). Another
advantage of this preparation is that while DA is present in very high
concentrations, there are little or no other catecholamines, and only
very small amounts of indoleamines (Fonnum and Walaas, 1979).
Dissociation from other DA rich areas is also important as uptake,
release and metabolism of DA (and their controls) appear to differ in
the different areas of the brain (Broxterman et al., 1981; Annunziato,
1979; Annunziato et al., 1980; Nicolaou, 1980). Hence much of the
evidence for presynaptic receptor control of DA release and metabolism
comes from studies on the striatum and in particular from striatal
slices. Farnebo (1971) has, however, pointed out that striatal slices
undergo changes in their microscopic appearance during incubation.
Synaptosomal preparations can also be induced to release neurotrans¬
mitters (Ca++ dependently) while avoiding any short interneuron
network (Jones, 1975), presently available synaptosomal preparations,
however, are heterogenous.
With very few exceptions, studies on the presynaptic regulation
of transmitter release have relied on the use of labelled transmitters,
after preincubation with the labelled transmitter or its precursor.
There are several possible sources of error in this technique which
cast some doubt on the validity of using 3H (or 1I+C) overflow as an
index of endogenous transmitter release.
1. Labelled compounds may be taken up into cells other than
those containing the endogenous transmitter, and may subsequently
be released from the "wrong" structure. For example, 3H-DA can
be taken up and be converted to 3H-NA, as well as being released
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together with NA as a "false transmitter" from noradrenergic
nerve endings (Farnebo et al., 1971). Similarly, 3H-NA may be
released from dopaminergic nerve endings or adrenaline containing
neurons, or the recently discovered "amine handling cells" (Howe
et al., 1980).
Although such difficulties may be reduced by choosing appropriate
brain areas, e.g. the striatum for studying 3H-DA release, the
occipital cortex for 3H-NA release, the release of label from other
structures, e.g. glia (Jafe and Cuello, 1981) or blood vessels,
remains in most cases to be investigated.
2. Majority of the papers published on the overflow of 3H trans¬
mitters (previously preincubated), use the overflow of total 3H
as an index of authentic transmitter release. As pointed out
earlier (see page 6 ), the major part of the basal overflow of 3H
after preloading with 3H-NA or 3H-DA appears to be associated
with 3H-DOPEG and 3H-DOPAC respectively (Farah et al., 1977;
Taube et al. , 1977). In the case of 3H-DA, basal overflow
consists of 61-68% 3H-DOPAC and only 6-10% 3H-DA (Cubeddu
et al., 1979a,b; Zumstein et al., 1981). Westfall et al. (1976b)
reported much lower 3H-DOPAC levels possibly because the very
low recovery of 3H-DOPAC by their technique (58%) was not
corrected for. The work of these authors has emphasised the
dangers of false interpretation of results when the chemical nature
of the released label is not known.
To try and circumvent the above mentioned problems, many
authors have resorted to the use of monoamineoxidase inhibitors
(MAOI). However, when pargyline is present during the preincuba¬
tion with 3H-DA, there appears to be a large increase in the accumula-
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tion of 3H by the tissues, and in the K+ (20mM) and amphetamine
induced overflow of the 3H (Arbilla and Langer, 1980), suggesting
that MAOI alter the intraneuronal distribution of 3H-DA, which in
turn alters release. Pargyline present only during superfusion of
striatal tissue preloaded with 3H-DA reduces the basal and evoked
overflow of 3H (Zumstein et al. , 1981). Subsequent to a rise in DA
concentration after MAOI (Glowinski ef a!., 1972; Kehr, 1976),
there is a decrease in the synthesis rate of DA (Roth et al., 1973;
Javoy et ah, 1973) which probably also affects release.
3. Intraneuronal compartmentation of dopamine: Van Rossum
et al. (1962) and Weissman and Koe (1965) showed that while the
behavioural effects of amphetamine persisted even after depletion
of catecholamines with reserpine, they were quickly abolished by
AMPT even before the severe depletion of catecholamines, suggesting
that the effects of amphetamine were due to the release of newly
synthesised catecholamines. Subsequent work by Enna et a/., (1973)
and Chieuh and Moore (1974) on the in vivo release of labelled
catecholamines suggested that although amphetamine initially released
both stored and newly synthesised catecholamines, maintenance of
the amphetamine induced release depended on de novo synthesis.
Initial studies on the disappearance of DA after synthesis inhibition
(AMPT) showed a log-linear decline of DA for several hours (Neff
and Costa, 1968), but subsequent detailed work showed an initial
fast phase followed by a slower decline phase (Javoy and Glowinski,
1971). The authors suggested that the two phases represented
a small (26%) "newly-synthesised releasable pool" and a "storage
pool" of DA. Doteuchi et cr/., (1974), however, have suggested that
the result may be an artifact caused by metabolites of AMPT, and if
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present the releasable newly-synthesised pool cannot be more than
5% of the total DA in the neurons. Since then, work by Glowinski,
Besson, Cheramy, Javoy and Thierry on the release of 3H-DA,
recently synthesised from 3H-tyrosine, both in vivo and in vitro
has suggested that there is preferential release of newly-synthesised
DA (see review by Glowinski, 1975, for details and references).
More recently, Groppetti et at. (1977) by detailed analyses of the
specific activity of DA and its metabolites soon after (5 min) in vivo
(intraventricular) administration of 3H-tyrosine, found that the
specific activity of the metabolites of DA was higher than that of DA,
indicating that they were derived from separate pools. Shore and
Dorris (1975) found that short exposure to AMPT (30 min) markedly
potentiated the haloperidol induced catalepsy, even though 80% of
striatal DA was still intact; again suggesting that newly-synthesised
(releasable) DA is preferentially released and that release from the
large stable (stored) compartment is inadequate in the presence of
haloperidol.
Although not complete, available data suggests that there are at
least two "pools" of DA within the nerve terminal; a "releasable
pool" into which newly-synthesised and recently taken up DA initially
enter, and from which there is preferential release; and a "storage
pool" which only slowly equilibrates with the releasable pool (Shore,
1976; see Figure 1.3).
The assumption of a small releasable pool of DA, implies that changes
in the synthesis rate of DA induced by drugs, would have a marked
effect on the specific activity of DA in the releasable pool and hence
on the specific activity of the overflow of total DA. Therefore, the
release of 3H-DA previously taken up by the tissue can at best
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FIGURE 1.3: Schematic representation of the intraneuronal flux
of dopamine.
The relative size of the releasable and storage pools
of DA (less than 1 : 4) remains to be established.
Although the movement of DA between the two pools
of DA appears to be slow, its precise rate has not been
established.
Site 1 may be taken to represent a 'cytoplasmic' pool
of DA.
DA - dopamine; DOPAC - dihydroxyphenylacetic acid;
Uptake 1 - neuronal uptake; Uptake 2 - extraneuronal
uptake.
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represent only part of the actual release of endogenous DA, and
in most cases may not accurately reflect drug induced changes in
the release of endogenous DA.
Most of the evidence presented above was obtained from the
striatum, and as pointed out earlier is unlikely to hold, in every
respect, for other dopaminergic areas of the CNS. Although there is
some evidence to suggest that NA in noradrenergic nerve terminals,
also exists in separate pools (Glowinski, 1975), evidence gathered by
McMillen et al\, (1980) suggests that the separate pools of NA, unlike
those of DA, are in rapid equilibrium, thereby more closely approxi¬
mate a, one-pool, system.
7. 3. 2:
Central noradrenergic nerve terminals, like peripheral ones,
appear to be endowed with presynaptic cradrenoreceptors, stimulation
of which results in the feedback inhibition of evoked NA release. This
was first demonstrated by Farnebo and Hamberger (1971b) and has
since been confirmed for electrically induced and K+ induced overflow
from both slice and synaptosomal preparations (Starke, 1973; Pelayo
et al., 1978; Mulder et at., 1979; Baumann and Koella, 1980; Werner
et at., 1981). Taube ef a/.,(1977) showed that the decreases and
increases in 3H overflow caused by a-agonists and a-antagonists
respectively, was reflected in decreases and increases in 3H-NA and
its major metabolite 3H-DOPEG overflow, a-Adrenergic agonists and
antagonists have also been shown to decrease and increase, respectively,
the 'turnover' of NA in the CNS (Anden and Garbowska, 1977; Anden,
1980).
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The turnover of a neurotransmitter is generally defined as the
rate of synthesis and/or utilization of the transmitter. Usually these
are assumed to be equal, resulting in a more or less constant 'pool
size' of the transmitter within the tissues. With increasing evidence
for more than one pool of neurotransmitter within the presynaptic
nerve terminal, and preferential release from a small (>20%) newly-
synthesized pool (see above, Uvnas and Aborg, 1980) some reserva¬
tions about the validity of turnover measurements has been expressed
(Sharman, 1981). It appears therefore that the measurement of
turnover after dopamine synthesis inhibition is more likely to be
indicative of the rate of exchange between the storage and releasable
pools; other methods used in turnover measurement (Westerink, 1979b;
Sharman, 1981) are likely to be complicated by the disruption of the
dynamic equilibrium of synthesis and utilization, and post-mortem
changes (Carlsson etal., 1974; Moleman ef al., 1977). These
'turnover' measurements are nevertheless useful indicators of a change
in the rate of synthesis/utilization of neurotransmitters.
Neuroleptics have been shown to increase the turnover of NA in
the CNS (Anden et al., 1970; Nyback and Sedvall, 1970), and despite
potentiation of basal release, neuroleptics also increase the evoked
release of 3H-NA from cerebral cortex slices (Farnebo and Hamberger,
1971b; GorL and Schumann, 1980). Although Arbilla eta/.,(1978)
similarly found increases in the basal release of 3H-NA with neuro¬
leptics, the effect of neuroleptics on K+ induced release, in the
presence of pargyline, was generally found to be facilitatory at low
doses but inhibitory at high doses.
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Dopaminergic presynaptic receptors
Dopaminergic presynaptic receptors have been reported to be
facilitatory on 5-HT release (Reubi et al. , 1978; Cox et al., 1980)
but inhibitory on glutamate release (Mitchell and Doggett, 1980;
Rowlands and Roberts, 1980), while both facilitatory (Reubi et al.,
1977), and inhibitory (Brase, 1980; Van Der Heyden et al., 1980),
dopaminergic presynaptic receptors have been described regulating
the release of GAB A.
There appears to be general agreement in the literature that
the release of ACh from the striatum can be inhibited by dopaminergic
presynaptic receptors (Miller and Friedhoff, 1979; Bianchi et al.,
1979; Stoof et al. , 1979; De Belleroche et al. , 1982; Scatton, 1982).
An inhibitory influence of dopaminergic presynaptic receptors on ACh
turnover has also been demonstrated (Guyenet et al., 1975; Trabucchi
et al., 1975; Scatton, 1982). Hertting et al.,( 1980) showed that ACh
release from the striatum could be depressed by endogenous DA and
suggested that the dopaminergic receptor subtype involved (Seeman,
1982) is of the D2 type (see also Sethy, 1979; Scatton, 1982, Helmreich,
1981; Starke and Adelung, 1982). Destruction of the dopaminergic
nerve terminals or chronic inhibition of the dopaminergic receptors
appears to lead to a supersensitivity of the dopaminergic presynaptic
receptors on cholinergic neurons (Stoof et al. , 1979; Miller and
Friedhoff, 1979a).
Presynaptic modulation of dopamine release and turnover
In view of the methodological considerations set out above (1.3.1),
it seems hardly surprising that a great deal of controversy surrounds
almost every aspect of the control of DA release by presynaptic
receptors (see Table 1).
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TABLE 1: Summary of presynaptic receptors on dopaminergic neurons




Benzodiazepine Release + Mitchell and Martin, 1980
Turnover- Taylor and Laverty, 1973
Biswas and Carlsson, 1979
Prolactin Release + Perkins and Westfall, 1978
aGudelsky and Porter, 1980
aForeman and Porter, 1981
Turnover + a Johnston et al ., 1980
aGudelsky and Porter, 1980
Prostaglandin E2 Release +
Turnover
Baldessarini, 1975
Bergstrom et al. , 1973
Bergstrom et al., 1973
Angiotensin II Release + /Simonnett and Giorguieff-Chesselet,
1979
Adenosine Release Harms et al., 1979
Michaelis et aI., 1979
Glycine Release - /Giorguieff-Chesselet et al., 1979
*Kerwin and Pycock, 1979
ARoberts and Anderson, 1979
Martin and Mitchell, 1980
Glutamate Release
Release 0
A Roberts and Anderson, 1979
/Giorguieff et a!., 1977b
ADe Belleroche and Bradford, 1980
GABA Release + /Giorguieff-Chesselet, 1979b
*Kervin and Pycock, 1979
ARoberts and Anderson, 1979
* Starr, 1979
Stoof et al., 1979
^Sharman et al., 1982
Release - Bartholini, 1980











*Loh et al., 1976
Subramanian et al., 1977
Arbilla and Langer, 1978
Bosse and Kuschinsky, 1978
Starr, 1978
/Gauchy eta!., 1973
Chesselet et al., 1981
Laverty and Sharman, 1965
Gauchy et al. , 1973
a Deyo et al., 1979
Moleman and Bruinvels, 1979
Wood et al., 1980
ACh, Nicotinic Release /Giorguieff et al., 1976, 1977b, 1979a
/De Belleroche and Bradford, 1978
ACh, Muscarinic Release +
Release
Turnover +
Lloyd and Bartholini, 1975
/Giorguieff et al., 1977b
a Perkins and Westfall, 1979
Bartholini, 1980
b*De Belleroche and Gardiner, 1982
Marchi et al., 1982
Westfall, 1974a,b,c
/*De Belleroche and Bradford, 1978
Laverty and Sharman, 1965
Anden and Bedard, 1971
Perez-Curet et al ., 1971
Nose and Takemoto, 1974
Javoy et a I ., 1975
cPaalzov and Paalzov, 1975
De Belleroche and Bradford, 1980
5-HT Release - a Cox et al., 1980
*Ennis et al., 1981
Turnover - Andrews et al., 1978






Dopamine Release + *Seeman and Lee, 1975, 1977
*Dismukes and Mulder, 1977
*De Belleroche and Bradford, 1981
Release 0 *Raiteri eta!., 1978a,b, 1979
*Arbilla et al., 1978
Release - Farnebo and Hamberger, 1971
Lloyd and Bartholini, 1975
Plotsky et al., 1977
Starke et al. , 1978
Reimann et al., 1979
Jackish et al. , 1980
Arbilla et al., 1981
dDubocovich and Weiner, 1981
Turnover - Carlsson and Lindqvist, 1963
Laverty and Sharman, 1965
Sharman, 1966, 1967
O'Keeffe et al., 1970
Kehr et al., 1972
Christiansen and Squires, 1974
Walters and Roth, 1974, 1976
Iversen et al., 1975
Westfall etal., 1976, 1979
DiChiara et al., 1977
Garcia-Munoz et al., 1977
Nowycky and Roth, 1978
Gale, 1979
Kapatos and Zigmond, 1979
Kehr and Debus, 1979
Bannon et al., 1980
Haubrich and Pifueger, 1982
Notations:
/- experiments during which only basal overflow was measured
* - experiments conducted in the presence of a monoamine oxidase
inhibitor
+ - facilitatory effects
- - inhibitory effects
0 - no change
Striatal tissue was used in all reports with the following exceptions:
a - medial basal hypothalamus d _ retina
b - nucleus accumbens
c - cortex
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While the effects of drugs on DA turnover are generally agreed
upon, effects on release remain ambiguous. For example, while the
facilitatory effects of opiates on DA turnover have been known for
some time (see Table 1), such drugs have been demonstrated to have
either no effect, or inhibit the release of 3H-DA from striatal slices.
Although Anden and Garbowska-Anden (1978) suggested that this may
be because opiate induced increases in DA turnover are mediated from
outside the striatum, in vivo experiments by Chesselet et a/., (1981)
demonstrated that local infusion of morphine into the striatum increases
the overflow of newly-synthesized DA. An in vitro increase in DA
synthesis (from double labelled tyrosine) and basal release was also
demonstrated by Gauchy et a/., (1973) supporting the view that opiates
have a direct effect on dopaminergic nerve terminals of the striatum.
The initial observation of Anden and Garbowska (1976) on a yohimbine
(a2-adrenoceptor antagonist) mediated increase in DA turnover, has
recently been shown to be mediated by an action of the drug on
dopaminergic rather than a2-adrenergic presynaptic receptors (Scatton
et at., 1980; Dedek et a/., 1982), it is suggested therefore that
striatal dopaminergic nerve terminals do not have (functional) ct2~
adrenergic presynaptic receptors.
Despite ample evidence suggesting an increase in DA turnover and
utilization by muscarinic agents in vivo, the effects of these agents
on the in vitro release of 3H-DA remains confused (see Table 1).
Much of the confusion arises because the experiments show nicotinic
or muscarinic effects on basal release only, the physiological signify
icance and mechanism of which remains obscure. This confusion is
compounded by the fact that during these experiments (Giorguieff
eta!., 1976, 1977a, 1979a; de Belleroche and Bradford, 1978) the
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effect of drugs was examined on the basal release of newly-synthesized
DA (which may be preferentially released), hence the possibility of
an increased specific activity of a constant basal release (secondary
to an increase in turnover) was not excluded.
Striatal dopaminergic neurons
i) Feedback regulation of dopamine turnover:
The feedback regulation of DA turnover has been known since
the 1960's (Carlsson and Lindqvist, 1963; Sharman, 1966). The early
suggestion of Carlsson and Lindqvist (1963) that the changes in DA
turnover were mediated by a neuronal feedback loop (the striatonigral
pathway, see Wright et al., 1977) still has some support (Gale et a/.,
1978; Gale, 1979). However, evidence gathered by Walters and Roth
(1976a).and Kehr et ai(1972) after inhibition of impulse flow in the
nigrostriatal pathway, after lesioning the striatonigral pathway,
Garcia-Munoz et a/., (1977) and DiChiara et a/., (1977) and in vitro
work by Westfall et al.,(1976a, 1979) showed that despite effective
isolation of the nigrostriatal terminals from effects mediated via the
output pathway the actions of dopaminergic agonists and antagonists
on DA turnover persist; suggesting that the effects are mediated, at
least in part, by presynaptic dopaminergic receptors (see reviews by
Nowycky and Roth, 1978; Westerink, 1979b). It is important to note
that when impulse flow is inhibited in the nigrostriatal pathway (by
lesioning or chemically) there is a paradoxical increase in DA turnover
(Carlsson et al., 1972; Kehr et al., 1972). Hence neuroleptics are
effective in inhibiting the actions of dopaminergic agonists on DA
turnover (i.e. disinhibition of the decreased DA turnover), both
in vivo after impulse inhibition (Kehr et a!., 1972; Walters and Roth,
1974, 1976a; Kehr and Debus, 1979), and in vitro (Christiansen and
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Squires, 1974; Iversen et al., 1976; Westfall et at., 1979; Haubrich
and Plfueger, 1982) while remaining largely ineffective when admin¬
istered alone under these conditions. This suggests that when impulse
flow is inhibited there is no release of DA and so presynaptic receptors
are not activated, hence DA turnover is markedly increased (Nowycky
and Roth, 1978). Support for this suggestion comes from the findings
that neuroleptics are effective in increasing DA turnover in vitro, if
tested during high K+ depolarization (Westfall et al., 1976a), or if the
neuroleptics are administered in vivo initially (Goldstein et al., 1973;
Kapatos and Zigmond, 1979).
While there is growing evidence for a presynaptic dopamine
receptor supersensitivity following chronic administration of neuro¬
leptics (Nowycky and Roth, 1977; Skirboll et al., 1979; Bannon
et a!., 1980) and subsensitivity after chronic antidepressants (Serra
et al., 1979; Chiodo and Antl man, 1980) or dopaminergic agonists
(Muller and Seeman, 1979); the suggested involvement of cAMP as
a second messenger mediating the effects of the presynaptic receptor
(Roth et al., 1975) remain in doubt (Kehr and Debus, 1979; Anagnoste
et al., 1974). Although all these workers showed that cAMP does
elevate the turnover of DA (see also Ebstein et al., 1974), dopaminergic
agonists which decrease DA turnover are associated with an increase
in cAMP formation via the Di receptor (Kebabian and Calne, 1979;
Seeman, 1981). Recent findings, however, suggest that the presynaptic
effects of drugs acting at dopaminergic receptors are mediated by a
D2 type receptor (Helmreich, 1981; Starke and Adelung, 1982;
Scatton, 1982), and most interestingly these D2 sites have been shown
to decrease cAMP formation after stimulation of adenylate cyclase with
Di agonists in the striatum (Stoof and Kebabian, 1981) or isoprenaline
(Tsuruta, 1981), in vitro.
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ii) Feedback regulation of dopamine release:
After the initial observation of Farnebo and Hamberger (1971b)
that the neuroleptic, chlorpromazine facilitates the evoked release
of 3H-DA, several authors have reported either no effect or an
inhibition of release of 3H-DA (Seeman and Lee, 1975; Dismukes
and Mulder, 1977; de Belleroche and Bradford, 1981) with classical
neuroleptics.
The evidence for facilitatory release modulating DA presynaptic
receptors is based on the effects of neuroleptics on 3H-DA release,
it was usually found that DA agonists were ineffective in modulating
the overflow of 3H-DA (Dismukes and Mulder, 1977; Raiteri et al.,
1977a,b, 1979). Similarly (in the presence of MAOI), Miller and
Friedhoff (1979b) found no consistent effect of apomorphine on 3H-DA
overflow, however, they did report a biphasic effect of haloperidol
on 3H-DA overflow, being stimulatory at low doses but inhibitory at
high doses. While Seeman and Lee (1975) found fluphenazine to be
more active than haloperidol in inhibiting the release of 3H-DA,
Dismukes and Mulder (1977) reported it to be inactive, however,
Westfall et al.,(1976a) found that fluphenazine increased the synthesis
and release of 3H-DA, newly synthesized from 3H-tyrosine, at a
concentration of 10~6M.
There is now increasing evidence for inhibitory release modulating
dopaminergic presynaptic receptors, mainly from the laboratories of
Langer and Starke (see Table 1), inhibiting the release of 3H-DA
(notably, neuroleptics are used in low doses and in the absence of
MAOI). The most likely explanation for the discrepancies in the
literature, therefore, is that as suggested earlier, 3H-DA overflow
is a poor index of endogenous DA release; the use of MAOI and high
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concentrations of ascorbate (Lehmann et at., 1981) makes a bad
situation worse! Note that during experiments in which endogenous
DA release (in vivo, Lloyd and Bartholini, 1975; or in vitro, Plotsky
et ai., 1977) or the release of newly-synthesized-DA (Westfall et ai.,
1976a) is measured, neuroleptics have been found to be facilitatory
on DA release.
7. 3. 3 Background and aims of present investigation
The advent of the very sensitive catechol-O-methyl transferase
radioenzymatic (COMT-RE) (Coyle and Henry, 1973) allowed the assay
of endogenous catecholamines released from brain slice and synaptosom¬
al preparations (Arnold et al., 1977; Lane and Arison, 1977; Meyerhoff
and Kant, 1978), however because COMT-RE is tedious, time-consuming
and expensive, it was generally not used for this purpose. Similar
considerations concerning other highly sensitive techniques (e.g.
gas chromatography coupled with masa spectrometry [GCMS])
restricted most workers to studying the release of radiolabeled trans¬
mitters, which had been used so successfully to study neurotransmitter
uptake (Iversen, 1975).
Recent advances in the development of high performance (pressure)
liquid chromatography (HPLC) (see Knox, 1979), combined with electro¬
chemical detection (HPLC-ECD), has provided a techniqueThat is more
suitable to the study of the release and metabolism of endogenous
transmitters. "Soap-chromatography" or reverse-phase ion-pair
exchange chromatography recently developed by Knox and Jurand (1976),
is a technique which uses a reversed phase packing material in combina¬
tion with a hydrophilic eluent containing an organic modifier (e.g.
10-15% methanol) and a small concentration of a detergent (e.g. 0.1%
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sodium octyl sulphonate) which acts as an ion-pair reagent. The
detergent appears to act in two ways to improve the efficiency of
the column: 1) the detergent is adsorbed by the reversed-phase
surface to form a layer which is in some ways similar to an ion-
exchanger; 2) the detergent chosen has the potential to form an
ion-pair with an ionized form of the solute (the pH is controlled to
ensure that the solutes of interest are ionized). Thus for amines an
acidic eluent containing a cationic detergent is generally used. The
ion-pairs formed, being more hydrophobic, dissolve in the stationary
phase to achieve separation. Hence both catecholamines and their
metabolites can be separated in one step (Felice et a!., 1978).
The electrochemical detector, refined and applied to catecholamine
assay by Kissinger and Adams (Kissinger et al., 1973), works on the
following principle: From Figure 1.4, the variable power source,
connected through an operational amplifier (OP amp) to the reference
(Y) and auxiliary (R) electrode is used to maintain a predetermined
constant voltage at the reference electrode. A potential difference
is then established between the surface of the working electrode (B)
(maintained at virtual zero) and the solvent (i.e. the mobile phase
of the HPLC) in the low volume chamber. Any electroactive species,
oxidisable at or below the potential set up at the reference electrode,
is oxidized, as shown in Figure 1.4 for dopamine, which then liberates
protons and electrons. The electrons flow down the potential gradient
into the working electrode (involving a phase transfer for the electron),
the current is converted to a voltage capable of driving a chart
recorder. The general expression developed by Levich (1962) for this
current at an electrode under forced convection conditions (e.g. in
a flowing stream; amperometric detectors in stirred solutions;
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FIGURE 1.4: A. Skeleton circuit of the electrochemical detector.
-15V and +15V = operational amplifier regulated power
source.
A1 and A2 = operation amplifiers.
ECD cell = electrochemical detector cell.
Y = reference; R = auxiliary; B = working electrodes.
B. Levich (1962) equation for the limiting current at an
electrode under forced convection conditions. Where ip = limiting
current obtainable from oxidation or reduction of a compound; K = cell
constant which depends on the diffusion coefficient of the compound of
interest, the kinjmetic viscosity of the solvent and the geometry and
area of the electrode; n = number of electrons involved in oxidation/
reduction of one molecule of the compound of interest; F = Faraday's
constant; Va = velocity of the solution passing over the electrode to
some power, a; Cp = bulk concentration of the compound present in
solution. All else being constant ip becomes directly proportional to Cp.
C. The oxidative mechanism for catecholamines.
Dopamine is oxidized to a quinone liberating two electrons and two protons.
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rotating disc electrodes) is also shown in Figure 1.4. Note that
under isocratic chromatographic conditions at a constant flow rate
and temperature (since the diffusion constants and viscosity,
represented by K, are temperature dependent), the current obtained,
iL, will depend only on the concentration of the electroactive species
in solution C5.
Using a modification of the electrochemical detector designed by
Kissinger et a/., (1973) and Keller et al., (1976), and reverse-phase
ion-pair chromatography, a protocol for studying the release and
metabolism of endogenous DA, in vitro, was established. A series of
experiments was carried out to examine the influence of cholinergic







Figure 2.1 shows the circuit diagram of the amperometric detector,
modified after Keller et al. (1976) and Kissinger et al. (1973). The
points marked +15V and -15V are connected to a standard operational
amplifier (op-amp) regulated power supply (Farnell). The circuit
contains three op-amps, Al, 2 and 3 (Analog Devices), which form the
basis of the three part circuit:
Al - constant voltage source, maintaining a constant voltage
at the reference electrode.
A2 - current to voltage converter, for the current picked up
by the working electrode.
A3 - amplifies the voltage from A2, and controls the gain
and offset - null.
The detector was housed in a small aluminium box and the output
fed to a two-channel Bryans strip chart recorder (Model BS600). Great
care was taken to ensure that everything including the HPLC was
properly earthed and screened leads were used to connect the detector
cell to the amperometric detector, to reduce background noise as much
i
as possible.
Briefly the setting up procedure was as follows. With the polarity
switch at -15V, the reference and auxiliary electrodes were connected
to the detector. The potential control potentiometer was adjusted so
as to give the desired voltage (0.5-0.75V) between the reference
electrode and earth (0V). With the gain setting at lOOnA/V, the working
electrode was allowed 60-90 min to settle down before any injections were
made. Using the offset potentiometers, the background current was
nulled out and several test injections were made to test the electrode
sensitivity and stability. The amperometric detector was normally left







switched on overnight at a very low HPLC flow rate (0.1 ml/min) to
minimize setting up and electrode "settling down" time. This did
not appear to have any adverse effect on the sensitivity or operational
life of the detector cell.
Detector cell
Perspex detector cell blocks of the same basic design as Kissinger
et a/., (1973) were made, as shown in Figure 2.2. In some later experi¬
ments, the Bioanalytical systems plexiglas thin layer detector cell
(TL3) was used, the only difference being that the working electrode
was in the centre of the lower block of the cell, and a small metal
outlet tube acted as the auxiliary electrode in the reference/auxiliary
electrode compartment.
The most important point in the care of the detector cell was to
avoid scratching in the inner surface of the perspex, and to ensure
that the inlet/outlet holes, and the depression made for the working
electrode, were carefully machined to give perfect edges. The surfaces
of the blocks were polished by gently rubbing the blocks on wet paper
towels and using a silver polish (Silvo, Reckitt and Colman Ltd.).
The carbon paste (CP-S) generally used was made up as follows:
3.25 gm of graphite powder (Ko ch-Light Labs Ltd.) + 1.75 g High
Vacuum Grease (Edwards High Vacuum) were thoroughly mixed in a
mortar and pestle to give uniform consistency. The graphite paste
was tightly packed into the depression for the working electrode with
a matchstick (when repacking, as much as possible of the old paste
was removed). Sufficient paste was then gently pressed on to leave a
small mound. The final electrode surface was formed by carefully
rubbing the overpacked electrode block on 3-4 sheets of lens cleaning
tissue placed on a clean glass sheet or tile. The electrode surface was
41.
FIGURE 2.2: Detector cell and Reference/Auxiliary electrode design.
A. Detector cell made to the specification of Kissinger
et at. , 1973.
B. Reference /Auxiliary electrode compartment. The
calomel or Ag/AgCl reference electrode was held in
a perspex box, using a rubber bung. A piece of
silver wire, wound around the inside of the perspex
box, acted as the auxiliary electrode.
C. Low dead volume Reference/Auxiliary electrode
compartment. Chloridized silver wire pieces, inside
a teflon tube (i6") acted as the Reference and
Auxiliary electrodes.
















examined under a dissecting microscope and when free from scratches,
and polished, any residual carbon paste around the working electrode
was rubbed off the perspex block with some soft tissue paper soaked
in ethanol. The CP-S paste was found to be generally easy to polish
but took longer to equiiibriate when new, however the response was
the same as CP-0 (Nujol-oil based graphite paste, Bioanalytical Systems)
at +0.7V. CP-0 allowed for slightly greater sensitivity at lower
potentials (+0.55V) but was more difficult to polish in order to get
an adequately "quiet" cell. CP-0 was used in later experiments.
The reference electrodes used were calomel electrodes (Russell
pH Ltd.) or the Ag/AgCl electrodes (REl, Bioanalytical Systems).
Chloridised silver wire (Ag/AgCl) electrodes were made by quickly
dipping silver wire into molten silver chloride, while ensuring an even
coating of the silver chloride onto the wire. Modifications to the refer¬
ence/auxiliary compartment, depicted in Figure 2.2c, was especially
designed to allow collection of the peaks immediately after detection.
Dead space in the teflon tubing was less than 400ul.
During the setting up of a new cell, a common problem encountered
(apart from an inadequately polished electrode surface) was air bubbles
getting trapped in the detector cell. While these could generally be
dislodged by connecting a syringe with a luer-adapter to the inlet port
and flushing the system with buffer, to carry out this operation it was
necessary to switch off the amperometric detector, with an inevitable
delay when restarting to allow time for the electrode current to reach
the basal level. Once set up, the detector cell and reference and auxiliary
electrode compartments were covered with a wire cage which served as a
"Faraday cage"; this was not always found to be necessary as the lab¬
oratory proved to be electrically quiet.
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The response of the ECD cell to injected catecholamines was
linear over a very large range (see Figure 2.3), and so could be easily
calibrated to measure unknown amounts in injected samples.
2.2 High performance liquid chromatography (HPLC)
HPLC pumps
Initially, during the development of the amperometric detector,
a Dupont 302, constant pressure HPLC pump was used. Since the pump
was gas (N2) operated it had the advantage of being electrically quiet;
however, several major disadvantages outweighed this advantage.
Firstly, this HPLC-pump was rather antiquated and proved to be
difficult to set up and maintain in working order. Secondly, while the
slowly wandering base line (due to changes in the flow rate) was not
a limiting factor, whenever the pump primed itself, there was a very
large transient drop in pressure and flow rate (piston volume 60 ml)
which was not damped. This was particularly evident when working at
the higher pressures required for ion-pair chromatography ( 1200 psi).
Hence after the rather drastic fluctuations in the base line (due to the
priming action of the pump every 2-3 injections) a considerable time
had to be allowed for the base line to re-establish itself. Thirdly,
because of inadequate degassing facilities, bubbles developing at the
end of the HPLC column were forced into the detector cell causing great
fluctuations in the base line and shortening the life of the working
electrode surface, again the problem was worse when working at higher
pressures. Fourthly, although the injection port with septum was
adequate during tests with the ion-exchange column (working pressure
= 450-500 psi), the stop-flow injection techniques had to be employed
during ion-pair soap chromatography (working pressure = 1200-1500 psi) -
FIGURE 2.3: The range of linear response of the electrochemical
detector for catecholamines, their metabolites and
derivatives.
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this of course caused fluctuations in the base line due to dramatic
changes in pressure (see Figure 2.4).
The pump subsequently used was a Gilson 301 constant flow pump
with a 10 ml pumping head which was far better suited for the purposes
of electrochemical detection. Three different pulse damping mechanisms:
1) a small metal frit in the pump head just before the outlet check
valve; 2) a long, empty column introduced into the flow; and 3) a
built-in electronic compensator (regulating the time taken for the pump
to prime) ensured an adequately pulse-free flow.
Difficulties with injecting samples at high working pressure were
overcome by using injection valves (Rheodyne 7125 or Altex 210-20)
normally using 20pl or 50|il sample loops. Figure 2.5 shows a flow
diagram of the equipment used for the HPLC-ECD analysis of all super-
fusate samples.
HPLC column packing
A 25 cm Partisil SCX-10u (Shandon) cation-ion exchange column
was used for ion exchange chromatography.
Ion pair chromatography was carried out using stainless steel
columns (25 cm) which were packed with C18 -reverse phase packing
material (Shandon, Hypersil-ODS, 5n particle size) using a Magnus
P6050 slurry packing unit. The slurry, made up with 3-4 g packing
material in 50 ml of 0.1M sodium acetate dissolved in HPLC grade
methanol (Rathburn Chemicals, Walkerburn, Scotland) was poured into
a small ultrasonic tank, to ensure that the packing material particles
were kept separate and then forced into the column at a pressure of
5000 psi with degassed methanol. The columns were then washed
thoroughly with methanol followed by 10% methanol in distilled and











FIGURE 2.4: A_^ Ion-exchange separation of 1 = noradrenaline;
2 = adrenaline; 3 = dopamine.
B. Ion-pair separation of 1 = noradrenaline;
2 = adrenaline; 3 = dopamine; 4 = dihydroxy-
phenylacetic acid.
FIGURE2.5:lowdiagramftheHighPerformanceL quidCh omatography withElectrochemicalDetectionanalysisfa ch lamines. A=buffer;Bpump;C=p lsedamp r;D=pr suregauge; E=injectionvalve;FC18-reversephac lumn;G=det ctor cell(s eFigure2.2);H=amperometricdet c or;I=chartr corde .
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buffer (see below) for at least 12 h. The columns were tested
(according' to Knox, 1979) and only columns with more than 1000
theoretical number plates (N) were used, where
N = 16(tR7Wt)2
where N = number of theoretical plates
tR = retention time
= peak width (time units) at base.
Peak spreading or trailing, especially in dirty overused columns,
could often be corrected by opening the top of the column, removing
1-2 mm of the packing material and replacing it with clean slurry.
Because the test samples injected onto the columns did not contain
high molecular weight, proteins, lipids etc, the columns were kept in
continuous use for the life-span of the detector cell (3-4 weeks). The
column was, at the time of changing the detector cell, washed (50 ml
distilled water, followed by 50 ml methanol, 50 ml of a 1:1 mixture of
methanol and chloroform, 50 ml of methanol and 50 ml of water, in that
order) before re-use.
Buffer systems
The buffer system used for ion exchange chromatography was
as described by Keller et a/., (1976) and made up as follows: (pH ca.
5.2)
Citric acid, 1H20 - 5.75 g
Sodium acetate, 3H20 - 6.80 g
Glacial acetic acid - 1.05 ml
Sodium hydroxide - 2.40 g
made up to 1 1 with distilled and deionized water,
flow rate: 1 ml/min.
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However, this form of separation was less efficient (see Figure
2.4) and because DOPAC cannot be measured directly, ion exchange
chromatography was substituted by ion pair chromatography for all
experimental purposes.
For reverse phase ion-pair chromatography the buffer used was
made up as follows:
Degassing of the buffers was done by first applying a vacuum for
about 2 min, and then bubbling with Helium gas for 20-30 min.
The HPLC flow rate was set at 0.8 ml/min, giving retention
times of approximately 7 min for DA and 10 min for DOPAC (see Figure
2.6). One great advantage of this type of chromatography was that
small alterations of the buffer composition altered the retention times
and the order of elution of the compounds. Retention times were
increased by: a) increasing the amount of ion pair reagent; b) de¬
creasing the methanol (organic modifier) content; c) altering the
ionization state of the catecholamines by decreasing the pH. Since,
for example, DOPAC with its acid group is more sensitive than catechol¬
amines to pH changes, the position of DOPAC relative to DA could be
altered by pH changes. Adding other ions to the buffer, e.g. sodium
acetate had, likewise, the effect of decreasing the retention time of
DOPAC greatly while leaving the DA retention time almost unaltered.
While these relationships were not examined in detail, they were used
to try to verify the identity of compounds, as two compounds are







made up to 1 1 with distilled and deionized water, and








FIGURE 2.6: Ion pair separation of 1 = dihydroxybenzyl amine;
2 = dopamine; 3 = dihydroxyphenylacetic acid;
4 = 3-methoxytyramine, under different chromatographic
conditions (flow rate 0.8 ml/min):
A. Standard buffer composition (see text). Amounts
injected: 1, 2 and 3=2 ng; 4 = 4 ng.
B. Buffer composition as above except pH =3.5.
Amounts injected: 1, 2 and 3 = 1 ng; 4 = 2 ng.
C. Buffer composition as above except methanol reduced
to 5%. Amounts injected: 1, 2 and 3 = 1 ng.
D. Buffer composition as above except sodium octyl
sulphonate increased to 125 mg/1. Amounts injected:
1, 2 and 3 = 2 ng; 4 = 4 ng.
Note that decreasing the methanol content increased the retention time
of all the compounds while changes in the pH only affected the retention
time of the acid metabolite and changes in the ion-pair reagent only
affected the amine retention times.
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unlikely to have the same retention times under different chromato¬
graphic conditions (see Figure 2.6). Retention times of authentic
compounds were checked before and at the end of every experiment,
as was the sensitivity of the detector cell.
2.3 Comparison with other techniques
UV spectrophotometry
Using the low dead volume reference and auxiliary electrode
compartments depicted in Figure 2.2c, the outflow from the detector
cell was connected to a spectrophotometer (Perkin-Elmer, LC-55) and
monitored at 280nM.
Cos chromatography-mass spectrometry {CCMS)K
Samples for GCMS, containing O.OlmM ascorbate, were evaporated
to dryness in a vacuum dessicator and then derivatized using hepta-
flurobutyric anhydride (HFB anhydride). The res ulting tri-HFB
catecholamine derivatives were evaporated to dryness and redissolved
in ethyl acetate and injected into the GCMS. The retention time of the
tri-HFB-DA derivative on the GC was about 3 min. Using mass
fragmentography with multiple ion detection, DA was identified and
quantified (528, 331 and 226 m/e, fragments of the tri-HFB-DA were
found, deuterated-DA was used as the internal standard).
2.4 Superfusion techniques
Superfusing solutions
For superfusion of striatal, median eminence and retinal tissue,
Krebs buffer was used. Its composition was as follows:
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g/1
Sodium chloride - 6.90
Sodium bicarbonate - 2.10
Glucose - 1.80
Potassium chloride - 0.28
Magnesium sulphate - 0.30
Potassium dihydrogen-orthophosphate - 0.16
Ascorbic acid - 0.02
Calcium chloride - 1.75 ml of a
1M solution
pH ca. 7.4
High K+ (15, 25, 35, 50mM K+) Krebs was made up by substituting
10, 20, 30 or 45mM NaCl respectively, with the equivalent amount of
potassium chloride.
Superfusion of cockroach salivary glands was carried out using
a Ringer solution of the following composition.
Sodium chloride - 9.35 g/1
Potassium chloride - 1.00 ml of 1M solution
Calcium chloride - 5.00 ml of 1M solution
Tris - 0.605 gm/1
Hydrochloric acid - 4.00 ml of 1M solution
Ascorbic acid - 0.02 g/1
pH ca. 7.6
All superfusing solutions were continuously bubbled with 95% oxygen,
5% carbon dioxide throughout the course of the experiments.
Superfusion chambers
The superfusion chambers, shown in Figure 2.7, were made of
perspex and used to run two experiments in parallel. Tissues were
placed in the perspex ring (internal volume 200jal), within the super-
fusion chamber, covered with a nylon gauze and held in place by a
perspex stopper which also served as the outlet port. At the end of
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FIGURE 2.7: Schematic diagram of the superfusion chambers.
Tissues were placed in the perspex rings (A for striatal
and retinal tissue; B for median eminence and cockroach salivary
glands) and covered with a nylon mesh. This was held in place by
a perspex stopper which also served as the outlet part. Silver foil
electrodes allowed for electrical stimulation of the tissue, the resistance
between them during superfusion with Krebs or Ringers solution was
2-3K Q. At the end of the experiments, the perspex rings were taken




the experiment the perspex ring was taken out, the tissues removed,
homogenized and assayed as necessary (see later).
For experiments with median eminence tissue pieces and cockroach
salivary glands, a modified perspex ring was used; the internal volume
was reduced to approximately 50pi because of the small amount of
tissue, and to decrease the dead volume in the system.
Basic superfusion protocol
A flow diagram of the basic superfusion technique, common to all
experiments, is shown in Figure 2.8. A Watson-Marlow peristaltic
pump with a head attachment that allowed different solutions to be
pumped simultaneously was used. Inlet tubes to the superfusion
chambers were supplied with rubber tube collars (RC) which permitted
water tight joints that could be quickly and easily interchanged, so
that a tube containing high K+ Krebs could be connected to the chambers
for two minutes and then the original Krebs solution ( + ,- drugs) could
be replaced to allow for a 2 min pulse of high K+ Krebs. Unless
otherwise stated, 25mM K+ Krebs was used. This procedure was
synchronized with the fraction collector (by measuring the flow rate
and dead volume in the tubing), allowing the 2 min pulse of high K +
to be collected as one sample. The fraction collector used was a Gilson
microcol TDC 80, set to collect 2 min samples. Drug stock solutions
were added directly to the Krebs (or Ringers) solutions.
As indicated in Figure 2.8, the superfusion chamber (and a
length of inlet tubing) was immersed in a water bath at 37°C for all
experiments except when working with cockroach salivary glands (these
experiments were carried out at room temperature, 20°C). Two
Digitimer isolated stimulators (Model DS2) were used to provide a
biphasic square wave pulse for electrical stimulation. The stimulators
tostimulator
FIGURE2.8:lowdiagramfthesuperfusiontechniquea dt equ pment employed. A1,2,3=superfusingsolutionandhighK+ioconcentrationmed a,with withoutdrugs,beingcontin ouslybubbledw th95%xygen,5carbondioxid . B=peristalticumpwithamulti-tubeh adattach ent.RC=bb rt co la forrapidchangingftubesollowf r2minpul efhighK+reb . C=superfusionchamber(Figur2.7)imm rs dnwat rb tht37°Cn connectedthstimulator.D=fractioncollector,to l ct2isamples intoEppendorftubesat0°C,containing7jjIfprotectivesolu ion+internal standard(seetext).
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were driven by a Digitimer D100 pulse generator and the output of
the stimulators constantly monitored on an oscilloscope (Telequipment
DM64) across a 500P. resistor. Two silver rings in the superfusion
chamber served as the stimulating electrodes. The resistance between
these electrodes was between 2-3K& under experimental conditions.
Unless otherwise stated, the stimulation parameters used were:
8-10mA amplitude, 2msec duration, at 20Hz for 30 sec.
Tissue dissection and details of superfusion
A) Striatal tissue: Male albino Wistar rats (180-220 gm) were used
throughout. Rats were killed by cervical dislocation, decapitated, and
the brains rapidly removed from the cranial cavity. The brains were
placed in ice cold, oxygenated Krebs for about 20 sec and then placed,
ventral side up, in a petri dish on ice. Two cuts were made, the first
1-2 mm anterior to the optic chiasma and the second just before the
optic chiasma. From the resulting slice of brain tissue, both striata
were dissected free and chopped (Mcllwain tissue chopper) at 0.3 mm
intervals, twice, at right angles. The tissue pieces were placed in
10 ml of oxygenated Krebs at 37°C, separated by one or two moderately
violent shakes, and allowed to (equilibriate) preincubate for 10 min.
The tissue was then transferred to the two superfusing chambers and
superfused at approximately 300-350|il/min (the exact value being
determined at the end of the experiment by averaging the volumes
collected into the sample tubes).
During experiments with unilaterally lesioned animals, the lesioned
and unlesioned striata were kept separate and put into different super-
fusing chambers.
After transferring the tissues to the superfusing chambers, they
were allowed a 10 min wash-out period before collection of the Krebs
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solution commenced. Normally, two periods of stimulation (using high
K+ Krebs or electrical stimulation as described) were applied during
an experiment, the first (S^ at 16 min, and the second (S2) 56 min
after the onset of superfusion. Drugs were applied 30 min after the
onset of superfusion, i.e. after the control S x. All the samples between
10-30 min and 50-70 min were analysed for their DA and DOPAC content.
At the end of the experiments the tissues were removed from the
chambers (as described previously) and homogenized in 1 ml of 0.1M
HC1 (containing 0.0ImM EDTA + .1jiM Ascorbate) solution. A 30|il
aliquot was immediately taken for protein estimation (Lowery et al.,
1951) and the rest spun down for 10 min at 12,000 rpm (Eppendorf 3200
centrifuge) at 4°C. lOOjil of this supernatant was diluted 1 : 10 and
injected directly into the HPLC-ECD for DA and DOPAC estimation.
The DA/DOPAC content of the tissues at the start of the experiment was
determined as above using a 3-4 mg (wet weight) sample of tissue
taken just after the preincubation period.
During experiments with labelled DA, 3H-DA was added to the
10 ml of Krebs solution during the preincubation stage. The slices were
then washed three times with label-free Krebs before being transferred
to the superfusion chambers. 3H overflow was determined by pipetting
500 pi of the superfusate into vials containing 8 ml of scintillant
(Aquasol). The radioactivity in the samples was determined by Liquid
Scintillation Counting (Searle, Mk.II, Nuclear Chicago Division). In
one set of experiments (3.1) the eluent of the HPLC-ECD was collected,
using the low-dead volume reference/auxilliary compartment. Radio¬
activity in these samples was determined as above. At the end of the
superfusion experiments, lOOpl of the tissue homogenate was used to
determine the amount of radioactivity left in the tissue.
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B) Median eminence tissue: The following alterations were made to the
protocol mentioned above during experiments with median eminence
tissue:
1) The chilled brain of the rat was placed in a petri-dish, on ice,
under a dissecting microscope. With the aid of a green light source,
the median eminence was identified using the hypothalamo-hypophysial
portal blood vessels as a landmark. With the aid of a fine pair of
forceps, the remaining part of the pituitary stalk was gently lifted
and two incisions made, parallel to the blood vessels using the stalk
as a guide. The incision was made up to the optic chiasma and to the
depth of the third ventricle, using a pair of very fine iridectomy scissors.
The stalk was then detached, placed in oxygenated Krebs at 37°C and
incubated for approximately 20 min. Four median eminence stalks were
used for each experiment.
2) The modified perspex tissue holder (see above) was used, and the
tissues superfused with Krebs solution at a flow rate of approximately
150ul/min.
3) At the end of the experiment the tissues were removed from the
chambers and homogenized in 100|il of 0.1M HC1. 30y.1 was used for
protein estimation and the rest used to estimate the DA and DOPAC
content of the tissues, as above, for the DA/DOPAC assay.
C) Retinal tissue: Using the same basic procedure as detailed for
striatal tissue, the following modifications were made for experiments
with retinal tissue:
1) After killing the rats both the eyes were removed and placed in
ice cold Krebs solution. The eye ball was pierced and cut in half,
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using fine iridectomy scissors, just behind the cornea. The half
containing the retina was held with a fine pair of forceps, turned
inside out, and the retina gently teased off. The retina was pre-
incubated in Krebs solution at 37°C for 10 min before superfusion.
Both the retina from each animal were used for one experiment.
2) At the end of the experiment, the tissue was removed, homo¬
genized, centrifuged, and the supernatant used directly for DA and
DOPAC estimation without dilution.
3) The flow rate of the Krebs solution used was approximately
150ul/min.
4) During attempts to induce DA release with light stimulation,
the dissection procedure was carried out with greatly reduced back¬
ground light. The superfusion chambers were enclosed in a black
cardboard box, with a window which was opened only during the light
stimulation periods. A Xenon tube stroboscope placed 45 cm from
the superfusion chambers, flashing at 2-3Hz for 2 min, was used as the
light stimulus.
D) Cockroach salivary glands:
1) Both adults and nymphs of Nauphoeta cinerea (Olivier) were used
^University of Edinburgh, Veterinary School).
2) After excising the legs, wings and antennae, the cockroaches
were pinned (through the head and abdomen) onto a pad of silicone
gel, under some ice cold Ringers solution. By making cuts along both
sides of the body, the dorsal exoskeleton (tergum) was removed (from
3-4 segments of abdomen and thorax) and the gastrointestinal tract
pinned to one side of the body. The salivary glands, visualized under
the dissecting microscope, were then carefully lifted by holding the
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salivary reservoirs, detached from the gut, dissected free and placed
in Ringers solution for about 20 min (room temperature).
3) Four glands were used for each experiment, placed in the
modified tissue holder (see chamber modification for median eminence
tissues) and superfused with oxygenated Ringers solution at room tem¬
perature, at a flow rate of 150|il/min. The rest of the superfusion and
stimulation procedures were the same as those used for striatal tissues.
4) At the end of the experiments, the tissues were removed and
homogenized and centrifuged as described previously, and the super¬
natant used directly for DA estimation.
Conditions of superfusate analysis
All superfusate samples were collected on ice, into Eppendorf
tubes (1.5 ml capacity) at 2 min intervals, using a fraction collector.
7ul of a protective solution containing 1M HC1, ImM EDTA, 1 nM
Ascorbate and 2 n g/ml of an internal standard was added to each tube
before the onset of collection. The internal standards used were N-
acetyl dopamine (nADA) or dihydroxybenzyl amine (DHBA). During
experiments with cockroach salivary glands, only DHBA was used as
the internal standard.
Recovery of the internal standard was calculated by measuring
the flow rate and then working back from the peak height of the
authentic standards (injected at the start and end of each experiment)
and the dilution factor to give an expected peak height for the internal
standard. Only results with a greater than 90% recovery were included,
corrections for recovery were not made. Superfusate samples were
kept at 0°C, and were always analysed on the same day.
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2. 5 Other methods
Kainic acid (KA] and 6-hydroxydopamine (6-OHDA) lesions
Rats (200 g male, albino Wistars) were anaesthetized with
Equithesin (1 ml injected i.p., approximate duration 3-4 h) and
placed in a stereotaxic frame.
2ug of KA (Sigma) in 0.2|il of saline (pH adjusted to 7.4) was
unilaterally injected into the striatum. The injection was made over
4 min from a Hamilton syringe (lul), attached to a 30-gauge needle,
the needle was left in place for a further 5 min to prevent reflux.
The injection co-ordinates were as follows:
1.0 mm anterior to bregma
2.8 mm lateral to bregma
5.0 mm ventral from brain surface
After pretreatment of the animals with pargyline (50 mg/kg)
and desmethylimipramine (25 mg/kg, Geigy Pharmaceuticals) for 30
min, using the same procedure as above, 8ugof 6-OHDA (containing
0.5 mg/ml ascorbic acid) was injected into the lateral hypothalamic
area in the region of the Medial Fore-brain Bundle. The co-ordinates
for the injection site were:
3.6 mm posterior to bregma
1.0 mm lateral to bregma
8.5 mm ventral from the skull surface
Behavioural assessment of the lesions
Seven to 14 days after the operation, the animals were challenged
with apomorphine (MacFarlane Smith Ltd.) to determine turning response
to the drug. This was done by placing the rats in a hemispherical
plastic bowl, 18 in. in diameter and attaching them to a spring by a
length of bandage. The spring was attached to automatic counters
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(rat rotameters, see Ungerstedt and Arbuthnott, 1970), counting
the number of revolutions made by the rat, in each direction, over
a fixed period of time.
The 6-OHDA lesioned animals were given 0.3 mg7kg apomorphine
(dissolved in saline + 10uM ascorbic acid) i.p. A response of 200 or
more turns, contralateral to the lesioned side, in 45 min was taken to
be indicative of a successful lesion.
KA lesioned animals were given 2 mg/kg apomorphine and 50 or
more turns, ipsilateral to the lesioned side in 30 min was suggestive
of a successful lesion.
A 2 to 7-day rest period was allowed before the animals were
used for superfusion experiments after this behavioural assessment.
Histology of the KA lesion site
After removing a slice of brain for the superfusion experiment,
the rest of the brain was frozen and mounted on a cryostat chuck for
sectioning. 20-40|iM slices were cut and melted onto glass slides and
stained by a modification of the Kluver and Barrera technique to
visualize mylenated fibres and cell bodies.
The procedure is listed below:
a) Dehydrated in 70% alcohol for 5 min.
b) Dehydrated in 95% alcohol for 5 min.
c) Stained for 30 min in a 95% alcohol solution containing 1 mg/ml
Luxol Fast Blue (BDH Chemicals Ltd.) and 5pl/ml of 10% acetic
acid.
d) Rinsed in 95% alcohol to remove excess stain.
e) Rinsed in distilled water.
f) Differentiated by immersion in 0.05% lithium carbonate for
10 sec, followed by immersion in 70% alcohol for 30 sec. The
differentiation steps were repeated four or five times until a
clear distinction was seen between the blue stained white matter
and the colourless grey matter.
g) Washed in distilled water and transferred to a solution con¬
taining 0.1% Cresyl Fast Violet (Fluka) in distilled water for 5 min.
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h) Rinsed in distilled water.
i) Dehydrate in changes of 70%, 95% and 100% alcohol,
5 mm each.
j) Cleared in Xylene for 10 min.
k) Coverslipped using DPX (BDH Chemicals Ltd.)
The slides were then examined under a light microscope.
Collection of portal blood and alumina extraction
Portal blood was collected by the method of Worthington (1964)
(as modified by Fink and Jamieson, 1976), spun down for 10 min at
2000 rpm, and the plasma aliquoted (50-lOOnl samples) into tubes con¬
taining 10ul of a ImM ascorbic acid and 10 ng/ml nADA solution. The
tubes were stored at -70°C. For analysis the plasma was thawed, the
proteins precipitated by adding 30jil of 1M trichloroacetic acid, and
spun at 12,000 rpm for 5 min. 50ul of ImM sodium thiosulphate was
then added to the supernatant followed by approximately 25 mg of acid
washed alumina (Bioanalytical Systems). To this was added 500|il of
1M Tris buffer (pH adjusted to 8.6) and the tubes shaken for 15 min
in a cold room. After allowing the alumina particles to settle, the
supernatant was aspirated off and the alumina washed four times, twice
with O.lmM Tris buffer and twice with distilled water. The alumina
was then dried in a vacuum desiccator after which the catecholamines
were eluted into 60|il of 0.5M HC1. After shaking for 5 min in the cold
room, the tubes were spun for 30 sec, to settle the alumina. The
supernatant was then injected into the HPLC-ECD to measure DA, etc.
2.6 Materials
All chemicals used were "Analar" grade, from British Drug House.
The radiolabelled DA used was: 1) [ 3H-7]-Dopamine , New England
Nuclear (20-40mCi/mM for experiments described in 3.1);
64.
2) [3H-7,8]-Dopamine, Amersham (30-50Ci/mM for all other experi¬
ments).
Unless otherwise stated, all drugs, catecholamines and their
metabolites were obtained from the Sigma Chemical Company. The
following compounds were generously donated by the parties mentioned:
1. LY5953A, Eli Lilley and Co.
2. Nomifensine, Hoechst Pharmaceuticals.
3. 3-(3-hydroxyphenyl)-N-n-propylpiperidin hydrochloride,




3.1 Identity of the DA peak
In order to confirm that the peak eluting at the retention time
of authentic DA, from tissue homogenates or superfusate samples,
was actually DA several tests were carried out.
(a) U.V. Spectrophotometry
Connecting the outflow of the ECD cell to a spectrophotometer
cell, as described in Chapter II, 2.3.1, allowed the simultaneous
measurement of the electrochemical signal and the UV absorbance of
the compound. This set-up could be used successfully only if large
doses of standards were injected. Compounds like tyrosine, tyramine
and octopamine (redox potentials greater than +0.8V) could be detected
by spectrophotometry but not by ECD (set at a working potential of
+0.65V). It was not possible to simultaneously measure catecholamines
from tissue homogenates with any degree of accuracy, as spectro¬
photometry proved to be about four orders of magnitude less sensitive
than ECD (see Figure 3.1).
(b) Gas Chromatography with Mass Spectrometry (GCMS)
The supernatants of tissue homogenates were simultaneously
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FIGURE 3.1: Simultaneous detection of catecholamines, their precursors
and metabolites by:
Top inverted trace = U.V. spectrophotometry at 280nM
Bottom trace = Electrochemical detection at +0.65V.
A:
B :
An injection (at point marked by arrow) of standards under
standard chromatographic conditions (see page 47 for details)
An injection of striatal tissue extract.
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(c) Alteration of chromatographic conditions
The supernatant of homogenates of striatal tissue was analysed
by HPLC-ECD under different chromatographic conditions (see Figure 2.6,
3.2). The results, tabulated below, show that changes in the
chromatographic condition did not alter the observed DA and DOPAC
content of the tissues. The retention time of DA and DOPAC in the














6.75 94.2 ± 3.8
(n=6)
10.0 4.8 ± 0.4
(n=6)
pH = 3.5, rest as
above
7.0 89.4 ± 4.0
(n=4)









12.5 96.8 ± 5.1
(n=4)
10.5 6.1 ± 0.8
(n=4)
(d) Alumina extraction
Striatal slices, superfused with Krebs solution were stimulated
once with 25mlV! K+ Krebs, as described in Section 2.2. The superfusate
sample collected during the stimulation period (i.e. 16 min from the
onset of superfusion) was first analysed by HPLC-ECD to determine
the DA and DOPAC content. DA and DOPAC were then extracted from
the rest of the supernatant using acid washed alumina (see page 62).
The eluent of the alumina extracts was injected into the HPLC-ECD,
and the total DA and DOPAC content of the superfusate determined
after correction for the recovery. The DA and DOPAC content of the


















FIGURE 3.2: Comparison of the retention times of authentic standards
and striatal tissue extracts for dopamine and DOPAC
(see also Figure 2.6).
1 = dihydroxybenzylamine
2 = dopamine
3 = dihydroxyphenylacetic acid (DOPAC)
At A, A' standard chromatographic conditions were used (see page 47)
A = standards - 1 ng of each.
A' = striatal extract, diluted 1 in 10 after homogenization in 1 ml,
using approximately 15 mg wet weight of tissue, 20|il injection
volume (see page 56).
At B, B' the methanol content of the buffer was reduced to 5%.
B = standards, as above.
B' = striatal extract, as above.
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Alumina extract
ng/mg protein Direct analysis (corrected for recovery)




No significant difference was found between the two sets of values.
(e) Chemical composition of released tritium
Striatal tissue, preincubated with 3H-DA (20pl of [3H-7]-dopamine) .
was stimulated once with a 2 min pulse of 35mM K + . The supernatant
fractions were then analysed as follows:
1. DA overflow by HPLC-ECD, in 20pl of the superfusate.
2. Total 3H overflow. Expressed as a fractional rate constant
X100, i.e. [release 3H (cpm) -5- total 3H (cpm) left in tissue & superr&t&it
at the start of the respective 2 min collection] X100.
3. The HPLC eluent from 1. was collected at 1 min intervals and
the radioactivity determined in each sample.
The results are shown in Figure 3.3. 1) A 2 min pulse of 35mM
K+ greatly enhanced the overflow of DA as measured by KPLC-ECD
and as total 3H overflow, concomittantly. 2) The radioactivity profile
of the HPLC separation shows that during the stimulation period,
most of the 3H released coelutes with the DA peak. Expressing the
amount of radioactivity under the DA peaks as a percentage of the
total radioactivity in the sample, showed that basal overflow (1.4 ±
0.1% fractional overflow) consisted of 15 ± 3% 3H-DA; during stimulation
with 35mM K + , the 13 ± 1% fractional overflow of 3H consisted of
72 ± 8% 3H-DA. Changes in the overflow of 3H-DOPAC were not












FIGURE.3.3: Striatal tissue preincubated with 3H-DA was stimulated
once with a 2 min pulse of 35mM K + . The superfusate
was analysed for its DA content by HPLC-ECD and its 3II content by
liquid scintillation counting.
A = comparison of the DA overflow (expressed as nA in 20gl of super¬
fusate) and total 3H overflow (expressed as % fractional release).
Vertical bars show s.e.m. (only sem >15% are shown). The overflow
of both DA and 3H is simultaneously and rapidly increased by
35mM K+ Krebs.
B = Radioactive (3H) profile of an HPLC separation of the superfusate;
sample taken during superfusion with 35mM K +
1 = Dihydroxybenzylamine - internal standard
2 = Dopamine
3 = Dihydroxyphenylacetic acid (DOPAC)
More than 70% of the 3H present in the sample co-elutes with
dopamine.
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phenyl ring and so may have been lost during deamination with MAO
(Starke et al., 1980), as indicated by the 3H associated with the
solvent front.
3.2 K+ induced overflow of DA from superfused striatal slices
Experiments carried out to investigate the K+ induced overflow
of DA/DOPAC, and its alteration by physiological or pharmacological
manipulation are described in this section.
Unless otherwise stated, striatal slices (approximately 0.3 x 0.3 x
1 mm) superfused with oxygenated Krebs at 37°C, at a flow rate of
approximately 350|il/min were stimulated twice with 25mM K+ at 16 and
56 min from the onset of superfusion. Drugs were added 30 min after
onset of superfusion (i.e. before S2) to allow a comparison between
drug induced effects at S2 and the internal control Sx. All results
were calculated according to the following equation (as demonstrated
in Appendix I):
ng/mg protein/2 min =
peak height flow rate/2 min 1
—. . r-—x amount of standards x t—:—— : x —:—
peak height of injection volume proteins
standards
(a) 25mM K + induced overflow of DA and DOPAC. Control
Basal overflow: during incubation with Krebs solution, the initial
basal overflow of DA was found to be 0.08 ± 0.02 (range 0.29 to >0.02)
ng/mg protein/2 min (mean is.e.m., n=8). The initial basal overflow
of DOPAC was found to be much higher, i.e. 0.65 ± 0.05 (range 1.05
to 0.42) ng/mg protein/2 min. The basal release of DOPAC 50 min
after start of superfusion, i.e. before the second stimulation, S2, was
found to be significantly higher, i.e. 0.96 ± 0.08 ng/mg protein/2 min
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(p <0.05, two-tailed, paired student "t" test, see Figure 3.5), but
the DA basal overflow did not differ from that at St.
Evoked overflow: as shown in Figure 3.4, the evoked overflow
of DA, induced by a 2 min pulse of high K+ Krebs, was complete
(>95%) within 6 min of the onset of stimulation, i.e. 3 sample times.
The K+ induced overflow of DA was, therefore, estimated as the total
increase (above basal overflow) in DA overflow during these 6 min,
and found to be 6.3 ± 0.4 (range 4.34 to 7.85) ng/mg protein during
the first stimulation (S^. A second 2 min pulse of 25mM K + , S2,
consistently induced an approximately 20% higher overflow of DA, i.e.
7.7 ± 0.6 (range 10.4 to 5.8) ng7mg protein.
DOPAC overflow after K+ stimulation showed a slower rate of
increase and decline. The increase in DOPAC, during the 6 min after
the onset of stimulation, was used to compare changes in the evoked
overflow of DOPAC. Hence the increase in DOPAC overflow during 25mM
K+ stimulation was taken as 2.24 ± 0.14 (range 3.06 to 1.8) ng/mg
protein during Sx and 3.69 ± 0.28 (range 5.02 to 2.62)ng/mg protein
at S2. The difference was significant at the p <0.05 level by a two-
tailed, paired student "t" test (see Figure 3.5).
(b) Ca++ dependence
Substituting O.lmM EGTA for calcium chloride in the Krebs
solution during the second stimulation, S2, with 25mM K+ Krebs,
resulted in the complete inhibition of the stimulation evoked increase
in the overflow of DA and DOPAC as shown in Figure 3.6.
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FIGURE 3.4: Striatal slices superfused with Krebs solution were
stimulated twice, at Si and S2, with a two-minute pulse
of 25mM K + . Two-minute fractions of the superfusate were collected
and analysed for their DA and DOPAC content by HPLC-ECD. The
results are shown below: and expressed as ng DA or DOPAC/mg protein
in each fraction (vertical bars show s.e.m., n=8). A summary of the
















n = 8 FIGURE 3.5: Summary of the results of
two (Sx and S2) 2 min
pulses of 25mM K+ Krebs, shown in detail
in Figure 3.4.
Each pair of histograms represent the
basal and the evoked (25mM K+) overflow
of DA and DOPAC in that order (vertical
bars = s.e.m.). The basal overflow of
DOPAC and the evoked overflow of both
DA and DOPAC were significantly higher
at S2 when compared to the internal control
Si (* = p <0.05, two-tailed, paired Student
Tt' test).
For this and subsequent diagrams the
basal overflow was calculated as the average
overflow of DA/DOPA found during the
6 min before the onset of stimulation,
i.e. between 10-16 min for Sx and 50-56
min for S2 from the onset of superfusion.
Hence, basal overflow measurements are
shown as ng DA or DOPAC/mg protein/
2 min.
The evoked overflow of DA/DOPAC was
taken as (see text) the total amount of DA/
DOPAC during the 6 min after the onset of
stimulation minus the basal overflow and






FIGURE 3.6: Histograms showing the DA and DOPAC content of the
superfusate from striatal tissue, superfused with normal
Krebs solution and stimulated with a 2 min pulse of 25mM K+ Krebs at
Si and then superfused with Ca++ free Krebs (starting 30 min after the
onset of superfusion) and again stimulated with 25mM K+ (Ca++ free)
Krebs at S2 (n=3). Omission of Ca + + from the Krebs and 25mM K +
Krebs solution abolished the 25mM I<+ induced increase of DA and DOPAC
overflow. A small ongoing increase in the basal overflow of both DA and
DOPAC was noted in the absence of Ca++.
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(c) Potassium concentration
Striatal slices (approximately 16 mg wet weight) superfused
with Krebs solution (325|il/min), were stimulated once each with 15,
25, 35 or 50mM K+ for 2 min. The results, calculated as above, are
shown in Figure 3.7. The large increase in DA overflow with in¬
creasing K+ concentration is accompanied by a smaller increase in
DOPAC overflow.
(d) Influence of muscarinic agents on DA and DOPAC overflow
i) Indirectly acting muscarinic agonists:
In order to evaluate the influence of cholinergic agents on DA
overflow, acetylcholine esterase inhibitors were used to see the effect
of increased endogenous ACh release on the overflow of DA.
Physostigmine added 30 min after the onset of superfusion
resulted in a dose dependent increase in the overflow of DA evoked
by a 2 min pulse of 25mM K+ at S2. Using the first stimulation, Sl5
as an internal control, the results were expressed as the ratio Sj/Sj..
The control, S2/Sx, for DA was found to be 1.20 ± 0.04 (n=10, range
1.49 to 0.94) and 1.74 ± 0.12 for DOPAC (n=10, range 2.58 to 1.31).
Addition of lyM physostigmine elevated the evoked overflow of both
DA and DOPAC as indicated by the increased S2/Sx ratios for DA,
2.19 ± 0.17 (n=6, range 1.75 to 2.86) and for DOPAC, 2.88 ± 0.10
(n=6, range 2.68 to 3.22). The dose-response relationship for
physostigmine is shown in Figure 3.8.
Neostigmine (l|iM) similarly increased the ratios for the
evoked overflow DA to 2.23 ± 0.09 (n=8, range 1.91 to 2.69) and
DOPAC to 2.38 ± 0.10 (n=8, range 2.14 to 3.05). The addition of

































FIGURE 3.7: Striatal slices superfused with Krebs solution were
stimulated once with a two-minute pulse of 15, 25, 35
or 50mM K + . The evoked overflow of DA and DOPAC (calculated as in
Figure 3.5) is plotted against the K+ ion concentration (vertical bars =
s.e.m.; s.e.m.'s smaller than figure notations are now shown. n=4).
The very large difference in the increase of DA overflow between 15
and 50mM K+ stimulation was accompanied by only a small difference in the
DOPAC overflow.
P >0.05, Student 't' test, two-tailed, show differences from the over¬
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FIGURE 3.8: The dose/response relation for physiostigmine.
Striatal slices superfused with Krebs solution were
stimulated with 25mM K+ at 16 min from the onset of superfusion as the
internal control, Si. At 30 min, physiostigmine (0.01 to lOgM) was
added to the superfusing Krebs solution and the slices stimulated again
with 25mIVl K+ at 56 min for the test S2.
The ratio of the test stimulation S2 to the internal control Si for the
evoked overflow of DA and DOPAC is shown above (vertical bars =
s. e. m. , n=3-6).
Physiostigmine dose dependently enhanced the 25mIVl K+ evoked overflow
of DA, as indicated by the increase in the S2/Si ratios for DA. Similarly,
DOPAC overflow was also enhanced by physiostigmine, indicating an
increased synthesis of DA (see later). The basal overflow of DA and
DOPAC was not affected by physiostigmine. +- p <0.05, Wilcoxon rank
test, indicates values significantly different from control.
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did not alter the response of neostigmine (see Figure 3.9). Atropine
(lpM) added with neostigmine, however, abolished the facilitatory
effect of neostigmine on DA and DOPAC overflow. Atropine (l|iM)
added alone reduced DA and DOPAC overflow, the S2/Sx ratios being
0.85 ± 0.10 (n=4, range 1.14 to 0.65) for DA and 1.45 ± 0.15 (n=4,
range 1.95 to 1.19) for DOPAC.
ii) Directly acting muscarinic agonist:
Addition of ACh (100|iM) to the Krebs solution before S2
similarly increased the S2/Sx ratios for both DA and DOPAC to 1.68 ±
0.16 (n=4, range 1.38 to 2.07) and 1.97 ± 0.07 (n=4, range 1.82 to
2.13) respectively. The effect of ACh was further increased at ImM
and could be abolished by the simultaneous addition of atropine (lpM)
(see Figure 3.10).
None of the above mentioned drugs altered the basal overflow of
either DA or DOPAC at any stage.
In an attempt to reduce ACh release, hemicholinium-3 (HC-3)
(5jiM) was added to striatal slices from the start of the experiment.
However, these experiments had to be abandoned as despite an in¬
creased DA overflow on stimulation with 25mM K + , the metabolism of
DA appeared to be drastically altered. Several unidentified peaks
appeared replacing the DOPAC peak, making measurement of DA over¬
flow difficult and casting doubt on the relevance of changes in DA
overflow (see Figure 3.11).
(e) KA lesion
The 25mM K+ evoked overflow of DA and DOPAC from KA lesioned
rats, from both the lesioned and unlesioned sides (superfused separately
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FIGURE 3.9: The effect of cholinergic antagonists on the facilitation
of DA and DOPAC evoked overflow induced by neostigmine.
As in Figure 3.8, neostigmine (lpM) added 30 min after the onset of
superfusion, enhanced the 25mM K+ evoked overflow of DA ana DOPAC,
indicated by the increases in the S2/Si ratios.
The nicotinic antagonists, gallamine (lpM) or tubocurarine (lpM) added
with the neostigmine, failed to alter the response of neostigmine. The
muscarinic agonist, atropine (lpM) added with neostigmine completely
abolished its effects.
Atropine (lpM) added alone reduced slightly the overflow of DA. This
indicates that a stimulation of muscarinic presynaptic receptors facilitates
the release and synthesis of DA (see later), t - values significantly
different from control, p <0.05, Wilcoxon Rank test (as with all diagrams,
vertical bars = s.e.m.).
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Control ACh 10_4M ACh 10"3M ACh10"4M
+
Atropine 10~6M
FIGURE 3.10: Facilitation of the evoked overflow of DA and DOPAC
by acetylcholine, and its inhibition by atropine.
As in Figure 3.8, ACh (O.lmM) added to the Krebs solution at 30 min,
enhanced the 25mM K+ evoked overflow of DA and DOPAC at S2. Hence
the S2/Si ratios were significantly increased. ACh (ImM) further
enhanced the overflow of DA and DOPAC.
The facilitatory effects of ACh (O.lmM) on the evoked overflow of DA
and DOPAC were abolished by the simultaneous addition of atropine
(lgM), again indicative of a muscarinic receptor mediated effect.






FIGURE 3.11: Comparison of HPLC-ECD traces obtained during
a 25mM K+ induced release from a control experiment,
and in the presence of hemicholinium-3.
A = Standards, 0.2 ng, N-acetyldopamine was used as the interna]
standard.
B = A 20|il injection of the superfusate of a control experiment,
collected during a 25mM K+ stimulation at 56 min (i.e. S2).
C = A 20|il injection of the superfusate during an experiment con¬
ducted in the presence of hemicholinium-3 (present from the start
of superfusion). The superfusate was collected during a 25mM
I\+ stimulation at 56 min (i.e. S2).
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controls (see Figure 3.12). The lesion site was confirmed by behav¬
ioural tests (see page 60) and histologically (see Figure 3.13).
Although the lesions were extensive this did not appear to interfere
with the response to neostigmine (l|iM) added 20 min before S2
(see Figure 3.12).
(f) Effect of uptake inhibitors on 25mM K + induced overflow of DA
Addition of nomifensine (l|iM) before S2 did not alter either the
































(g) Comparison between DA and 3H overflow
i] Simultaneous DA and 3H overflow induced by 25mM K +:
Striatal slices were preincubated with 3H-DA (4|il of [3H-7,8]~
dopamine 47Ci/mM) before the onset of superfusion. The slices were
stimulated twice (Si and S2) with 25mM K + , as above. The super-
fusate was analysed as follows: 1) a 20pl sample was injected into
the HPLC-ECD to measure DA and DOPAC; 2) 500|il of the super-
fusate was added to 8 ml of scintillant and its 3H content determined





























FIGURE 3.12: Unilaterally, kainic acid lesioned animals, were tested
behaviourally and histologically (see Figure 3.13) for
successful lesions. The lesioned and unlesioned striata from each
animal were superfused separately with Krebs solution, and stimulated
twice with 25mM K + . Neither the basal (not shown) nor the evoked
overflow of DA or DOPAC (above) at Si or S2 differed from control
animals (see Figure 3.5), from both the lesioned and the unlesioned sides.
The addition of neostigmine (l|iM) 30 min after the onset of superfusion
greatly enhanced the overflow of both DA and DOPAC at S2 , from both
the lesioned and the unlesioned sides.
(vertical bars = s.e.m.)
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FIGURE 3.13: Histology of the kainic acid lesion site. After cutting
the slice of brain required for the superfusion experi¬
ments, the remainder of the brain was frozen, sectioned and stained
(as on page 61) and examined under a light microscope. The lesion
site was usually visible with the naked eye, as the low power photo¬
graph above shows....
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The basal and evoked overflow of DA did not differ from experi¬
ments carried out in the absence of 3H-DA (see Figure 3.14). The
evoked overflow of DA was 6.6 ± 0.5 (range 8.25 to 4.2) ng/mg
protein (n=8) at S i and 8.5 ± 1.2 (range 10.64 to 4.47) ng/mg protein
at S2, giving an S2/Si ratio of 1.29. Although the basal overflow of
DOPAC did not differ from experiments carried out in the absence of
3H, there appeared to be a greater evoked overflow of DOPAC at Si,
i.e. 3.38 ± 0.35 (range 5.46 to 2.11) ng/mg protein, but a near control
level at S2, i.e. 3.61 ± 0.71 (range 5.88 to 2.11) ng/mg protein
reducing the S2/Sx ratio for DOPAC to 1.07 (cf. 1.74, page 71 and
Figure 3.5).
The evoked overflow of 3H (expressed as fractional release X
100, as before) at Sx was found to be 17.0 ± 1.3% (n=8, range 23.9 to
11.4%) and 14.7 ± 2.1% (n=4, range 19.9 to 8.41%) at S2, giving an
S2/Sx ratio of only 0.87 (see Figure 3.14). Hence, while the overflow
of endogenous DA was higher at S2, the overflow of 3H was lower at
S2, compared to Sx.
ii) The influence of neostigmine on the 3H and DAJDOPAC
overflow:
Addition of neostigmine (lpM) 26 min before S2, markedly
increased the overflow of both DA (14.28 ± 0.45, range 14.07 to 15.65
ng/mg protein) and DOPAC (8.63 ± 0.6, range 7.09 to 10.36 ng/mg
protein) giving S2/Sx ratios of 2.16 for DA and 2.39 for DOPAC.
There was, however, a more modest increase in the overflow of 3H to
21.6 ± 1.6% (n=4, range 17.28 to 25.37) which was not statistically
different from control, giving a S2/Sx ratio of 1.27 (see Figure 3.14).
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FIGURE 3.14: Comparison of the evoked overflow of endogenous
DA and DOPAC with the simultaneous overflow of 3H.
The 25mM K+ evoked overflow of endogenous DA and DOPAC at both
Sx ana S2 did not differ from experiments carried out in the absence
of 3H-DA preincubation (see Figure 3.5). Neostigmine (lglVI) added
to the Krebs solution 30 min after the onset of superfusion enhanced
the overflow of both DA and DOPAC to the same extent as in the absence
of 3H-DA preincubation (see Figure 3.9 - S2/Sx ratio here being 2.16 ±
0.17 for DA and 2.39 ± 0.16 for DOPAC).
The fractional overflow of 3H at S2 was lower than that at Sx (S2/Sx
ratio = 0.87) and in the presence of neostigmine the overflow of 3H
increased slightly but not significantly to give an S2/Sx ratio of 1.27.
Hence, while there was a more than twofold increase in the evoked
overflow of endogenous DA, the simultaneous measurement of 3H over¬
flow only showed a marginal increase (about 30-40%).
(* p <0.05, Student 't' test, two-tailed)
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3.3 Overflow of DA induced by electrical stimulation
(a) Electrical stimulation. Control.
The effect of electrical stimulation (biphasic, square wave pulses
of 8-10mA amplitude 2mSec duration, at 20Hz for 30 sec) on striatal
slices superfused with Krebs solution is shown in Figure 3.9. The
results of evoked overflow are, as with K+ stimulation, expressed as
the increase above basal overflow during the 6 min (3 sample times)
after the onset of stimulation. The basal overflow of both DA and
DOPAC was the same as that described for K+ stimulation (see Figure
3.9 and 3.15). Two stimulations, at 16 min (Sx) and 56 min (S2) from
the start of superfusion were applied. The increase in DA overflow
at Sls was found to be 0.44 ± 0.08 (range 0.8 to 0.21) ng/mg protein
(means ± s.e.m., n=8), the increase in DOPAC overflow was 2.75 ±
0.20 (range 3.68 to 1.58) ng/mg protein (see Figure 3.16). Hence
while there was a much smaller increase in the evoked DA overflow,
DOPAC overflow was similar to that observed during 25mM K+ stimula¬
tion, (c.f. Figures 3.5 and 3.16).
At S2 there was significantly larger overflow of DA, 0.74 ± 0.08
(range 0.92 to 0.24), ng/mg protein giving an S^Si ratio of 1.80 ±
0.20. The evoked overflow of DOPAC as S2, 2.93 ± 0.18 (range 3.42
to 1.78) ng/mg protein, did not differ significantly from that of Sx.
The ratio of S2/Sx for evoked DOPAC was 1.08 ± 0.04 during electrical
stimulation, compared to 1.74 ± 0.12 observed during K+ stimulation
(see Figure 3.16).
The DA and DOPAC content of a sample of striatal slices, taken
at the end of the preincubation period (before the start of superfusion),
was found to be 94.2 ± 3.8 ng/mg protein and 4.8 ± 0.4 ng/mg protein
respectively. At the end of the superfusion experiment, these values
89.
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FIGURE 3.15: Striatal slices superfused with Krebs solution were
stimulated twice, at Si and S2, electrically. The
stimulation parameters were (as with all the other experiments, unless
otherwise stated):
2msec pulse duration, 8-10mA amplitude, 20Hz for 30 sec.
The superfusate was collected as 2 min fractions into tubes containing
an internal standard and a protective solution. 20-50pl of the super¬
fusate was used for an HPLC-ECD determination of DA and DOPAC.





FIGURE 3.16: A^_ Summary of the control electrically evoked overflow
of DA and DOPAC (from Figure 3.15). Each pair
of histograms at Si and S2 shows the basal and evoked overflow of DA
and DOPAC, for this and all subsequent figures (calculated as in
Figure 3.5).
The basal overflow of DOPAC and the evoked overflow of DA at S2
were significantly higher than at Sx (**p <0.05, two-tailed, paired
Student 't' test).
B. Summary of basal and electrically evoked overflow
of DA and DOPAC from striatal tissue superfused
with Krebs solution containing lpM LY5953A from the start of super-
fusion. While the basal overflow of DA and DOPAC at Si and S2 was
not different from control, the evoked overflow of DA was markedly
enhanced. DOPAC evoked overflow at Si did not differ from control,
but at S2 it was significantly lower (*p <0.05, two-tailed student *t'
test).
Ratio of S,/Si
Control DA: 1.80 ± 0.20 DOPAC: 1.08 ± 0.04
LY5953A (l|iM) DA: 1.23 ± 0.06 DOPAC: 0.91 ± 0.08+
(tp <0.05, Wilcoxon Rank test)
DA /DOPAC content of striatal tissue (ng/mg protein, mean ± s.e.m.)
From tissue taken before the start of superfusion.
Start DA: 94.2 + 3.8 DOPAC: 4.8 ± 0.4
From tissue taken at the end of experiments.
Control DA: 176.3 ± 6.9* DOPAC: 8.6 ± 0.6*
LY5953A (ljiM) DA: 190.7 + 11.6* DOPAC: 7.1 + 1.6*
(* p <0.05, two-tailed Student 't' test)
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were about twofold higher, i.e. DA was found to be 176.3 ± 6.9 ng/mg
protein and DOPAC was raised to 8.6 ± 0.6 ng/mg protein (n=8).
(b) Tetrodotoxin and Ca++ dependence
The evoked overflow of both DA and DOPAC at S2 was reduced
by more than 75% to 0.15 ± 0.05 and 0.22 ± 0.06 (n=4) ng/mg protein
respectively in the presence of tetrodotoxin (TTX, added to Krebs
solution 26 min before S2). Addition of TTX (IpM) did not have any
significant effect on the basal overflow of either DA or DOPAC. Similar
effects were seen when the tissues were superfused with Ca++ free
(+0.1mM EGTA) Krebs at S2 (see Figure 3.17).
(c) The effect of uptake inhibition on the electrically evoked over¬
flow of DA and DOPAC
Addition of the uptake inhibitor LY5953A (l|iM) increased the
basal overflow of DA by twofold from that seen in the absence of drugs
to 0.16 ± 0.02 ng/mg protein/2 min, there was, however, no significant
change in the basal overflow of DOPAC. The evoked overflow of DA
at Sx was increased by about four fold to 1.81 ± 0.22 (range 2.66 to
0.95) ng/mg protein (n=6), without any significant change in the
evoked overflow of DOPAC (see Figure 3.16). During S2, the evoked
overflow of DA was 2.32 ± 0.35 (range 3.96 to 1.2) ng/mg protein,
giving an S2/S! ratio of 1.23 ± 0.06. At S2, the evoked overflow of
DOPAC, 2.09 ± 0.23 (range 2.95 to 1.04) ng/mg protein, was signif¬
icantly lower than the control values (see Figure 3.16) giving an S2/Sx
ratio of 0.91 ± 0. 08.
The tissue content of DA at the end of experiments conducted in
the presence of lpM LY5953A, was found to be 190.7 ± 11.6 ng/mg
protein, the DOPAC content was 7.1 ± 1.6 ng/mg protein, and neither
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FIGURE 3.17: A_^ The control basal and electrically evoked overflow
of DA and DOPAC (as in Figure 3.16).
B. Tetrodotoxin (IjiM) was added to the Krebs solution
superfusing striatal slices, 30 min after the onset of superfusion, i.e.
after Si. The presence of TTX did not affect the basal overflow of
either DA or DOPAC before S2, however, the evoked overflow of DA
and DOPAC was reduced by more than 75%.
C. 30 min after the onset of superfusion and after the
control Si, the sfriatal slices were superfused with Ca++ free (+0.1mM
EGTA) Krebs. The basal overflow of DA and DOPAC before S2 remained
unaffected but the evoked overflow of DA and DOPAC at S2 was reduced
by more than 75%.
(* p <0.01, two-tailed, Student 't' test)
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(d) The effect of a unilateral 6-OHDA lesion
Seven to 14 days after a unilateral 6-OHDA lesion of the striato-
nigral pathway, the rats were tested for a successful lesion by
behavioural analysis. Only rats which turned contralateral to the
lesion site (200 or more turns in 30 min) when challenged with 0.3
mg/kg apomorphine (I.P.), were used. Two to 4 days after the
behavioural analysis, rats were sacrificed and the striata used for
superfusion experiments to study the overflow of endogenous DA/
DOPAC on electrical stimulation (8-10mA, 20Hz, 30 sec). The uptake
inhibitor, LY5953A (l|iM), was added to the superfusing solution
26 min before the onset of S2. The lesioned striatum and the contra¬
lateral control striatum from each animal were superfused in separate
chambers. While the basal and evoked overflow of both DA and
DOPAC from the contralateral striatum did not differ from control
values (see Figure 3.18 and Figure 3.19 cf. 3.16), there was no
detectable or evoked overflow of either DA or DOPAC from the lesioned
striatum, at Sj. or S2 despite the presence of LY5953A (lgM).
fe) Frequency dependence
Striatal slices superfused with Krebs solution (as before) were
stimulated twice at 8-10mA, for 200 pulses at 2, 10, 20 or 50Hz in a
random sequence. These experiments were carried out in the presence
of nomifensine (l|iM) present from the start of superfusion. The
results (calculated as above) averaged at each frequency are tabulated






FIGURE 3.18: The basal and evoked overflow of DA and DOPAC
from the unlesioned side of a unilaterally 6-OHDA
lesioned rat.
At Si, electrical stimulation evoked the overflow of DA and DOPAC
from the unlesioned striatum superfused in Krebs solution, values
were not different from control experiments (see Figure 3.16A).
30 min after the onset of superfusion, l^M LY5953A was added to
the Krebs solution. The basal and evoked overflow of DA/DOPAC






FIGURE 3.19: Comparison of the HPLC-ECD traces of superfusate
samples (collected during S2, i.e. at 56 min) from
A: the lesioned, and B: the unlesioned striatal slices of a unilaterally
6-OHDA lesioned rat. The DA/DOPAC content of superfusate samples
collected during the second electrical stimulation, S2, in the presence
of l|iM LY5953A, are shown above.
1 = Dihydroxybenzylamine, internal standard.
2 = Dopamine.
3 = Dihydroxybenzylamine (DOPAC).
No detectable DA or DOPAC was found in the lesioned side, even
during electrical stimulation (A), while the overflow of DA and DOPAC
from the unlesioned side (B) did not differ from control (see text).
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FIGURE 3.20: A_^ Striatal slices superfused with Krebs solution
containing lpM, nomifensine, were stimulated
twice (Sx and S2) at 2, 10, 20 or 50Hz for 200 pulses (all other
parameters remaining unaltered), in a random sequence. The results
for the evoked overflow of DA were calculated as in Figure 3.5, and
plotted against the stimulating frequency (see table of results on page
96). The evoked overflow of DA, during the 200 applied pulse, ap¬
peared to increase with increasing frequency of stimulation up to 20Hz.
B. Striatal slices superfused with Krebs solution
containing 5pM LY5953A, were stimulated once for
10, 30 or 60 sec at 20Hz (i.e. for 200, 600 or 1200 pulses at 20Hz).
The results of the evoked overflow of DA calculated as in Figure 3.5
were divided by the number of pulses applied and plotted against the
applied number of pulses. The results show that DA overflow per
impulse decreases with increasing number of pulses applied.
(* p <0.05, two-tailed Student 't' test, indicates values significantly
different from those at 20Hz, 200 pulse stimulation.)
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Frequency DA (ng/mg DOPAC (ng/mg
(Hz) protein protein n
2 1.16 ± 0.10* 1.82 ± 0.17 8
10 1.37 + 0.11 1.89 ± 0.19 6
20 1.59 ± 0.13 1.94 ± 0.16 8
50 1.45 ± 0.15 1.95 ± 0.20 6
*Significantly different from values obtained at 20Hz
stimulation (p <0.05 student "t" test, two-tailed).
Keeping the number of pulses constant (i.e. 200), the evoked
release of DA and DOPAC increased from that seen at 2Hz to a maximum
during 20Hz stimulation. Preliminary experiments at 100 or 200Hz
stimulation indicated that the release was not increased with increasing
frequency after 20Hz.
(f) DA overflow per impulse
In order to see the effect on the evoked overflow of DA per
impulse, at a fixed frequency of 20Hz, striatal slices were stimulated
once for 10, 30 or 60 sec. The uptake inhibitor LY5953A (5pM) was
added to the Krebs solution from the start of superfusion. The
results calculated as before, were divided by the number of applied
pulses and expressed as overflow of DA ng/mg protein/impulse. The
results (Figure 3.20) show that the increase in the number of pulses
applied decreases the DA overflow per impulse.
(g) The effect of monoamine oxidase inhibition
Pargyline (l|iM) added to the Krebs solution, 26 min before
S2, reduced the basal overflow of DOPAC before S2 to 0.19 ± 0.02
(range 0.24 to 0.13) ng/mg protein/2 min (n=4, see Figure 3.21).
The overflow of DA in the presence of pargyline was not significantly
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different from control, i.e. 0.63 ± 0.08 (range 0.8 to 0.4) ng/mg
protein, however, the evoked overflow of DOPAC was completely
inhibited. At the end of the experiments, the tissue content of DA
was found to be significantly higher, i.e. 201.3 ±4.0 ng/mg protein.
(h) The effect of 'in vivo' tyrosine hydroxylase inhibition
Rats pretreated with crmethyl-para-tyrosine (AMPT), 25Qmg/kg
(I.P.), for 2 hr were sacrificed and the striata removed and super-
fused as before. The uptake inhibitor, LY5953A (lpM), was added to
the Krebs solution from the start of superfusion. No detectable basal
or evoked overflow of either DA or DOPAC was found. At the end of
the experiments there was no detectable DOPAC in the tissues; DA
content was found to be 40.8 ± 5.2 ng/mg protein (n=3).
(i) The effect of 'in vitro' tyrosine hydroxylase inhibition
AMPT (0.5mM) added to the Krebs solution from the start of
superfusion of striatal slices. Under these conditions, DA basal over¬
flow was found to be below detectable levels in most experiments, and
the basal DOPAC overflow was reduced by about half from control
values to 0.29 ± 0.05 (range 0.41 to 0.15) ng/mg protein (n=4).
A similar reduction was also found in the evoked overflow of DA (0.21
± 0.02, range 0.29 to 0.19 ng/mg protein) at S],. The evoked overflow
of DOPAC at Sx was found to be 0.19 ± 0.03 (range 0.2 to 0.08) ng/mg
protein. Compared to control values, the basal and evoked overflow
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FIGURE 3.21: The basal and electrically evoked overflow of DA
and DOPAC under control conditions, from Figure 3.16.
B. Pargyline (l|iM) added to the Krebs solution 30 min
after onset of superfusion significantly reduced the basal overflow of
DOPAC before, and abolished the evoked overflow of DOPAC, at S2.
The basal and evoked overflow of DA during S2, however, were unaltered.
C. AMPT (0.5mM) added to the Krebs solution from the
start of superfusion, decreased the basal overflow of DA and DOPAC
before Sx. The evoked overflow of DA was also reduced by about 50%,
and the evoked DOPAC overflow at Si was only 6% of control levels.
The basal overflow before S2 was reduced further. At S2 the evoked
overflow of DA was reduced by 70% and that of DOPAC was almost
abolished.













(* p <0.05, two-tailed Student 't' test, indicating values significantly
different from respective control values.)
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(j) The influence of muscarinic agents on the electrically evoked
overflow of DA and DOPAC
i) Indirectly acting muscarinic agonist:
Striatal slices superfused with Krebs solution were stimulated
twice (Si and S2) at 20Hz for 30 sec, as before. Neostigmine (liiM)
and tubocurarine (l|iM) added 30 min after the onset of superfusion,
increased the evoked overflow of DA to 1.95 ± 0.24 (range 3.17 to
1.02) ng/mg protein (n = 10). The evoked overflow of DOPAC was also
increased compared to the internal control (Sx) from 2.10 + 0.17 (range
3.01 to 1.45) ng/mg protein at S to 2.72 ± 0.21 (range 3.82 to 1.72)
ng/mg protein (paired student "t" test, p <0.05). The 83/8! ratio
for DA overflow was found to be 3.71 ± 0.47 and 1.31 ± 0.05 for
DOPAC; these values were significantly different from control by non-
parametric analysis (see Figure 3.22). The basal overflow of DA and
DOPAC remained unaffected by the drugs, but at the end of the experi¬
ment, the tissue content of DA was about 30% less than the control
value, i.e. 133.6 ±6.6 ng/mg protein, with a smaller reduction in the
DOPAC content to 6.8 ± 0.87 ng/mg protein (not significantly different
from control).
Addition of atropine (l|iM) with neostigmine (lpM) before S2
resulted in a significantly smaller evoked overflow of DA, 0.30 ± 0.03
(range 0.4 to 1.8) ng/mg protein (n=7) and DOPAC, 1.36 ± 0.32 (range
3.07 to 0.8) ng/mg protein. While the basal overflow of DA and DOPAC ,
and the DA tissue content at the end of the experiment were not
significantly different from control (see Figure 3.22), the DOPAC
content was lower, i.e. 4.56 + 0.36 (range 5.2 to 3.0) ng/mg protein.
FIGURE 3.22: A^_ The basal and electrically evoked overflow of DA
and DOPAC under control conditions, from Figure
3.16.
B. After the internal control stimulation, Si, neo¬
stigmine (luM) and tubocurarine (luM) was added to the superfusing
Krebs solution (at 30 min). The basal overflow of DA and DOPAC
before S2 remained unaltered. The evoked overflow of DA and DOPAC
was markedly enhanced at S2.
C, After the internal control stimulation, Si, neo¬
stigmine (lpM) and atropine (l|iM) was added to the superfusing
Krebs solution (at 30 min). While the basal overflow of DA and DOPAC
remained unaltered, a reduction in the evoked overflow of DA and
DOPAC was found.
S2/_Si ratios for the evoked overflow of DA and DOPAC
Control DA: 1.80 ± 0.20 DOPAC: 1.08 + 0.04
Neostigmine + 3.71 ±0.47+ DOPAC: 1.31 ±0.05 +
Tubocurarine
Neostigmine + DA. 0>75 + 0.12+ DOPAC: 0.70 ± 0.09 +
Atropine
(tp <0.05, Wilcoxin Rank test)
DA /DOPAC content of tissues at the end of the experiments (ng/mg
protein )
Control DA: 176.3 ±6.9 DOPAC: 8.6 ±0.6
Neostigmine + DA. 133.6 + 6.6* DOPAC: 6.8 ± 0.9
Tubocurarine
Neostigmine + DA. 155.8 + 8.4 DOPAC: 4.5 ± 0.6*
Atropine































ii) Directly acting muscarinic agonists:
Oxotremorine (5|iM) added to the Krebs solution 30 min after
onset of superfusion caused an almost threefold increase in the evoked
overflow of DA at S2, i.e. 2.17 ± 0.27 (range 3.11 to 1.59) ng/mg
protein (n=6). DOPAC overflow at S2 , at 2.76 + 0.25 (range 3.77 to
2.0) ng/mg protein, was 30% higher than that observed at Sx (2.12 ±
0.19, range 3.11 to 1.7, ng/mg protein), giving an S2/S! ratio of
1.31 ± 0.06 (significantly different from control, see Figure 3.23).
The basal overflow of both DA and DOPAC remained at control levels.
As with the indirectly acting muscarinic agents (above), oxotremorine
significantly reduced the DA content (145.8 ±13.4 ng/mg protein) of
the tissue at the end of the experiment, while DOPAC (8.4 ± 1.4 ng/
mg protein) remained unaltered.
Hi) The effect of neostigmine on the overflow of DA and DOPAC
in the presence of the uptake inhibitor, LY5953A:
In order to determine whether the effect of the acetylcholine
esterase inhibitor was due to an increase in the overflow or in the
release of DA, neostigmine (l|iM) was added to the Krebs solution
30 min after onset of superfusion in the presence of an uptake inhibitor.
As described before, LY5953A (lpM) was present from the start of
superfusion. The presence of neostigmine, with the uptake inhibitor
LY5953A further enhanced the overflow of DA at S2 (see Figure 3.24)
to 3.15 ± 0.38 (range 4.13 to 1.74) ng/mg protein (n=6), the evoked
rise in DOPAC overflow was similarly increased to 2.74 ± 0.18 (range
3.73 to 2.44) ng/mg protein at S2. The basal overflow did not differ
from that in the presence of LY5953A alone. As was found in the
absence of uptake inhibitors (see Figure 3.22), the tissue content of































FIGURE 3.23: The basal and evoked overflow of DA and DOPAC
under control conditions, from Figure 3.16.
B. Oxotremorine (Oxot.) (lp.M) enhanced the evoked
overflow of DA and DOPAC at S2 (added again 30
min after start of superfusion). The basal over¬
flow remained unaltered.
C. Nicotine (lpM) enhanced only the basal overflow
of DA and DOPAC before S2 (added at 30 min),
while the evoked overflows remained unchanged.
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DA /DOPAC content of the tissues at the end of the experiments
(ng/mg protein )
Control DA: 176.3 ± 6.9 DOPAC: 8.6 + 0.6
Oxot. DA: 145.8 ± 13.4* DOPAC: 8.4 ± 1.4*
Nicotine DA: 161.0 ± 13.6 DOPAC: 9.4 ± 0.2
(* p <0.05, two-tailed Student *t' test)



































FIGURE 3.24: The basal and evoked overflow of DA and DOPAC
in the presence of LY5953A (lpM), from Figure
3.16.
B. Neostigmine (ImM) added 30 min after the onset of
superfusion in the presence of lpM LY5953A, further enhanced the
evoked overflow of DA and increased the evoked overflow of DOPAC.
The basal overflow remained unaltered.
S7/S1 ratios for the evoked overflow of DA and DOPAC
LY5953A DA: 1.23 ± 0.06 DOPAC: 0.91 ± 0.08
LY5953A +
E)A. 1.95 ±0.13+ DOPAC: 1.24 ±0.07 +
neostigmine
DA /DOPAC content of the tissues at the end of the experiments (ng/mg
protein)
LY5953A DA: 190.7 ± 11.6 DOPAC: 7.1 ± 1.6
LY5953A +
DA: 148.4 ± 5.9* DOPAC: 6.2 ± 0.8
neostigmine
(* p <0.05, two-tailed Student 't' test)
(+p <0.05, Wilcoxin Rank test)
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presence of neostigmine at S2 compared to LY5953A only (see Figure
3.24) while DOPAC remained unaltered.
(k) The effect of a nicotinic agonist
Nicotine (5pM) added to the superfusing Krebs solution 30 min
after the onset of superfusion did not significantly alter the evoked
overflow of either DA or DOPAC (see Figure 3.23). The basal
overflow of DA was increased to 0.23 ± 0.05 ng/mg protein/2 min,
as was the basal overflow of DOPAC to 1.17 ± 0.29 ng/mg protein/
2 min at S 2.
(I) The effect of dopaminergic agents on the evoked overflow of DA
and DOPA C
i) Dopaminergic agonist effects:
The dopaminergic agonist, 3PPP [3-(3-hydroxyphenyl)-N-n-
propylpiperidin] at a dose of 5|iM added to the superfusing Krebs
solution 30 min after the onset of superfusion, decreased the evoked
overflow at S2,of both DA, to 0.35 ± 0.02 (range 0.4 to 0.28) ng/mg
protein (n=4), and DOPAC to 1.87 ± 0.24 (range 2.67 to 1.40) ng/mg
protein. The S2/Sl ratios for both evoked DA and DOPAC in the
presence of 3PPP were significantly different from control (see Figure
3.25). The basal overflow of DA before S2 was unaffected by 3PPP,
however, the basal overflow of DOPAC at the same point was about 30%
higher than control levels (i.e. 1.06 ± 0.14 ng/mg protein/2 min).
The S2/Sx ratio for basal DOPAC was significantly higher than control.
ii) The effect of the dopaminergic agonist, 3PPP in the presence
of an uptake inhibitor:
LY5953A (5uM) present from the start of superfusion greatly
enhanced the basal overflow of DA (to 0.23 ± 0.02 ng/mg protein/2
min) and the evoked overflow of DA, both at Si, i.e. 5.19 ± 0.50
FIGURE 3.25: The basal and evoked overflow of DA and DOPAC
under control conditions, from Figure 3.16.
B. The D2 agonist 3PPP (5|iM) added at 30 min of
superfusion decreased the evoked overflow of DA and DOPAC. The
basal overflow of DOPAC was also enhanced in the presence of 3PPP.
C, Haloperidol (O.OljiM) enhanced the basal overflow
of both DA and "DOPAC. The evoked overflow of DA and DOPAC at
S2 were also larger.
S7/S1 ratios of the evoked overflow of DA and DOPAC
Control DA: 1.80 ±0.10 DOPAC: 1.08 ±0.04
3PPP DA: 0.80 ± 0.09+ DOPAC: 0.77 + 0.06 +
Haloperidol DA: 7.57 ± 0.68+ DOPAC: 1.21 ± 0.02 +
DA /DOPAC content of the tissues at the end of the experiments (ng/mg
protein)
Control DA: 176.3 ± 6.9 DOPAC: 8.6 ± 0.61
3PPP DA: 148.8 ± 2.6* DOPAC 6.23 ± 0.71
Haloperidol DA: 120.3 + 6.16* DOPAC: 11.3 + 0.88
(* p <0.05, two-tailed Student 't' test)
(±p <0.05, Wilcoxin Rank test)
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(range 6.63 to 4.05) ng/mg protein (n=4) and at S2, i.e. 5.80 ± 0.23
(range 6.63 to 5.05) ng/mg protein compared to that seen in the
presence of luM LY5953A (cf. Figure 3.26 and 3.16).
The basal and evoked overflow of DOPAC remained unaltered
from those seen at l|iM LY5953A (see Figure 3.16). However, the
DA content of the tissues in the presence of 5^M LY5953A was
significantly reduced to 138.0 ±9.8 ng/mg protein.
The addition of 5|iM 3PPP at S2, in the presence of 5|iM LY5953A,
reduced the evoked overflow of DA to 4.23 ± 0.57 ng/mg protein (n=4)
and DOPAC to 1.65 ± 0.14 ng/mg protein. The DA/DOPAC content of
the tissues in the presence of 3PPP and LY5953A (both at 5|iM) did not
differ from that seen in the presence of only 5(iM LY5953A (see Figure
3.26).
iii) Dopaminergic antagonist effects:
The addition of haloperidol (O.OluM) before S2 greatly enhanced
both the basal and the evoked overflow of DA at S2 (see Figure 3.25).
The evoked overflow of DA was increased by more than four fold to
3.11 ± 0.5 (range 4.39 to 2.80) ng/mg protein (n=4). Both the basal
and evoked overflow of DOPAC were also increased; the 25% above
control increase in evoked DOPAC raised this value to 3.69 ± 0.38
(range 4.56 to 2.8) ng/mg protein.
As with 3PPP, haloperidol also decreased the tissue content of
DA at the end of the experiment to 120.3 ±6.2 ng/mg protein, however,
in this case DOPAC was raised to 11.3 ± 0.88 ng/mg protein.
Preliminary experiments with higher doses of haloperidol (l|iM)
showed no increase in either the basal or evoked (0.61 ng/mg protein,
n=2) overflow of DA at S2. The basal overflow of DOPAC was greatly


























FIGURE 3.26: A^_ The basal and evoked overflow of DA and DOPAC
in the presence of 5pM LY5953A. The basal and
evoked overflow of DA, both at Si and S2 are significantly higher
(p <0.05, Student *t' test, two-tailed) than in the presence of l|iM
LY5953A (see Figure 3.16).
B. 3PPP (5pM) added at 30 min, enhanced the basal
overflow of DOPXC, in the presence of the uptake inhibitor LY5953A
(5uM).
The evoked overflow of DA and DOPAC at S2 was significantly reduced.
DA /DOPAC content of the tissues at the end of the experiments (ng/mg
protein)
Control DA: 176.3 ± 6.9 DOPAC: 8.6 ± 0.61




(5|iM) + DA: 124.1+ 8.1* DOPAC: 5.9 + 0.8
3PPP ( 5|iM)
(* p <0.05, two-tailed Student 't' test)
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evoked overflow of DOPAC as well (to 4.32 ng/mg protein). Although
basal and evoked DOPAC were greatly increased the overflow of DA
was at about control level. Similarly, preliminary experiments with
low doses of 3PPP showed the opposite effect of the higher doses
(see above) in that DA evoked overflow was markedly enhanced at
S2 to 3.67 ng/mg protein (n=2) in the presence of O.lpM 3PPP.
(m) The long-term (non-stimulated) basal overflow of DA and DOPAC
In order to observe the variation of basal overflow over longer
periods of time, in the absence of applied depolarizing stimuli, striatal
slices were superfused with Krebs solution (as before) for 80 min.
Three superfusate samples from between, 10-20, 40-50 and 70-80 min
of superfusion were analysed for their DA and DOPAC content, as
shown in Figure 3.27.
In the absence of drugs (Figure 3.27), the average DA and
DOPAC basal overflow rose from a mean of 0.10 ± 0.01 (range 0.16 to
0.03) ngDA/mg protein/2 min and 0.50 ± 0.02 (range 0.69 to 0.38)
ngDOPAC/mg protein/2 min during 10-20 min of superfusion to 0.27 ±
0.05 (range 0.65 to 0.10) ngDA/mg protein/2 min and 0.97 ± 0.10
(range 2.03 to 0.76) ngDOPAC/mg protein/2 min during the 70-80 min
of superfusion. At the end of the experiment the DA/DOPAC content
of the tissues was found to be 173.2 ±5.2 and 4.6 ± 0.25 ng/mg
protein respectively, and hence, was not different from control.
During preliminary experiments with haloperidol (0.5pM),
present from the start of superfusion, none of the above mentioned
values appeared altered.
3PPP (5|iM) added to the superfusing Krebs solution from the
start of superfusion, abolished the increase with time, of the DA and
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FIGURE 3.27: The basal overflow of DA and DOPAC was
measured from three superfusate samples between
each of 10-20, 40-50 and 70-80 minutes of superfusion. No depolar¬
izing stimuli were applied. As shown above, the basal overflow of
both DA and DOPAC rose with time.
B. In the presence of 3PPP (5|iM), however, the
increase in the basal overflow of DA and DOPAC with time noted
above, was abolished.
DA /DOPAC content of the tissues at the end of the experiments (ng/mg
protein)
Control (non-stimulated) DA: 173.2 + 5.2 DOPAC: 6.0 ± 1.2
3PPP (non-stimulated) DA: 109.3 ± 2.6* DOPAC: 3.2 ± 0.4*
(* p <0.05, two-tailed Student 't' test)
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Basal overflow (mean + s.e.m.)
ng/mg protein/2 min
Superfusion time (min): 10-20 40-50 70-80
Dopamine 0.09 + 0.02 0.10 ± 0.01 0.13 ± 0.02
DOPAC 0.55 ± 0.06 0.58 ± 0.05 0.58 ± 0.06
At the end of the experiments in the presence of 3PPP, the DA
and DOPAC content of the tissues was found to be significantly lower
than in control experiments, i.e. 109.3 ±1.6 and 3.2 ± 0.4 ng/mg
protein, respectively (see Figure 3.27).
(n) Comparison between endogenous DA and 3H overflow
i) Control:
Striatal slices preincubated with 3H-DA (4|il of [3H-7,8]-dopamine,
47ci/mM) were superfused with oxygenated Krebs and stimulated twice
(as above). The superfusate from each 2 min collection was analysed
as follows:
1. 20pl was injected into the HPLC-ECD to determine the DA/
DOPAC content.
2. 500pl was added to 8 ml of scintillation fluid and its 3H content
analysed by liquid scintillation counting.
The results, calculated as before, show that while the basal over¬
flow of both DA and DOPAC was not different from control, the evoked
overflow of DA was markedly enhanced to 2.16 ± 0.47 (range 3.22 to
1.16) ng/mg protein (n=4) at Sx and 1.78 ± 0.28 (range 2.38 to 1.07)
ng/mg protein at S2, giving an S^Sx ratio of 0.88 ± 0.08 (see Figure
3.28). The evoked overflow of DOPAC did not significantly differ
from control levels (i.e. 2.44 ± 0.43 ng/mg protein at Sx and 2.15 ±
0.44 ng/mg protein at S2).
FIGURE 3.28: A. The basal and evoked overflow of DA and DOPAC
under control conditions, from Figure 3.16.
B. The basal and evoked overflow of DA and DOPAC
from tissue preincubated with 3H-DA. While the basal overflow of
DA and DOPAC remained unaltered both at Si and S2, the evoked
overflow of DA was greatly enhanced. The DOPAC evoked overflow
at S and S2 was not significantly different from control.
C. 3PPP (5pM) added to the superfusing solution of
tissue preincubated with 3H-DA at 30 min, enhanced the basal DOPAC
overflow while decreasing the evoked overflow of both DA and DOPAC.
D. The evoked overflow of 3H at Si was slightly but
not significantlyTTigher than that found at S2, from tissue pre¬
incubated with 3H-DA (simultaneous measurement from experiments
shown above, B). For basal overflow see text.
E. The simultaneous measurement of 3H overflow from
experiments described above in C, it was found that the evoked over¬
flow of 3H at Si was larger thanThat at S2, in the presence of 3PPP
(5nM). However, the presence of 3PPP did not significantly alter the
overflow 3H from that seen under control conditions (D).
DA /DOPAC content of the tissues at the end of the experiments (ng/mg
~
protein)
Control DA: 176.3 + 6.9 DOPAC: 8.6 + 0.61
3H-preincubated DA: 155.5 ± 6.6 DOPAC: 7.0 ± 0.75
+H3PPpmCUbated DA: 131-2 1 6-3* DOPAC: 6-9 1 °-77
(* p <0.05, two tailed Student *t* test)
(** p <0.05, two-tailed Student 't' test for values significantly












































The per cent fractional basal overflow of 3H at Sx did not differ
from that at S2 and was found to be 0.64 ± 0.08%. The evoked
fractional overflow at Sx was 4.56 ± 0.29 (range 5.21 to 3.68) % (n=4)
with a decrease (not significant) at S2 to 3.30 ± 0.47 (range 4.36 to
1.79) %.
ii) The effect of uptake inhibition on the evoked overflow of
DA and 3H:
In the presence (from the start of superfusion) of LY5953A
(5|iM) the basal overflow of DA from tissue preincubated with 3H-DA
was significantly higher both at Sx, i.e. 0.29 ± 0.04 ng/mg protein/
2 min and at S2, i.e. 0.50 ± 0.03 ng/mg protein/2 min, than that
found in control tissue (see Figure 3.29). The basal overflow of
DOPAC, however, did not differ significantly from that found in
presence of 5|iM LY5953A in the absence of 3H-DA preincubation.
The evoked overflow of DA at Sx, in the presence of the uptake
inhibitor, from tissue preincubated with 3H-DA was about 30% higher
(i.e. 6.83 ± 0.34, range 7.98 to 5.91, ng/mg protein) than that
observed from control tissue in the presence of 5|iM LY5953A.
Hence while there was a fourfold difference in the DA overflow,
between control tissue and tissue preincubated with 3H-DA, in the
presence of the uptake inhibitor this difference was reduced to 30%.
At S2, however, the evoked overflow of DA under these conditions
was more than 20% lower than that seen from control tissue in the
presence of 5|iM LY5953A (see Figure 3.29). The evoked overflow of
DOPAC at S2 was also reduced to 1.52 ± 0.34 ng/mg protein, although
DOPAC overflow at Sx remained unaltered, giving an S2/Sx ratio of
0.51 ± 0.09.
FIGURE 3.29: The basal and evoked overflow of DA and DOPAC
in the presence of 5|iM LY5953A, from control
tissue (from Figure 3.26).
B. The basal and evoked overflow of DA and DOPAC
in the presence of 5|iM LY5953A, from tissue preincubated with
3H-DA. The evoked overflow of DA at Si was significantly higher
than control, while that at S2 was significantly lower than control.
The evoked overflow of DOPAC at S2 also appeared to be lower than
control.
C. The addition of haloperidol (0.5uM) (Halop.), to
tissue preincubated with 3H-DA and superfused in the presence of
5pM LY5953A significantly enhanced the evoked overflow of DA and
DOPAC at S2 from that seen in the presence of LY5953A alone (B, ** -
values significantly different, p <0.05 two-tailed Student 't' test).
D. The evoked overflow of 3H, at Si, in the presence
of LY5953A (5|iM"Twas significantly higher than control (see Figure
3.28); however, despite the continued presence of LY5953A, the
evoked overflow of 3H at S2 did not differ from control.
E. Haloperidol (0.5pM) (Halop.) did not alter the
evoked overflow-of 3H at S2 (in the presence of LY5953A, 5mM).
DA /DOPAC content of the tissue at the end of the experiments (ng/mg
protein)
LY5953A (5|iM) DA: 132.0 ±11.6 DOPAC: 6.9 + 0.8
LYMMA (5UM) DA: 124'0± 8"1 DOPAC:
3H-DA +
LY5953A (5uM) DA: 165.0 + 3.7* DOPAC: 10.8 + 0.6*
+ Halop. (0. 5|iM)
























































The basal overflow of 3H (fractional overflow x 100) at Si (0.93
± 0.09%) and S2 (1.3 ± 0.1%) was significantly higher than in the
absence of LY5953A. The evoked overflow of 3H in the presence of
the uptake inhibitor at Si was significantly higher than control, i.e.
7.75 ± 0.59%; this ratio of evoked 3H in the presence and absence of
the uptake inhibitor at Si was 1.7, compared to 3.2 for authentic DA
during the same experiments (the same ratio in the absence of 3H-DA
preincubation was 11.8, see Figure 3.29 and Figure 3.16).
The evoked overflow of 3H at S2 in the presence of an uptake
inhibitor did not differ significantly from control, during the same
experiment, however, DA overflow was still 2.5-fold higher in the
presence than in the absence of the uptake inhibitor (see Figures
3.29 and 3.28 ) .
iii) The effect of 3PPP on the evoked overflow of DA and 3H
Addition of 3PPP (5pM) before S2, to tissue preincubated with
3H-DA enhanced the basal overflow of DOPAC at S2 to 1.42 ± 0.16
(range 2.01 to 0.84) ng/mg protein/2 min while not affecting the DA
basal overflow. The evoked overflow of both DA (1.13 ± 0.22, range
1.62 to 0.55 ng/mg protein) and DOPAC (1.33 ± 0.21, range 2.01 to
0.84, ng/mg protein) at S2 were reduced (see Figure 3.28, cf. Figure
3.25). The DA content of the tissue at the end of the experiment was
136.0 ±8.6 ng/mg protein; although lower than control values, it did
not significantly differ from that found in the presence of 3H only.
The evoked overflow of 3H at S2, in the presence of 3PPP, was slightly
(but not significantly) lower than control levels (see Figure 3.28).
The basal overflow of 3H remained unaffected.
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iv) The effect of haloperidol on the evoked DA and 3H overflow
in the presence of an uptake inhibitor:
Preliminary experiments with 3PPP (5|iM) added before S2 in
the presence of 5|iM LY5953A showed no difference in the basal or
evoked overflow of either DA or DOPAC. 0.5|iM haloperidol added
30 min after the onset of superfusion, in the presence of 5|iM LY5953A,
enhanced the basal overflow of DOPAC to 0.99 ± 0.05 (range 1.09 to
0.89) ng/rog protein/2 min while not affecting DA basal overflow.
The evoked overflow of DA was increased to 7.12 + 0.36 (range 8.22
to 6.2) ng/mg protein (n=4) as was the evoked overflow of DOPAC,
1.e. 3.92 ± 0.23 (range 4.38 to 3.20) ng/mg protein.
Both the DA and DOPAC content of the tissue at the end of the
experiment were significantly higher than those found during experi¬
ments without haloperidol (see Figure 3.29).
Although the basal and evoked overflow of 3H at S2 were higher
in the presence of haloperidol (1.51 ± 0.09% and 4.75 ± 0.20%, respec¬
tively), they were not significantly different from values obtained in
the presence of only uptake inhibitor (i.e. basal overflow, 1.31 ± 0.1%
and evoked overflow, 4.05 ± 0.30%).
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3.4 Discussion
The results presented in Chapter 3.1 confirm that the DA/DOPAC
measured by a direct analysis of tissue extracts or superfusate samples
use mostly authentic DA/DOPAC, as simultaneous measurements by
GCMS and under different chromatographic conditions during HPLC-ECD,
yielded similar results. The evoked overflow of 3H-DA, previously
preincubated with the tissue, co-eluted with endogenous DA and the
peaks eluting at the retention time of authentic DA/DOPAC from super¬
fusate samples were alumina extractable. This conclusion was further
justified by the finding that the increases in DA/DOPAC in superfusate
samples during depolarizing stimuli were Ca++ dependent (electrically
evoked overflow of DA/DOPAC was also TTX dependent). While the
DA/DOPAC overflow remained unaltered after KA lesions of the striatum,
it was completely abolished by 6-OHDA lesions. Pargyline abolished
the DOPAC peak selectively, while AMPT inhibited the overflow of
both DA and DOPAC.
Since the development of HPLC-ECD in the early 1970's (Keller
et al., 1976; Kissinger et al., 1973), it has already come to be
routinely used for measuring catecholamines, indolamines and their
metabolites from tissue and plasma samples (for recent reviews, see
Kissinger et al., 1981; Mefford, 1981). Mayer and Shoup (1982) have
recently suggested that the ratio of the peak height of a compound
oxidised at different working potentials may be used as a 'fingerprint'
for that compound to enhance the selectivity of HPLC-ECD.
The use of HPLC-ECD to detect the overflow of endogenous
catecholaminergic neurotransmitters in vitro was first described by
Plotsky et al., 1977. However, this and subsequent experiments
measuring endogenous DA overflow from striatal tissue (Nahorski ana
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Strupish, 1981; Bennet et al., 1981) were conducted on tissue
"incubated" in Krebs solution and not superfused (present results),
making a direct comparison of values difficult. Despite these dif¬
ficulties, however, the basal overflow of DA found by Bennet et al.,
(1981) and here are almost identical (0.08 ng/mg protein/2 min).
50mM K+ during the present study induced roughly the same amount of
DA overflow as 55mM K+ as described by Bennet et a!.,{ 1981).
Using similar techniques, the in vitro overflow of endogenous
5-HT from brain slice preparations (Bennet et al., 1980; Irons et al.,
1982; C.A. Marsden, personal communication) and from fore-brain
synaptosomes (Collard et al., 1981) have also been described. Although
these authors found a higher (about sixfold) basal overflow of 5-HIAA
compared to the basal overflow of 5-HT, no increases in the overflow
of 5-HIAA during the high K+ induced overflow of 5-HT were found.
Little data on the overflow of endogenous DOPAC in vitro is
available, however, recent investigations by Ungerstedt and co-workers
(personal communication; Ungerstedt et al., 1982; Bennet et al.,
1982) on the in vivo overflow of DA and DOPAC mainly from the
striatum (intra cerebral dialysis combined with HPLC-ECD) shows a
similar pattern to that found in the present investigations during
electrical stimulation (i.e. a large overflow of DOPAC accompanied by
more than an order of magnitude smaller overflow of DA) despite
differences in methodology.
In vivo determination of endogenous DA (see Glowinski et al.,
1979) and its metabolite overflow (HVA, Portig and Vogt, 1969) also
showed similar trends to those found during the present thesis.
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The site of origin of DOPAC
A mainly presynaptic origin of DOPAC (for early evidence see
review by Sharman, 1973) has been suggested since indirectly acting
sympathomimetics drugs (e.g. reserpine) increase only the overflow
of DOPAC (Cubeddu et al., 1979) and the relatively high basal over¬
flow of 3H-DOPAC, from tissue preincubatea with 3H-DA (i.e. 68%
of the fractional release), is unaffected by uptake inhibitors (Zumstein
et al., 1981) but is inhibited by amezinium which inhibits MAO inside
nerve terminals after being taken up (Steppler and Starke, 1980).
This is supported by the present findings that inhibition of impulse
flow by TTX, or DA release by Ca++ free media does not affect basal
overflow of DOPAC (i.e. no inherent depolarizing mechanisms appear
to be necessary), and the basal and evoked overflow of DOPAC are
largely unaffected under conditions of uptake inhibition, despite
marked increases in DA overflow.
Therefore, DOPAC which appears to leak out of the presynaptic
terminal readily (Trendelenberg et al., 1980) may reflect changes in
DA formation more closely than in DA release (Westerink and Korf,
1976). Hence, the increase in tissue levels of DOPAC in vivo after
impulse inhibition reflects an increased synthesis of DA (Di Giulio
et al., 1978; Broxterman et al., 1980).
During the present experiments, this important distinction, that
the DOPAC overflow reflects mainly alterations of the rate of formation
of DA and not primarily in its rate of utilization, was suggested by the
findings that:
1. During the K+ induced overflow of DA (which is not affected by
the uptake inhibitor, nomifensine, and so appears to approximate
DA release) there is a marked increase in DOPAC formation, suggesting
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an increase in DA synthesis. In support of this view, Schwarz et at.
(1980) showed an increase in the rate of synthesis of 3H-L-DOPA
(from 3H-tyrosine) during incubation of striatal slices with 55mM K +
media.
Interestingly, while DA overflow increases dramatically with
increasing K+ concentration during K+ stimulation (about 15-fold
between 15 and 50mM K+), there is a smaller increase in DOPAC over¬
flow (about threefold), suggesting a different dose/response relation¬
ship. This implies that the formation of DOPAC does not depend
entirely on the release (utilization) of DA, but depends on the synthesis
of DA since DOPAC is derived from DA; as is suggested in the finding
that DOPAC formation during electrical and K+ stimulation is the same
while there is a large difference in DA overflow.
2. Despite a marked increase in the basal and electrically evoked
overflow of DA in the presence of an uptake inhibitor, the basal
and evoked overflow of DOPAC remained largely unaltered, as mentioned
before. It was not possible, however, to determine what part of the
overflow of DOPAC represents the deamination of the recaptured DA
during the present experiments.
The implication of the lack of effect of uptake inhibitors on the
electrically evoked overflow of endogenous DOPAC at Sx, and the small
reduction at S2, is either: a) little recaptured DA is deaminated,
or b) since Zumstein et c/.,(1981) have shown that some of the released
3H-DA (electrically evoked), is taken up by nerve terminals and
deaminated resulting in an evoked overflow of 3H-DOPAC, implies
that the decrease in endogenous DOPAC overflow expected after DA
uptake inhibition, may be compensated for by an increased DOPAC
formation from newly-synthesised DA. Thus, the evoked DOPAC
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overflow may reflect the increased DA synthesis associated with
stimulation.
3. Ten minutes after the administration of A1V1PT to striatal slices,
although inhibition of TH may have been incomplete (Doteuchi
et al., 1974), the basal overflow of DOPAC was reduced by about 40%,
and on stimulation the evoked overflow of DOPAC was only about 8%
of control values, even though DA overflow was reduced by only about
50% (see later). Twenty-six minutes later, the basal overflow of
DOPAC was reduced by 70% and the evoked overflow almost abolished
(at S2), in spite of the fact that at the end of the experiment the
tissue content of DA was the same as values found before the start of
superfusion of control experiments (i.e. about half the amount present
at the end of control experiments).
After long-term inhibition of TH with AMPT (2 h after in vivo
administration) while the tissue content of DA is reduced (40% of
control start of experiment values), no overflow of either DA or DOPAC
could be detected. This implies that most of the DOPAC overflow is
derived from the 'newly synthesized-releasable pool' of DA or the
'cytoplasmic pool' described by Broxterman et al. (1979).
These suggestions are in line with the findings of Groppetti
et o/., (1977) that the specific activity of DOPAC rises faster than that
of DA after intra-ventricular administration of 3H-tyrosine.
4. The basal overflow of DA and DOPAC increased with time in the
absence of applied depolarizing stimuli.
Interestingly, the increase and rate of increase of DOPAC over¬
flow found in vitro, are similar to those found in vivo by Broxterman
et al.,( 1980) after HA-966 (a y-butyrolactone, GBL, like drug)
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administration. The DA content of the tissue at the end of in vitro
non-stimulated experiments was also similar to that described by the
above mentioned authors in vivo.
Hence it appears that non-stimulated striatal slices in vitro,
behave similar to the striatum in vivo under conditions of impulse flow
inhibition.
The D2 agonist 3PPP (Hjorth et al., 1981; Watling and Williams,
1982) abolished the in vitro increase in DOPAC overflow seen in the
absence of applied depolarizing stimuli, suggesting that in the absence
of DA release, dopaminergic presynaptic receptors which decrease DA
turnover, are not stimulated.
Similarly, Walters and Roth (1976) showed that the in vivo
increase in DA. turnover after GBL administration could be abolished
by dopaminergic agonists, but remains unaffected by dopaminergic
antagonists (Nowycky and Roth, 1978; see page 32 ).
Dopamine overflow
The basal overflow of DA was found to be very low under control
conditions (less than 0.1% of tissue DA content). In the absence of
applied depolarizing stimuli, an increased basal overflow of DA with
time was found during the present study.
Similarly, Cheramy et al(1977),while examining the overflow of
3H-DA newly synthesized from 3H-tyrosine in vivo after impulse flow
inhibition with y-hydroxybutyrate, found an increasing basal overflow
of 3H-DA in the absence of impulse flow. The in vitro increase of DA
basal overflow was found to be inhibited with 3PPP during the present
study.
The large increase in the electrically evoked overflow of DA in
the presence of 5|iM LY5953A (a specific DA uptake blocker, Wedley
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et al., 1978), suggested that up to 90% of the released DA is taken
back up by nerve terminals .
In a detailed study of the chemical composition of the released
3H (3H-DA preincubation) from the rabbit caudate nucleus, Zumstein
et a/., (1981) showed that the increase in 3H-DA overflow after nomi¬
fensine (l|iM) was completely obscured by the 3H-DOPAC overflow when
only total 3H overflow was examined.
While the electrically evoked overflow of DA was increased by
nomifensine (lgM) during the present experiments, the K+ evoked
overflow of DA was unaffected. Raiteri et al., (1978) also found no
effect of lyM nomifensine on the 55mM K+ evoked overflow of 3H-DA
(which consists mainly of 3H-DA, De Langen et a!., 1979; Cubeddu
et al., 1979), Dambiec and Cohen (1981) reported a decreased K +
evoked overflow of 3H (alumina extract) in the presence of uptake
inhibitors at higher doses (10uM).
A larger overflow of DA during K+ compared to electrical
depolarization may be indicative of the presence of a high affinity
uptake system, which is inhibited by high K+ concentrations.
While changes in current strength were not tested, the evoked
overflow of DA and DOPAC was Ca++ and TTX dependent at 8-10mA.
Aceves and Cuello (1981) showed that while the overflow of 3H was
Ca++ and TTX dependent up to 9mA stimulation amplitude, the larger
current strengths commonly used (20mA) resulted in a Ca++ and TTX
independent overflow of 3H.
The overflow of DA increased with increasing frequency (constant
number of pulses) to a maximum around 20Hz, similar values have been
reported by various authors for a maximal increase in tissue metabolite
levels after in vivo stimulation of the median fore-brain bundle (Korf
eta!., 1976; Roth eta!., 1976).
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Altering the duration the stimulus was applied for, at a constant
frequency (20Hz), showed that the overflow of DA per impulse declined
with increasing number of applied pulses. Bennet and Middleton
(1975) found that a similar train length dependent depression of NA
release in the peripheral nervous system appeared to be inhibited by
a-antagonists. It would be interesting to see the effect of dopaminergic
antagonists and agonist on the depression of DA overflow from striatal
slices.
Compartmentation of intraneuronal dopamine
Interestingly, even at the highest concentrations tried (50mM),
K+ depolarization resulted in the overflow (release) of only about 30%
of the tissue content of DA, suggesting that not all the DA present in
the tissue is available for release.
Further support for the compartmentation of intraneuronal DA
into stored and releasable pools (see introduction, 3.3), was obtained
from a study of the overflow of DA after TH inhibition. Two hours
after in vivo administration of AMPT, although more than 40% of tissue
DA was retained, neither basal nor evoked overflow of DA was detectable
despite the presence of 5|iM LY5953A. Short term in vitro inhibition of
TH with AMPT significantly inhibited the electrically induced overflow
of DA (despite the possibility of uptake inhibition of DA by the AMPT,
and incomplete inhibition of TH at Si as suggested earlier).
These findings support the suggestion of Glowinski ( 1975),
Groppetti et at. ,(1977) and Shore et a/., (1980) of a preferential release
of newly synthesized DA.
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The effects of presynaptic receptors on the DA and
DOPAC overflow
(1) Muscarinic agonists:
The present investigations show that cholinergic agents -
directing acting muscarinic agonists or acetylcholine esterase inhibitors
(elevating the levels of evoked endogenous ACh overflow), markedly
potentiated the K+ and electrically evoked DA and DOPAC overflow.
These effects could be inhibited by atropine, but not by tubocurarine
or gallamine, indicating the involvement of muscarinic type cholinergic
receptors. The effect of the muscarinic agents persisted in the
presence of the DA uptake inhibitor, LY5953A, suggesting that
muscarinic presynaptic receptor stimulation increases the release and
rate of synthesis of DA.
The effects of acetylcholine esterase inhibitors was unaffected by
KA lesions of the striatum, indicating the possible involvement of
cholinergic afferents to the striatum (Smike and Saelens, 1977), or
that not all the cholinergic cell bodies within the striatum are destroyed
by KA (Kramer et al., 1979).
Since all the evidence presented above was obtained from striatal
slices containing nerve terminals in the absence of cell bodies, a
presynaptic site of action is implied. Although the existence of a
'short loop feedback' by cholinergic interneurons was not completely
ruled out, its absence is suggested by the persistence of the muscarinic
presynaptic effects after KA lesions of the striatum, and in synaptosomal
preparations, as was recently found by Marchi et a/., (1982).
The present findings support those of Lloyd and Bartholini
(1975), who, using a push-pull cannula in vivo, showed that oxo-
tremorine markedly potentiated the overflow of endogenous DA.
Although Giorguieff et al.f( 1977b) reported a muscarinic presynaptic
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receptor mediated increase in the basal overflow of 3H-DA (newly-
synthesized from 3H-tyrosine), interpretation of their results is
complicated by the fact that an increased specific activity of the over¬
flow of DA during a constant basal release was not ruled out (see
introduction, page 34 ).
The influence of muscarinic agents on the evoked overflow of
3H-DA (after preincubation) is more controversial. While Westfall
(1974a,b,c) and De Belleroche and Bradford (1978) reported an
inhibitory influence of muscarinic agonists on 3H-DA overflow, the
work of Marchi et al. (1982) on striatal synaptosomes, and that of De
Belleroche and Gardinier (1982) on nucleus accumbens slices and Perkins
and Westfall (1979) on hypothalamic slices, indicates a small (30-40%)
facilitation of evoked 3H overflow with muscarinic agonists.
During the present thesis, the simultaneous determination of 3H
and endogenous DA/DOPAC overflow, showed that while the endogenous
DA/DOPAC evoked overflow was facilitated (>80%) by muscarinic
agonists, there was only a small (about 35%) simultaneous facilitation
of 3H overflow.
Hence, the implication is that muscarinic agonists facilitate the
synthesis and utilization of the newly-synthesized DA.
A muscarinic agonist induced increase of DA turnover has been
reported by several authors. Paalzov and Paalzov (1975) found an
increased AMPT-induced disappearance of cerebral DA.^ Muscarinic
agonists have also been shown to raise dopamine metabolite (HVA and
DOPAC) levels (Laverty and Sharman, 1965; Nose and Takemoto, 1974)
in the striatum, while O'Keeffe et a/.,(1970) found a decrease in
striatal HVA after atropine. Interestingly, HVA has been shown to
be derived mainly (80%) from DOPAC (Westerink and Spaan, 1982a)
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and so most likely reflects changes in the rate of DA synthesis. 3-MT
on the other hand, is thought to be a better index of DA overflow
(Westerink and Spaan, 1982a,b; Westerink and Korf, 1976; Kehr,
1976).
Javoy et a/., (1975) showed an increased L-DOPA formation
in vivo after oxotremorine administration (Westerink et al., 1982c).
The same authors also reported that although the specific activity of
tissue DA (3H-tyrosine administered I.V.) was also enhanced, the
total DA content of the striatal tissue remained unaltered, suggesting
a muscarinic receptor mediated facilitation of DA synthesis and
utilization simulationeously.
Nicotine enhanced the basal overflow of both DA and DOPAC
confirming the findings of Giorguieff et al.,( 1976, 1979a). Nicotine
did not, however, have any significant effect on the evoked overflow
of either DA or DOPAC during the current investigations.
(2) Dopaminergic presynaptic receptors:
The involvement of dopaminergic presynaptic receptors regulating
the rate of synthesis of DA, in the absence of depolarizing stimuli has
been discussed above (see also introduction, page 31 , and Table 1).
The present investigations showed that the dopaminergic agonist,
3PPP, decreased the evoked overflow of both DA and DOPAC, while
haloperidol had the opposite effect. The effects of these dopaminergic
agents persisted in the presence of the uptake inhibitor, LY5953A,
indicating that release rather than overflow of DA was altered.
Alterations of the overflow of DOPAC suggest an inhibitory effect of
dopaminergic presynaptic receptors on the rate of synthesis of DA
during stimulation.
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The controversy in the literature about the actions of neuro¬
leptics on the overflow of 3H-DA remains unresolved; Lehmann
ef a/.,(1981) have recently ruled out species difference (rabbit, cat,
rat) and the inhibitory effects of ascorbic acid on dopamine receptor
mediated actions (Thomas and Zemp, 1977; Kayaalp and Neff, 1980)
as possible causes of the differences of opinion expresses in the
literature (see Table 1). As suggested in the introduction (page 33),
the most likely explanation for the lack of effect or inhibition of 3H-DA
release with neuroleptics is the presence of MAOI and perhaps small
differences in experimental protocol. This view is supported by the
finding of Zumstein et a/.,(1981) that the inhibitory effects of apo-
morphine on the overflow of 3H are abolished by pargyline.
After the original description of 3H-DA overflow inhibiting
dopaminergic presynaptic receptors by Farnebo and Hamberger (1971),
further supportive evidence came from in vivo studies of endogenous
DA overflow (Lloyd and Bartholini, 1975) and in vitro studies on the
overflow of endogenous (Plotsky et a!., 1977) and newly-synthesized
(Westfall et al., 1976) DA. Starke eta/., (1978) subsequently confirmed
the findings of Farnebo and Hamberger (1971) and showed a presynaptic
dopamine receptor mediated depression of 3H-DA overflow in vitro,
using dopaminergic agonists and antagonists (as have several authors
since then, see Table 1 for references).
During the above mentioned studies, the neuroleptic induced
facilitation of 3H-DA release is usually found to be no more than about
50-60% above control levels (Starke et a/. , 1978; Miller and Friedhoff,
1979), the facilitation of endogenous or newly-synthesized DA with
neuroleptics is, however, reported to be much higher, i.e. about
150-300% (see above for references, present study). This suggests
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that dopaminergic antagonists facilitate the release mainly of newly
synthesized DA. During the present study, this suggestion is sup¬
ported by the finding that although there was a marked facilitatory
effect of haloperidol on endogenous DA and DOPAC overflow and a
significant inhibitory effect of 3PPP, simultaneous determination of
3H overflow failed to follow these changes accurately.
Comparison between endogenous DA /DOPAC and 3H overflow
During experiments with tissue preincubated with 3H-DA, the
overflow of endogenous DA and DOPAC (as measured by HPLC-ECD)
differed from that found during control experiments in several ways:
1. There was a much greater electrically evoked overflow of endogenous
DA from tissue preincubated with 3H-DA compared to control tissue.
When uptake was inhibited (high K+ or electrical stimulation in the
presence of 5^M LY5953A), however, the overflow of endogenous DA
from control or 3H-DA preincubated tissue did not markedly differ.
Initial studies measuring the overflow of DA from tissue preincubated
with 'cold' DA (results not presented) indicated that part of the
apparent uptake inhibition with 3H-DA may be due to an inhibitory
action of exogenous DA on uptake. However, the possibility of uptake
inhibition by ethanol or acetic acid, in which the 3H-DA is supplied, or
the presence of 3H, was not ruled out. The overflow of exogenous DA
from sites other than DA nerve terminal may also have contributed to
this apparent uptake inhibition.
2. The evoked overflow of DA from control slices in the presence of
LY5953A was roughly the same at both Si and S2 (S2/Si = 1.12).
However, there was a significantly lower release at S2, from striata
preincubated in with 3H-DA and superfused in the presence of 5gM
LY5953A (S2/Si = 0.65), a similar reduction of DOPAC overflow was also
found at S2, which was not seen in control striatal slices.
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Persistence of the inhibitory actions of 3PPP on DA/DOPAC over¬
flow in control but not 3H-DA preincubated slices (in the presence
of LY5953A), and the effectiveness of haloperidol in facilitating the
overflow of DA from both tissues under the same conditions, suggests
that part of the inhibition of DA/DOPAC at S2 may have been due to
an action of 3H-DA at the presynaptic dopaminergic receptors.
3. Although LY5953A enhanced the overflow of 3H at Sx by about 80%
(c.f. about a tenfold increase of endogenous DA from control
tissue), the overflow of 3H at S2 was not significantly different from
control (simultaneous determination of endogenous DA, showed it to be
at least 250% higher than control at this stage). This small S2/S!
ratio of 3H overflow was unaffected by haloperidol, although as noted
above, the S2/Si ratio for endogenous DA, measured simultaneously
increased from 0.65 to 1.05 in the presence of haloperidol.
Hence the decreased overflow of 3H at S2 in the presence of
LY5953A may have been due to a depletion of the label from the
releasable pool of DA, whereas, as suggested above, the concomitant
decrease of endogenous DA may have been due to a stimulation of
presynaptic dopaminergic receptors by the added 3H-DA.
DA content of striatal tissue slices:
From an estimation of the total amount of DA and DOPAC overflow
into the superfusing Krebs solution, during control electrical stimula¬
tions , and the difference between the DA content of the tissue at the
start and at the end of the experiments, the value for the total amount
of in vitro synthesis and utilization of DA per hour was found to be
approximately 60nM/g wet weight/hr (assuming that 1 mg protein =
10 mg wet weight). This, however, should not be compared to the
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values of DA turnover obtained in vivo (Sharman, 1981) as numerous
conditions are different, mostly that in vivo an ongoing impulse flow
from the nigra probably greatly modifies the turnover of DA in the
nigro-striatal nerve terminals, whereas in vitro, only two 30 sec,
20Hz trains of pulses were applied. The important point, neverthless,
is that in vitro more than 60% of this 'rate of synthesis' measure
actually relates to an increased tissue content of DA; the actual
'utilization' of DA was only about 24nM/g wet weight/hr (most of which
was DOPAC overflow and only about 10% comprises DA overflow).
This increase of the tissue content of DA is not seen in vivo
even after electrical stimulation of the median forebrain bundle (Korf
et a!., 1976). The findings of Shore et a/., (1976, 1979) (see McMillen
et al., 1980) on the non-amphetamine class central stimulant atnfonelic
acid, and its interactions with haloperidol and AMPT, may help to
explain the in vitro increase in the tissue content of DA. The above
mentioned authors have suggested that presynaptic dopaminergic
receptors can alter the rate of exchange of DA between the 'newly-
synthesised, releasable' and 'storage' pools. This, as suggested
earlier, is also implied by the increased depletion of DA by drugs like
haloperidol, after synthesis inhibition with AMPT, given the assumption
of a preferential release of newly-synthesised DA.
The hypothesis, therefore, is that presynaptic dopaminergic
receptors on stimulation decrease not only the synthesis and release
of DA, but in addition to this, also decrease the rate of exchange of DA
between the storage and releasable pools.
Given the above mentioned hypothesis, and assuming that because
of the high rate of flow of the super fusing solution in vitro, pre¬
synaptic receptors are only stimulated during or immediately after the
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evoked release of neurotransmitters. The implication, therefore, is
that the in vitro increase of the DAcontent of the tissues after
electrical stimulation (as was found in the absence of stimulation) is
due to the lack of adequate stimulation of presynaptic receptors which
inhibit the transfer of newly synthesised DA to the storage pool.
Hence, in the absence of depolarization, despite an uneffected initial
basal overflow of DOPAC, the DA content of striatal tissue remains
largely unaltered in the presence of 3PPP but increases about twofold
in its absence. Similarly, during electrical stimulation in the presence
of 3PPP, while the estimated total DOPAC overflow was not much lower
than during control experiments (>5%, despite the 30% decrease of
evoked DOPAC overflow at S2), the actual DAcontent of the tissue
fell by over 30% in the presence of 3PPP. This implies that less newly-
synthesised DA was stored, and perhaps more deaminated as indicated
by the higher basal overflow of DOPAC in the presence of 3PPP before
S2. It may then be suggested that the higher basal and evoked overflow
of DOPAC with haloperidol reflects an increased synthesis and utiliza¬
tion of DA from both the releasable and storage pools, resulting in a
reduced tissue content of DA.
The effect of muscarinic agents supports this tentative suggestion
with the finding that despite an increased evoked overflow of DOPAC,
implying an increased synthesis of DA, the tissue content of DA fell
by over 30%. This suggests that muscarinic agents enhance the
synthesis and utilization of newly-synthesized DA but inhibit the
translocation of DA between the storage and releasable pools. Hence,
while an increased accumulation of L-DOPA after oxotremorine has been
demonstrated (Javoy et al., 1975; Westerink et al. , 1982c) , an
increased DA depletion after AMPT by muscarinic agents was not found
by some authors (Paalzov and Paalzov, 1975).
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This rather involved interpretation is tentatively suggested,
and in order to gain more information on the subject, more detailed
experiments are proposed. A study of the specific activity of DA/
DOPAC overflow and tissue content, during continuous superfusion
with 14 C-tyrosine may provide further insight into the role of pre¬
synaptic receptors on the release and storage of newly-synthesized
DA and the utilization of preformed stored DA.
CHAPTER IV
The overflow of dopamine from other dopamine
rich tissue
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4.1 Overflow of endogenous DA from median eminence (ME) tissue
in vitro
A) Results
Four median eminence tissue pieces (ME - approximate total wet
weight, 3.5 mg), dissected as described in the methods section (page
57) were superfused with oxygenated Krebs solution at 37°C, at a flow
rate of approximately 150ul/min. Electrical stimulations (20Hz, 8-10mA,
30 sec) were carried out as before.
The basal overflow of DA and DOPAC was generally found to be
below detectable levels (<0.15 ng/4ME/2 min). Electrical stimulation
resulted in a rapid increase in DA overflow (see Figure 4.1), which
declined to basal levels within 2 minutes. Usually no evoked overflow
of metabolites was detectable (see Figure 4.2). The overflow of DA
at Si (0.33 + 0.06, range 0.51 to 0.22 ngDA/4ME) did not differ from
that at S2 (0.33 + 0.07, range 0.56 to 0.22 ngDA/ME). A two-minute
pulse of 45mM K+ also resulted in approximately the same evoked
overflow of DA as seen during electrical stimulation (see Figure 4.1).
The tissue content at the end of control experiments with two
electrical stimulations was found to be 6.11 + 0.38 ng/ME, and although
generally lower, was not significantly different from values of DA content
of ME immediately after dissection (7.85 + 0.63 ng/ME).
Addition of the dopaminergic uptake inhibitor nomifensine (l|iM),
30 min after the onset of superfusion, enhanced the evoked overflow of
DA at S2 by about 50% to 0.53 ±0.05 (range 0.61 to 0.36) ngDA/ME
(see Figure 4.3).
Addition of oxotremorine (10|im) or prolactin (0.5(ig/ml) did not

















FIGURE 4.1: A. 4 median eminence (ME) pieces superfused with
oxygenated Krebs solution (approximately 150pl/
min) were stimulated twice at 16 min (Si) and 56 min (S2) of
superfusion, two minute superfusate sample collections were
analysed for their catecholamine content by HPLC-ECD (see Figure
4.2). The basal overflow of DA was generally below detectable
levels. During stimulation, however, there was a marked and rapid
increase in DA overflow as shown above. Electrical stimulation at
Si and S2, and 45mM K+ stimulation (2 minute pulse) induced the
same overflow of DA.
Tissue DA content (ng/ME)
Freshly dissected tissue DA: 7.85 ± 0.63
Tissue from end of control c „ 0o MC




FIGURE 4.2: HPLC-ECD traces of median eminence (ME) super-
fusate samples. 4 ME tissue pieces superfused in
Krebs solution (350pl/2 min) were stimulated twice (electrically).
The traces shown above show the DA content of superfusate samples
taken immediately before (14, numbers refer to superfusion time,
min), during (16) and immediately after (18) the first electrical
stimulation (Si).
























FIGURE 4.3: 4 median eminence tissue pieces superfused in Krebs
solution were stimulated twice (electrically) at Si and
S2. After the control Si, nomifensine (lpM) was added 30 min after
the onset of superfusion. Nomifensine increased the overflow of DA
at S2 by about 50%.
(* p <0.05, Student 't1 test, one tailed vs. control S2, see Figure






















FIGURE 4.4: Summary of the electrically evoked overflow of DA from
ME tissue superfused with Krebs solution.
Addition of prolactin (0.5jig7ml) or oxotremorine (10pM) 30 min after
the onset of superfusion, failed to alter the evoked overflow of DA
at S2 (basal overflow remained below detectable levels).
As noted in Figure 4.3, nomifensine (lpM) increased the overflow
of DA at S2 by about 50%.
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B) Discussion
The present experiments demonstrate an electrically evoked and
K+ evoked overflow of endogenous DA from the median eminence
in vitro.
Recently the overflow of endogenous DA from the medial-basal
hypothalamus (MBH) has been demonstrated by Sharman et al. (1982),
using MBH tissue incubated in Krebs solution and the incubating fluid
analysed by HPLC-ECD (see also Bennet et al., 1981) and by Foreman
and Porter (1981), using MBH tissue superfused with Krebs solution
and superfusate analysed by a radioenzymatic assay. Despite differ¬
ences in the dissection procedures, and in the experimental protocol
(allowing for differences in the duration of stimulation), the values
found by the above mentioned authors during high K+ stimulation and
those found during the present work, are roughly similar. This
suggests that much of the DA in the MBH is localized around the ME.
As the K+ and electrically induced overflow of DA did not differ
markedly (c.f. striatal DA overflow, Figures 3.5 and 3.16 ), and
nomifensine increased the overflow of DA by only 50%, the implication
is that the ME lacks a high affinity DA uptake system, or that uptake
plays a different role in transmitter metabolism.
Although a DA uptake system in the ME has been described
(Cuello and Iversen, 1973), detailed studies by Demarest and Moore
(1979) and Annunziato et al. (1980) have demonstrated that the ME DA
uptake system has a very much lower affinity for DA than the striatal
DA uptake system.
These observations are consistent with the postulated role of DA
as a Prolactin Inhibitory Factor (McLeod, 1976).
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Prolactin and oxotremorine failed to alter the evoked overflow
of DA from the ME in vitro. Perkins and Westfall (1978, 1979) and
Foreman and Porter (1981) have, however, recently reported facil-
itatory effects of these agents on the evoked overflow of DA in vitro
from the MBH. Similarly, several authors (Gudelsky and Porter, 1980;
Johnston et al., 1980; Pilotte et at., 1980) have demonstrated an
increase of DA release and turnover in vivo with prolactin. It may be
suggested, therefore, that the effects of prolactin and muscarinic
agents are mediated by an action of these drugs on cell bodies rather
than on nerve terminals (Yamada, 1975).
While the electrically evoked overflow of DA from the ME was similar
to that induced from striatal slices in the presence of an uptake
inhibitor (luM nomifensine or LY5953A), the difference was that very
little or no DOPAC overflow was detectable from the ME tissue. Umezu
and Moore (1979) similarly found very low levels of DOPAC in the ME,
which remained unaltered during treatment with haloperidol or reserpine,
although the DOPAC levels in the striatum, olfactory tubercle, and
hypothalamus were raised. Since Gudelsky and Moore (1977) showed
an increased AMPT induced disappearance of DA from the ME with
haloperidol, which implies increased DA utilization and synthesis, the
implication is that the compartmentation and access of DA to MAO may
differ in the ME from that seen in the striatum (Annunzaito, 1979).
4.2 The overflow of endogenous DA from cockroach salivary glands
in vitro
A) Results
Cockroach salivary glands (CSG) superfused in vitro with
oxygenated Ringers solution at room temperature, were stimulated twice
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(electrically - 8-10mA at 20Hz for 30 sec). The basal overflow of DA
was generally found to be at or below the limits of sensitivity of the
HPLC-ECD (about 20 pg/sample) as was the 'metabolite peak'. The
retention time of this metabolite peak corresponded to that of nADA
(N-acetyl-dopamine) (see Figure 4.5).
During electrical stimulation there was a sharp rise in the over¬
flow of DA (see Figure 4.6) accompanied by a slower increase in the
overflow of nADA. A second electrical stimulation induced roughly the
same increase in DA and nADA overflow as the first.
Omission of Ca++ ions from the Ringers solution during the
second stimulation (S2), abolished the electrically evoked overflow of
DA and nADA.
An unidentified compound (hereafter referred to as R) was also
detected in CSG extracts and in the superfusate of CSGs. R had a
much longer retention time than NA, Adr, octopamine, DA or 5-HT,
eluting in that order under the conditions employed. During electrical
stimulation, R was also released, Ca++ dependently, with a slower time-
course to that of DA (see Figure 4.6). The presence of large amounts
of R in tissue extracts (although it was not possible to quantify R
content of CSG's, R peak height was approximately an order of magnitude
larger than that of DA) argued against it being a metabolite of a neuro¬
transmitter (see Figure 4.7).
Since R may have been a secretory product of the salivary gland,
attempts to induce R release by adding NA (10|iM) to the superfusing
Ringer solution proved unsuccessful. Similarly, blockade of post¬
synaptic receptors with phenoxybenzamine (10|iM) failed to inhibit its
release during nerve stimulation (the overflow of DA and nADA being
unaltered as well).
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superfusate samples (numbers refer to superfusion time).
Samples taken before (14); during (16); and immediately after (18)
electrical stimulation is shown.
1 = Dopamine
2 = N-acetyl dopamine





















FIGURE 4.6: A^_ 4 cockroach salivary glands, superfused in
oxygenated Ringers solution were stimulated twice
(electrically) at 16 min (Si) and 56 min (S2). Superfusate samples
collected at 2 min intervals were analysed for catecholamines by HPLC-
ECD. Electrical stimulation induced a rapid rise (and subsequent
decline of DA overflow as shown above. Omission of Ca++ from the
Ringers solution prevent the increase in DA overflow due to electrical
stimulation.
B. During the experiments described above, an unknown
compound, R (see Figure 4.7), with a retention time greater than that
of NA, Adr, DA or 5-HT was simultaneously 'released' during electrical
stimulation. The evoked overflow of R was also found to be Ca++
dependent. The overflow of R, expressed as the limiting current
obtained (nA) from a 20|il injection of the CSG superfusate into the









FIGURE 4.7: HPLC-ECD trace of the supernatent (20|il injection)
of a cockroach salivary gland homogenate.
A. Standards: 1 = noradrenaline; 2 = adrenaline; 3 = dihydroxy-
benzylamine; 4 = dopamine; 5 = dihydroxyphenylacetic acid;
6 = N-acetyldopamine; 7 = 5-hydroxytryptamine.
• B. 20|il of a CSG homogenate showing the position of R relative to
the other catechol/indoleamines of interest.
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Preliminary experiments with carbacol (lOpM) did not show any
alteration of the basal or evoked overflow of DA, nADA or R.
B) Discussion
The presence of catecholamines in the salivary glands of Nauphoeta
cinerea Oliver has been demonstrated histochemically (Bland et at.,
1973); radioenzymatic measurement by Fry et a/., (1974) suggest that
DA and not NA was the major catecholamine present. Recently,
Mitchell and Williams (1981) reported the presence of DA and octopamine
in the CSG by GCMS. The authors also reported a reduction of DA and
octopamine content of the CSG after in vitro degeneration of nerve
terminals with 6-OHDA. A neurotransmitter role for DA has also been
suggested by electrophysiological methods, nerve stimulation and
dopamine elicit similar changes in the membrane potential and conduct¬
ance of acinar cells, which can be blocked by dopaminergic and
ct-adrenergic antagonists (Ginsborg et a!., 1976). Salivary secretion
response of CSG in vitro can also be initiated by nerve stimulation or
bath application of DA, NA, Adr and 5-HT, of which DA was found to
be the most potent (House and Smith, 1978).
The pharmacology of the postsynaptic receptors on acinar cells
indicates the presence of two types of receptors, a dopaminergic and a
'5-HT-type' receptor (Bowser-Riley et al., 1978; see House and
Ginsborg, 1979 for a recent review). Light and electron micrscopy has
revealed a dual innervation of each gland (see House, 1980).
The results of the present investigations support a neurotrans¬
mitter role for DA at the CSG neurosecretory synapse.
Large amounts of DA (1.9 + 0.2 ng/gland) were shown to be
present in the CSG, which could be released, Ca++ dependently,
in vitro, by electrical stimulation. Since the ratio of released DA to
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DA content of the preparation for the CSG is similar to that found for
the ME preparation and much higher than that for the striatal tissue,
it may be suggested that the CSG, like the ME, may only have a low
affinity DA uptake system. nADA appeared to be the major metabolite
of DA (Mir and Vaughn, 1981).
Preliminary attempts to isolate R by HPLC and characterize it by
GCMS failed (probably due to its instability since it is easily oxidisable
at +0.70), its identity remains unknown. Since R was present in what
appeared to be relatively large amounts in tissue extracts and was
released Ca++ dependently during electrical stimulation, a neurotrans¬
mitter for R is visualized.
4.3 Overflow of endogenous DA from the rat retina in vitro
A) Results
Rat retina, superfused with oxygenated Krebs solution at 37°C,
were stimulated twice, at Sx with light (flashing at 2-3Hz for 2 min) and
electrically at S2 (8-10mA, 20Hz, 30 sec).
Although the average DA content of each retina was relatively low
(4.05 ±0.55 ng/retina), the basal overflow of DA in the superfusate was
relatively high around 0.07 ± 0.006 ng/retina/2 min. Although occasion¬
ally a peak eluting at the retention time of 3-MT was found, it was
generally at or below the limits of sensitivity and so was not quantified
(see Figure 4.8).
Light stimulation failed to modify the basal overflow of DA.
During electrical stimulation, however, there was a marked increase
in the overflow of DA, which declined slowly (see Figure 4.9), this
electrically evoked overflow of DA was abolished when superfusing with
Ca++ free Krebs.
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FIGURE 4.8: HPLC-ECD traces of the superfusate from retinal tissue
(numbers refer to superfusion time of sample). Samples
taken before (54), during (56) and immediately after (58) electrical
stimulation (S2) of retinal tissue (see Figure 4.9).
1 = Dihydroxybenzylamine, Internal standard
2 = Dopamine




FIGURE 4.9: Retinal tissue superfused with Krebs solution was
stimulated first with a light stimulus (strobe flashing at
2-3Hz for 2 min) at Si and then electrically at S2 (20Hz, 8-10mA for
30 sec). The superfusate collected at 2 min intervals was analysed
for its catecholamine content by HPLC-ECD.
The relatively high basal overflow of DA was unaffected by light
stimulation at Si. Electrical stimulation did evoke an increase in the
overflow of DA, which was abolished when superfusing the tissue with
Ca++ free (+0.1mM EGTA) Krebs solution (broken line histogram).
The DA content of the tissue at the end of the experiments was found
to be 3.89 ± 0.54 ng/retina, and was not significantly different from
the DA content of freshly dissected retina (4.05 ± 0.55 ng/retina).
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The major metabolite of DA appeared to be 3-MT, although it
was present in very small amounts. The DA content of the retina
(3.89 ±0.56 ng/retina) at the end of the experiments did not differ
from that found in freshly dissected retina (see above).
B) Discussion
Dopamine in the retina of most mammalian species appears to be
localized in the amacrine neurons within the inner nuclear layer
(Dowling and Ehinger, 1978; Haggendal and Malmfors, 1965; Malmfors,
1963). A light induced release of 3H-DA has been demonstrated
(Kramer, 1971) associated with an increase in TH activity and DA
utilization (Iuvone et al., 1978; Morgan and Kamp, 1980).
However, I was unable to demonstrate a light induced overflow
of DA from the rat retina in vitro, possibly because there was in¬
sufficient DA released due to inadequate stimulation or insufficient dark-
adaptation of the preparation.
An electrically induced, Ca++ dependent, overflow of DA (with
3-MT as the major metabolite) was found, confirming the results of
Dubocovich and Weiner (1981) on the overflow of 3H-DA from the
rabbit retina. The report by the above mentioned authors that the
high basal overflow of 3H was unaltered in the absence of Ca++ ions,
was also confirmed during the present study. The DA content of the
retina at the start and the end of the experiments did not differ,
supporting the findings of Iuvone et a/., (1978) that the DA content
of the dark adapted retina does not differ from that found in retina
after light stimulation.
The present results confirm a neurotransmitter role for DA in the
rat retina (for dopaminergic receptor characterization see Goodale
et a!., 1980; Makman et a!., 1980) and it is suggested that differences
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in the catabolism of DA between the retina and striatum indicate
a difference in the subcellular compartmentation and metabolism of DA
in the two tissues.
4.4 Estimation of dopamine in portal plasma
A) Results
Hypophysial portal blood collected as described in the methods
(see page 62) was centrifuged and the plasma stored at -70°C
until analysis. For analysis, after precipitation of the proteins,
catecholamines were alumina extracted and analysed by HPLC-ECD.
To investigate the influence of hyperprolactinemia on DA release
into portal blood, male rats were made hyperprolactinemic by implanting
two pituitary glands under the kidney capsule a month prior to col¬
lection of portal blood. The DA/DOFAC content of portal plasma
measured before, during and after stimulation of the ME (60Hz, 1mA,
applied in trains of 30 sec over 30 min) were as follows:




DA 3.62 ± 0.35 2.66 + 0.98 2.20 + 0.07
DOPAC 7.20 ± 0.24 4.60 + 0.28 7.00 + 1.98
Hyper-Prl (n=5)
DA 4.48 + 0.34 4.56 + 0.39
DOPAC 9.47 ± 1.32 12.20 + 1.10
The recoveries found during these experiments tended to be
rather low (20-60%). In an attempt to improve on the alumina extraction,
and avoid batch variation, alumina was acid washed and dried several








FIGURE 4.10: HPLC-ECD trace of an alumina extract of portal
plasma.
1 = Dopamine
2 = Dihydroxyphenylacetic acid
3 = N-acetyl dopamine, Internal standard
X = Unknown peaks probably eluting off the alumina.
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Preliminary experiments with cycling female rats suggested that
the DA concentrations in portal plasma were higher at proestrus
(a.m.). than at estrus or diestrus.
An attempt to look for differences in portal plasma levels of
catecholamines after destruction of the ME dopaminergic nerve terminals
by peripheral injections of 6-OHDA failed, due to inadequate recoveries
from the alumina extraction. and the appearance of unidentified
electroactive peaks eluting off the alumina. However, 48 hr after
a peripheral injection of 6-OHDA (+ ascorbate and desmethylimapramine),
the DA content of the ME tissue decreased from (control) 7.85 ± 0.63
ng/ME (n=8) to 4.72 ± 0.50 ng/ME (n=8).
B) Discussion
The limiting step of the HPLC-ECD assay for plasma catecholamines
appears to be the alumina extraction step. Recoveries from different
batches of alumina varied from 50-70% to 20-60%; a large solvent front
(perhaps due to uric acid and its metabolites, C.A. Marsden, personal
communication) - and the appearance of unknown peaks (see Figure
4.10) eluting off the alumina (Falconer et al., 1982) severely limited
the sensitivity of the assay.
Studies on hyperprolactinemic male rats suggest that despite a
lowered ME DA content (Simpkin et al., 1982), DA release into portal
plasma is higher than control even during stimulation of the ME. The
relevance of the stimulation induced decrease of DA release in control
animals remains obscure.
Peripheral injections of 6-OHDA (Smith et al., 1982) lowered the
DA content of the ME by about 50%, despite the possibility that part
of the DA measured from the 6-OHDA lesioned ME may have been the
DA accumulation in the lesioned end of the ME axons (C.G. Smith,
personal communication).
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The findings of Smith et al. t (1982) that prolactin release
remains unaltered after destruction of the ME dopaminergic nerve
terminals, despite a decrease in the ME DA levels (present thesis)
and reduction in ME fluorescence (Smith et al., 1982} raises the
possibility that DA accumulated in the 'cut' DA axons is releasable as




From the evidence presented in this thesis, the following sequence
for the metabolism of DA in the striatum is suggested:
DA is synthesized (from tyrosine by tyrosine hydroxylase and
DOPA decarboxylase) presumably at a site at which it has access to
MAO. This site may be the 'newly-synthesized releasable pool' of DA,
or the 'cytoplasmic pool' as suggested by Broxterman et al. (1979)
(see Figure 5.1).
The rather large amount of basal DOPAC overflow found during
the present thesis, implies that a significant proportion of the newly
synthesized DA is immediately deaminated. The remaining newly-
synthesized DA is then available for release or transfer to the storage
pool. As time goes on, the possibility that a newly-svnthesized (or
recently take up) molecule of DA is released, declines; while the
possibility that it is deaminated or stored increases. The release and
uptake of DA, therefore, appears to involve mainly the newly-synthesized
releasable pool of DA, which only slowly equilibrates with the larger
storage pool.
Most of the released DA (>90%) is taken back up by the nerve
terminal, while much of it is recycled, presumably initially entering
the releasable pool, some of it may be deaminated.
However, several major points about the compartmentaticn of
DA remain to be determined; especially the size of the releasable pool,
which is most probably less than 40% but more than about 5% of the
total tissue DA.
DOPAC was found to be the most abundant metabolite of DA in
the striatum, however changes in the rate of formation of DOPAC
appear to relate better to changes in the rate of synthesis and not
the release of DA. It has been further suggested that HVA is formed
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FIGURE 5.1: Schematic representation of the intraneuronal flux of
dopamine in striatal nerve endings.
Newly synthesized dopamine initially enters the releasable pool. A
large part of this newly-synthesized dopamine appears to be deaminated
either at '1 - the cytoplasmic pool', or because DA within the releas¬
able pool has access to MAO. The releasable pool of DA (about 5-30%
of total tissue DA) is then available for release. Release appears to
take place preferentially from this pool. DA taken up at uptake 1
(neuronal uptake) also appears to initially enter the releasable pool,
little of it being deaminated.
The rate of transfer of DA between the releasable and storage pools
(2) appears to be very slow, and inadequate to supply sufficient DA
for release in the absence of DA synthesis. This may be an important
point for the regulation of DA storage by presynaptic receptor mechanisms.
Presynaptic receptors also appear to regulate the rate of synthesis of
DA, and the release of newly-synthesized DA.
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mostly extra-neuronally and is derived mainly from DOPAC. An extra-
neuronal site of 3-MT formation, mainly from released DA, has also
been suggested.
The release of DA appears to increase with increasing frequency
of stimulation, with a maximum around 20Hz. A depression of release
per impulse with increasing train length was demonstrated, although
the effect of presynaptic receptor mediated mechanisms on this depres¬
sion of release per impulse remains to be investigated.
There is now increasing evidence in the literature that dopamin¬
ergic presynaptic receptors can depress the release of (preincubated)
3H-DA, and increase the 'turnover' of DA (see Table 1, page 31 , for
references). This implies that the presynaptic effects of dopaminergic
agents on the release of DA are to some extent independent of de novo
synthesis. However, a further implication is that the release of newly-
synthesized DA should also be increased, since it has been suggested
that newly-synthesized DA is preferentially released. Evidence for
this was obtained during the present thesis, and it was found that the
effects of dopaminergic agents on endogenous DA release were more
marked than the effects on 3H release. The above mentioned findings
suggest that 3H overflow, after preincubation of the tissues with
3H-DA, is not a reliable index of total endogenous DA overflow.
Similarly, muscarinic agonists increased the release of endogenous
DA to a much greater extent than the release of 3H. A similar small
facilitation of 3H release from striatal synaptosomes has recently been
reported (Marchi et at., 1982). This further emphasises the view
that the major mechanisms affected by presynaptic receptor mediated
effects are the rate of synthesis and the release of newly-synthesized
DA, and perhaps to a lesser extent the transfer of DA between the
releasable and storage pools.
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The control of release and metabolism of DA from the other DA
rich areas examined appeared to differ from that found in the striatum
in several respects:
1. The median eminence nerve terminals appear to lack a high
affinity DA uptake system, and the intraneuronal DA appears to
have a more limited access to MAO. These nerve terminals did not
appear to have active muscarinic or prolactin presynaptic receptors,
and so the effects of these drugs on the release of DA are probably
mediated via an action on the cell bodies of the tuberoinfundibular
neurons.
2. The retinal intraneuronal stores of DA also appear to have only
limited access to MAO, the major metabolite of released DA is
most likely to be 3-MT. The retinal dopaminergic neurons appear
to have a much higher basal overflow of DA than striatal or ME
nerve terminals, the implications of which are as yet obscure.
3. Further evidence for DA being a neurotransmitter in the
cockroach salivary gland was obtained as endogenous DA could
be Ca++ dependently released by electrical stimulation of the
glands in vitro. The major metabolite of DA in this tissue appears
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Examples of HPLC-ECD traces of superfusate samples (numbers
refer to superfusion time, stimulations were carried out at 16 and
56 min) from one experiment are shown on the preceeding two pages.
All results were calculated using the following equation:
ng/mg protein/sample =
peak height of sample amount of standards
peak height of standards
average flow rate/2 min ^ 1
injection volume proteins
Only experiments with more than a 90% recovery of the internal
standard were used, corrections for recovery were not made.
An example of the format in which the results were stored is shown
overleaf (calculated from the experimental results shown on the previous
two pages).
Date: Chamber = /W Gain of HPLC-ECD = 0*5*^
Paper speed = (UcmM1
Flow rate of superfusing Krebs =
Protein content of tissue =
Drugs used = • Time of addition of drugs =















time DA DOPAC Superfusion time DA DOPAC
10 O'Ol- 50 0 -Dif- Gt%b
12 0.0/f 52 O0(, Off]
14 e-o(o os°\ 54 o-oi 0 $b
16 W 1^5 56 7-So /$2
18 Ml 58 W w
20 0-4 60 D.tS
22 o4 [■% 62 o-q 4-01
24 O-o^ [■51 64 oof n ■
26 0<D1 oW 66
28 0'0(o Q& 1 68 0-0$ Mo
30 0% 0$\ 70 0-01 I'M
Average basal overflow before (ng/mg protein/2 min)
Sx = DA: DOPAC: OZfl
S2 = DA: DOPAC: 0.&
Evoked overflow (ng/mg protein)
51 = DA: DOPAC:
52 = DA: DOPAC : $-0^
Tissue content at the end of the experiment (ng/mg protein)
DA = 135,(p DOPAC =
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Regional changes in cerebral glucose utilization
in kindled rats during convulsions
D.H.R. BLACKWOOD & V. KAPOOR
(introduced by.J.K. McQUEEN)
MRC Brain Metabolism Unit. Department of Pharmacology.
University of Edinhurph
Rats were kindled (Goddard. Mclntyre & Leach,
1969) from the left amygdala by a daily one second
pulse at 60 Hz with a current intensity of 300 pa
(Farjo & Blackwood, 1978).
To identify the brain regions in which glucose














kindling, a modification of the technique developed
by SokolofT et al. (1977) was used. Two minutes after
the tail vein injection of 2-deoxy-d-[l-3H]-glucose
(200 pCi/Kg) one group of kindled rats received a
stimulus which provoked a generalised convulsion. A
second group of kindled rats and groups of sham
operated and unoperated controls received no stimu¬
lus. All animals were killed and decapitated at 45 min
after injection, the brains rapidly removed and frozen
at —20 C. One mm coronal slices were prepared and
specilic regions removed with the aid of a dissecting
microscope. The degree of labelling (counts min " ' mg
protein"') for each brain region was expressed as a
percentage of the value for the visual cortex in each
animal.
In the brain areas shown in Table I, glucose utiliza¬
tion was significantly increased in the kindled rats
which had convulsed, when compared with the other
three groups. Kindled rats which had not been con¬
vulsed did not differ significantly from the sham oper¬
ated or unoperated groups. No significant difference
betweed the groups was found in fronto-parietal cor¬
tex, caudate/putamen, thalamus, cerebellar hemi¬
spheres, dentate nucleus, brain stem reticular forma¬
tion, inferior colliculus or olfactory bulb.
These results suggest that generalised seizures,
associated with kindling of the amygdala selectively
involves sub-cortical structures listed in Table 1.
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Kindled Kindled Sham Analysis
(convulsed) (not convulsed) operated Unoperated of
n = 9 n = 6 n = 9 n = II Variance
x + s.d. x ± s.d. x ± s.d. x + s.d. F ratio
Amygdala 82 + 5.1 74 + 5.5 71 + 5.3 69 + 4.7 6.9a
Amygdala 83 ± 5.1 72 + 5.5 72 + 4.6 70 + 5.6 9.4a
Hippocampus 92 + 11 79 ± 5.1 75 + 3.9 70 ± 3.1 10.8a
Hippocampus 93 + 7.1 79 + 3.4 75 + 3.5 71 + 4.4 14.4a
Hypothalamus 83 + 5.6 77 ± 3.6 73 + 5 66 + 6.6 11.8a
Hypothalamus 83 + 5.5 76 + 2.6 72 + 4.9 67 ± 7.2 10.5a
Septal Region 85 + 5.3 77 + 4.7 72 ± 5.5 65 + 6.7 11.9a
Septal Region 91 + 9.1 76 + 4.2 74 + 7.6 66 + 5.7 13a
Subst. Nigra 87 + 9.9 77 + 5.4 64 ± 10.4 66 ± 5.2 9.1a
Subst. Nigra 89 + 6.2 72 + 4.2 66 + 12.8 65 + 5.3 9.8a
Superior Colliculus 108 ± 6.9 94 ± 6.3 93 + 8.1 88 ± 8.9 9.2a
Superior Colliculus 106 + 6.6 91 + 6.7 91 + 5.5 89 ± 5.5 7.5b
The accumulation of tritium in each brain region was measured as (ct/min)/mg protein and then expressed as a
percentage of the value for the visual cortex in each rat. The table gives the mean and standard deviation of this '
percentage. The analysis of variance showed a significant difference between groups in all these areas, a.
P < 0.0005. b. P < 0.001.
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Regional changes in cerebral glucose utilization associated with amygdaloid
kindling and electroshock in the rat*
D. H. R. BLACKWOOD, V. KAPOOR and M. J. MARTIN
MRC Brain Metabolism Unit, Department of Pharmacology, University of Edinburgh, 1, George
Square, Edinburgh (U.K.)
(Accepted July 23rd, 1981)
Key words', amygdala — 2-deoxyglucose — electroconvulsive shock — epilepsy — hippocampus —
kindling
A method using [3H]2-deoxygIucose was used to identify brain areas activated during partial
and generalized amygdaloid kindled seizures and generalized seizures following electro-convulsive
shock in rats. The amygdala, hippocampus, septal nuclei and hypothalamus were bilaterally activated
in kindled convulsions. Electroshock caused a more widespread involvement including the thalamus,
striatum, reticular formation and cerebellum. Changes in the amygdala and hippocampus but not
hypothalamus, were found after partial kindling.
Methods which employ [14C]2-deoxyglucose as described by Sokoloff12 have
been used to study the functional anatomy of seizures in a number of experimental
models of epilepsy including kindling1-3'6-7'9. In this study a relative measure of
glucose utilization in selected brain regions has been used to investigate patterns of
activity following seizures induced by amygdaloid kindling, partial kindling and
electroshock in rats. Kindling described by Goddard5 is a lasting change in brain
function following repeated spaced low intensity electrical stimulation.
Male Wistar rats (180-200 g) were prospectively allotted to 6 groups as follows.
Group 1:11 unoperated controls. Group 2: 9 operated controls which were implanted
with an electrode in the left amygdala but received no stimulation. Group 3: 6 fully
kindled animals did not receive a stimulus and did not convulse following deoxyglu-
cose injection. Group 4: 6 animals kindled partially to stage two10 (after 4-8
stimulations) had partial seizures with repetitive jaw movements following deoxyglu-
cose injection. Group 5: 9 animals were fully kindled from the left amygdala (mean
16.1, range 12-23 stimulations). Each had a generalized seizure following deoxyglu-
cose injection. Group 6: 10 unoperated animals received electroconvulsive shock
following deoxyglucose injection (150 V sine wave for 1 s; maximum 50 mC).
The implantation of bipolar stainless steel electrodes and the kindling procedure
were as previously described4. The kindling stimulus was a 1 s train of monophasic
* A preliminary report of this research was made at the British Pharmacological Society meeting in
September 1979.
0006-8993/81/0000-0000/S02.50 © Elsevier/North-Holland Biomedical Press
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Fig. 1. A diagrammatic representation of the results of a multiple comparison test (Student-Newman-
Keul) applied to the mean relative glucose utilization in the brain regions given in Table I. Groups: 1,
unoperated controls; 2, operated controls; 3, kindled rats not convulsed after deoxyglucose injection;
4, partially kindled; 5, kindled. Convulsed after deoxyglucose injection; 6, electroconvulsive shock.
The mean glucose utilization in any two groups enclosed by the range of any one line are not
significantly different. Groups not enclosed by the same line have mean glucose utilizations which
differ significantly at the 5 % level.
pulse at 60 Hz and 300 /xA. At least one week elapsed between the completion of
kindling (3 consecutive seizures) and the deoxyglucose injection. Aliquots of 200
,uCi/kg D-[l-3H]2-deoxyglucose (Radiochemicals Amersham) in 300 /d saline were
injected by tail vein and after 2 min animals in groups 4 and 5 received a kindling
stimulus and group 6 an electroshock. In group 4 mean afterdischarge duration was 46
s (range 24-84 s) and in group 5 afterdischarge duration was 78 s (range 25-120 s). In
group 6 the generalized seizure lasted 20-90 s (mean 64 s).
Following ictus animals were unrestrained and individually housed for 45 min,
then killed by a blow on the thorax, decapitated and the brain quickly removed and
frozen to —74 °C (Drikold) before being hand cut into approximately 1 mm slices. The
selected brain regions shown in Table I were dissected at 0-4 °C under a dissecting
microscope. Individual slices were thawed for only 2-4 min. The septal nuclei were all
those structures enclosed by the lateral ventricles, corpus callosum and anterior
commisure. The striatum included the globus pallidus.
Brain samples were homogenized in 100 /x\ distilled water in Ependorf micro¬
tubules and after removal of a sample for protein estimation8 the homogenate was
added to 10 ml Scintillator (NE 260 New England Nuclear) for liquid scintillation
207
counting. Activity in each brain region was expressed as cpm per mg protein. Because
during seizure a steady state for glucose utilization does not obtain, quantitative
measurement is not possible by these methods. A relative measure of energy
metabolism was obtained by expressing the activity of each brain region as a
percentage of the mean value from right and left occipital cortex in each animal. The
results are shown in Table I. There is no significant difference between the right and
left sides in any brain region using the paired t-test. A one-way analysis of variance
showed significant differences (P < 0.0005) between the means of the 6 groups in all
brain regions on right and left sides, except the frontal cortex. For further analysis
data from right and left sides were combined and the Student-Newman-Keul
procedure11 enabled multiple comparisons to be made among the means.
The results of this analysis depicted in Fig. 1 show that in all groups changes in
the frontoparietal cortex parallel those in the reference area — the occipital cortex.
The effect of amygdaloid kindled convulsions (group 5 compared with group 2) is to
cause a relative increase in energy metabolism in the amygdala, hippocampus, septal
nuclei and the hypothalamus. In partially kindled animals only 4 brain regions were
dissected and the results were intermediate between fully kindled and controls. The
changes were bilateral and significantly higher than operated controls (group 2) in the
amygdala and hippocampus but not the hypothalamus.
In no area did group 3 differ significantly from group 2 which suggests that the
changes observed following kindling in group 5 are the result of the convulsion and
not other aspects of kindling. Electroshock gives a different pattern of change from
kindling and is accompanied by a relative increase in metabolic activity in all regions
studied apart from the parietal cortex (group 6 compared with group 1).
Finally in the hypothalamus and the septal nuclei unoperated controls showed a
significantly lower uptake than either of the two control groups with implanted
electrodes (group 2 and 3). This finding suggests that electrode implantation to the
amygdala may lead to an increased activity in these regions. This effect appears to be
bilateral.
The results suggest a functional relationship between the amygdala, hippo¬
campus, septal nuclei and hypothalamus in generalized amygdaloid kindled seizures.
This is supported by the finding of less marked and less widespread changes in partial
kindling and more widespread changes associated with the generalised seizures
induced by electroshock.
The authors wish to thank Dr. J. McQueen and Dr. G. Arbuthnott for advice
and encouragement in this project and Dr. B. Meldrum for helpful comments on the
manuscript.
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Presynaptic cholinergic modulation of endogenous dopamine and dihydr-
oxyphenylacetic acid release from superfused rat striatal slices
By V. Kapoor. M.R.C. Brain Metabolism Unit. University Department of Pharma¬
cology. 1 George Square. Edinburgh
The influence of the cholinergic system on endogenous striatal dopamine (DA)
release and metabolism was studied in vitro with the aid of the sensitive electrochemical
detection for catecholamines (Felice. Felice & Kissinger. 1978). Striata were dissected
out of rat-brain slices (1 mm thick) and cut twice at right angles, at 0 3 mm intervals
with a Mcllwain tissue chopper. The tissue pieces were separated and preincubated
in oxygenated Krcbs-bicarbonate buffer (KBB) for 10 min at 37 °C, and then
transferred to small chambers (0-2 ml. capacity) and superfused at 37 °C
(0-25 ml./min) with oxygenated KBB containing 10~4 M-ascorbic acid. After a 15 min
washout, the superfusate was collected every 2 min using a fraction collector. Samples
were acidified with HC1 (final concentration 0T mil) containing EDTA (0T m>i) and
the DA/DOPAC separated by high performance liquid chromatography (25 cm-5 p
Hvpersil ODS column, mobile phase 0-1 m-KH,P04-citrate buffer containing 30 mg/1.
sodium octyl sulphate. 10% methanol and 0T mii-EDTA, pH 4-0) and assayed by
electrochemical detection (Carbon Paste electrode set at +0-65 V).
Two-minute depolarizations with high K+ KBB (Xa+ replaced by K+. 25-50 m.m)
resulted in DA release which was related to K+ concentration and was Ca2+-dependent.
An increase in DOPAC release followed (by about 2 min) and K+-induced release of
DA and was similarly K+-concentration and Ca2+-dependent.
Routinely, two treatments with submaximal concentrations (25 m>i) of high K+
KBB (Sj. S2) were applied. S2 being initiated 20 min after Sj was completed. Addition
of physostigmine (10-8 to 10-5 m) to the KBB after Sj resulted in a dose-dependent
increase in S2 (with a maximal increase of 275 % for DA and 320% for DOPAC).
Neostigmine (10~6 m) had a similar effect which was blocked by atropine (10~6 m) but
not by gallamine (10~6 m) or tuboeurarine (10~6 m). The increase in K+ evoked release
after acetyl choline (10~4 to 10~2 m) was potentiated by physostigmine (10~8 M) and
was also blocked by atropine (10—6 m). Atropine (10—6 m) alone reduced the release
of DOPAC slightly".
These results, which parallel in vivo studies (O'Kcefc. Sharman & Vogt. 1970:
Perez-Cruet. Gessa. Tagliamontc & Tagliamonte. 1971). suggest the presence of
cholinergic presynaptic receptors, muscarinic in type, on dopaminergic nerve term¬
inals in the striatum. These receptors appear to mediate the cholinergic stimulation
of DA release and turnover.
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RELEASE OF ENDOGENOUS DOPAMINE FROM STRIATAL SLICES 'IN VITRO':
COMPARISON OF RELEASE FOLLOWING HIGH K+ AND ELECTRICAL STIMULATION
V.Kapoor* 4 G. Id. Arbuthnott, M.R.C. Brain Metabolism Unit, University Department
of Pharmacology, 1, George Square, Edinburgh, EH8 93Z.
Recent improvements in the methods for detecting catecholamines have allowed th
measurement of endogenous transmitter overflow from slices of rat brain
superfused 'in vitro' (Bennett et al, 1981; Nahorski 4 Strupish, 1981;
Kapoor, 1981).
The release of dopamine (DA) and its deaminated metabolite 3,4 dihydroxyphenyl-
acetic acid (DOPAC) from small slices of neostriatum from rat brain superfused
'in vitro was estimated after High Performance Liquid Chromatography
(5p,DDS-Hypersil Column, 0.1 M Phosphate - Citrate buffer pH 4.0 with 20mg/l
Sodium Octyl Sulphate, 10^ Methanol 4 0.1mM EOTA) and electrochemical detection
on a Carbon paste electrode (+0.65V). During superfusion with Krebs-bicarbonat
buffer (KBB) the output of DA and DOPAC was approximately 0.5pmole/mg protein/m
and 1.9 pmole/mg protein/min respectively. Superfusion for 2 min with KBB
containing 25mM K+ (K+ replacing 20mM Na+) raised these to about 6.5 pmole/mg
protein/min (DA) and 3.7 pmole/mg protein/min (DOPAC) (averaged over 6 min from
the onset of stimulation). Reducing the Ca++ in the superfusate to zero,
reduced the output in the presence of high K+ to control levels.
Electrical stimulation of the slices was performed through silver electrodes at
either end of the superfusion chamber. DA and DOPAC levels were increased by
stimulation (200 biphasic pulses 2ms wide and 8mA at 2 - 200Hz) but the effects
of such stimulation were comparatively small. The overflow of DA increased in
the presence of Nomifensine (lO^M). Figure 1 illustrates the frequency
dependence of transmitter overflow under these conditions.
In contrast to this marked effect on electrically induced release Nomifensine
had no detectable effect on the overflow of DA and DOPAC when high K+ was the
stimulus.
The effects of muscarinic agents on DA overflow which were demonstrated with K+
stimulation (Kapoor, 1981) can also be seen with electrical stimulation which
suggests that the release of DA is still sensitive to some kinds of presynaptic




FIGURE 1. Dopamine overflow in the presence (A) 4 absence (A) of Nomifensine.
Bennett, G.ld. , Marsden, C.A., Metcalf, G., 5harp, T., Tulloch, I.F. (1981)
Br. 3. Pharmac. 74. 227-228P
Nahorski, S.R. 4 Strupish. 3. (1981) 3, Physiol. 316, 3P
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CHARACTERISTICS OF ENDOGENOUS DOPAMINE AND DIHYOROXYPHENYLACETIC ACID (DOPAC)
RELEASE FROM SUPERFUSEO SLICES OF THE RAT STRIATUM
V. Kapoor* and G.W. Arbuthnott
MRC Brain Metabolism Unit, University Department of Pharmacology,
1 George Square, Edinburgh.
Although there have been many studies on the release of radioactive
Dopamine (DA) from striatal slices, we have taken the opportunity afforded by
the electrochemical detection method together with High Performance Liquid
Chromatography (HPLC) separation to study the release of endogenous DA (Plotsky
et al. , 1977).
Striatal slices (0.3 x 0.3 x 1mm) from the head of the Caudate were
preincubated in Krebs Bicarbonate Buffer (KBB) containing 10pM ascorbic acid,
for 10 min, transferred to small chambers and washed for a further 20 min at a
flow rate of 350pl per min. The suparfusate was then collected at 2 min intervals
using a fraction collector, into tubes containing an internal standard (Dihydroxy-
benzylamine 0.5ng), HC1 and EDTA (final concentration 0.1M and 0.1mM
respectively).
The superfusate was directly analysed for DA and DOPAC by HPLC with 5p-
Hypersil 0DS column using a 0.1M Phosphate-Citrate buffer, pH 4.0, containing
10$ Methanol, 25mg/l Sodium Octyl Sulfate and 0.1mM EDTA, Flow rate was set at
0.8ml/min giving a pressure of approximately 1000p.s.i. Electrochemical
Detection was performed with carbon paste, CP0, electrode set at +Q.65\/, with
respect to a Ag/AgCl reference electrode. Under these conditions the retention
times for DA and DOPAC were 8 min and 12 min respectively.
Resting release of DA and DOPAC was found to be about 0.5pMol/mg Protein/min and
1.9pMol/mg Protein/min respectively. Superfusion for 2 min with KBB containing
25mM K+ (K+ replacing 20mMNa+)raised these values to about 6.5pMol/mg Protein/min
(DA) and 3.7pMol/mg Protein/min (DOPAC) (averaged over 6 min from the onset of
stimulation). Release of DA by high K+ KBB was found to be maximal at
35-40mM K+, and completely dependent on thB presence of Ca++ in the KBB (Kapoor,
1982).
Electrical stimulation, performed through silver electrodes at either end of
the superfusion chamber, was maximal at 8-10mA(2msec biphasic pulses) and at
20Hz (Kapoor and Arbuthnott, 1982). Electrical release of DA was also Ca++
dependent. The release of DA per impulse was found to decrease with increasing
number of pulses.
Several differences between the two methods 'Of inducing release have been
demonstrated. Dopaminergic uptake inhibitors Nomifensine (lO^M) and LY5953A
(lO^M) increased the electrically induced release of DA markedly, they were
however without effect on the high K+ evoked release of DA. Acetylcholine-
esterase inhibitors, which revealed a clear muscarinic increase in DA release
after high K+ stimulation (Kapoor 1982) have much more complex effects on
electrically induced release.
(LY5953A was kindly supplied by E.Lilley 4 Co.)
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COMPARISON OF DOPAMINE OVERFLOW FROM STIMULATED SLICES OF THE
NEOSTRIATUM AND MEDIAN EMINENCE 'IN VITRO'
V. Kapoor, A. Horn 4 G.W. Arbuthnott, M.R.C. Brain Metabolism Unit, University
Department of Pharmacology, 1 George Square, Edinburgh, EH8 93Z, Scotland.
Because of the greater clinical accessibility of the hormones which they control,
the dopamine containing neurones of the median eminence are often used as a modal
system through which to examine the functional state of central dopaminergic
systems in general. The purpose of the present experiments was to compare, in as
direct a manner as possible, the release of transmitter from the dopamine contain¬
ing terminals of the neostriatum with that from the median eminence terminals.
Both areas were dissected from cooled rat brain and preincubated for 20 min. in
Krebs bicarbonate buffer at 37°C. Tissue pieces from both areas were then trans¬
ferred to small perspex chambers and superfused with the same Krebs buffer. The
release of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) was assayed in the
superfusate collected at two minute intervals from the chambers. The samples
were analysed by high performance liquid chromatography on a 5p ODS-Hypersil
column (0.1M phosphate-citrate buffer, pH 4.0, with 20mg/l _Sodium Octyl Sulphate,
10^ Methanol and 0.1mM EDTA) , and the dopamine and DOPAC in the samples measured
by electrochemical detection on a carbon paste electrode (+0.65 V). The
retention times of dopamine and DOPAC were 7 min. and 12 min. respectively.
(Kapoor and Arbuthnott, 1982).
Median eminence samples from four rats weigh only about 1.5mg but the dopamine
output in response to electrical stimulation at 20Hz (2msec biphasic pulses) , for
30sec at IDmAmps, is easily measureable and is about 17fmoles/mg protein/impulse,
which compares well with the 7fmoles/mg protein/impulse from the striatum.
Several differences in the characteristics of release are worthy of note. The
most striking is the very small amount of DOPAC coming from the median eminence
slices. Whereas DOPAC is a major component of the output from striatal slices,
the resting output of DOPAC from the eminence slices is very small, usually below
the detection limits of the assay even during stimulation. Umezu 4 Moore (1979)
also report low levels of DOPAC in tissue from the median eminence. The smaller
volume of tissue involved is reflected in the fact that pooled tissue from several
rats is required for the median eminence samples-, while ample dopamine is released
from single slices of neostriatum from one side of one rat brain in the exper¬
iments on that area. The effect of the uptake inhibitor, Nomifensine, is clear
on the stimulated release from the striatum where at lO^M it causes a three fold
increase of dopamine overflow. However Nomifensine (lO^M) has a very much
smaller effect on the median eminence slices, increasing the overflow of dopamine
by only about 50^. These results may be explained by the suggestion that the
median eminence neurones lack a high affinity dopamine"uptake system (Demarest and
Moore, 1979), although it has been shown (Sarkar et al., 1981) that Nomifensine
does block the uptake of 3H dopamine into similar slices of the median eminence.
These experiments suggest that the control of "dopamine release and metabolism in
the median eminence is different from that in the striatum and thus counsel
caution in the use of neuroendocrine markers to monitor the functional activity of
dopamine in areas of the brain other than the median eminence.
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'THE RELEASE OF DOPAMINE (DA) INTO HYPOPHYSIAL PORTAL BLOOD IN THE
MALE HYPERPROLACTINAEMIC RAT. A. Brar*, V. Kapoor*, A. McNeilly*+
G. Fink (SPON: D.W. Lincoln). MRC Brain Metabolism Unit, :
Department of Pharmacology, 1 George Square, Edinburgh, U.K., and
i+MRC Reproductive Biology Unit, 37 Chalmers Street, Edinburgh,U.K.
Studies in vitro and the measurement of DA in the hypothalamus
have suggested that prolactin (PRL) may increase DA release into
hypophysial portal vessel blood and thereby invoke a negative
feedback system. We have investigated this possibility by
measuring DA in hypophysial portal vessel blood in control adult
male rats and in male rats made hyperprolactinaemic by trans¬
planting two pituitary glands under the kidney capsule. Hypo¬
physial portal vessel blood was collected (Fink, G. and
Jamieson, M.G., J. Endocrinol. 68: 71, 1976) for 30 min before,
during and after the application of an electrical stimulus
(30 sec trains of biphasic square wave pulses, 60 Hz, 1mA peak
to peak and 1 mA duration) to the median eminence. The portal
blood was collected into Trasylol (20,000 KlU/ml) and EDTA
(5.4 mM 1"' ) at 4°C. The concentrations of DA and D0PAC were
measured in plasma extracts using HPLC with electrochemical
detection (Plotsky, M. etal, Endocrinology 102: 1887, 1978).
Concentration of DA and DOPAC in hypophysial portal plasma


















The table shows that DA and DOPAC levels were slightly higher
in the hyperprolactinaemic group than in the control group,
although the differences were only significant in the sample
collected during stimulation. These results suggest that long-
term elevations in plasma PRL (approx. 120 ng NIH-RP-l/ml)
elevate the turnover rate of the tuberoinfundibular DA system
without significantly affecting the DA concentration in portal
blood. Furthermore, despite a 47% depletion of DA concentration
in the median eminence (ME) produced by long-term hyperprolactin-
aemia (Simpkins, J.W. etal, Life Sci. 30: 1249, 1982),
electrical stimulation of the ME can augment the PRL-induced
elevation of DA turnover while keeping DA concentration constant.
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